USPTO Patents Application 10551504

(12) STANDARD PATENT (1 1 ) Application No. AU 2002210917 B2
(19) AUSTRALIAN PATENT OFFICE

(54)

Title

(51)

International Patent Classification(s)

C72N 75/05 (2006.01 ) C07K 76/28 (2006.01 )

C07K 76/24(2006.01)

(21)

Application No: 2002210917 (22) Date of Filing: 2001.10.22

(87)

WIPO No: WO02/33072

(30)

Priority Data

(31)

Number (32) Date (33) Country

2000- 321821 2000.10.20 JP

2001- 277314 2001.09.12 JP
JP01/03288 2001.04.17 WO

(43)
(43)
(44)

Publication Date: 2002.04.29
Publication Journal Date: 2002.07.04
Accepted Journal Date: 2006.05.18

V ' 1 )

A nn I n tYc;^

Chugai Seiyaku Kabushiki Kaisha

(72)

Inventor(s)

Ohtomo, Toshihiko;Tsunoda, Hiroyuki;Tsuchiya, Masayuki;Orita, Tetsuro;Yabuta,
Naohiro

(74)

Agent / Attorney

Griffith Hack, Level 29 Northpoint Tower 100 Miller Street, North Sydney, NSW, 2060

(56)

Related Art

Int. J. Cancer, 77(5): 763-72, 1988
WO 99/03495

Blood, 92(6): 1981-88, 1998

( J 2) 4# if «S ± St to I c £ -5 X » E! $ ti tz a R tb J£

<i9) ttt^tnWffiWJitiilia

(43) (10) BIK^ffl*^

2002 *M £25 B (25.04.2002) pct WO 02/33072 Al

(51) HRmtttgT:

C07K 16/28, A61K 39/395

(21) S»tb)B#^-:

(22) HSKftiffiB:

(25) BtSWBWBlS:

(26) fflSBttPwlCDsag:

CI2N 15/09, 15/62,

PCT/JP01/09259

2001 ^10 322 B (22.10.2001)

B*|g

B*S

(30)

«jfe«T-*:
mm 2000-32 1821

PCT/JPOI/03288
<r**B2001-277314

2000 *f 10 3 20 B (20.10.2000) JP
2001 ^4 3 17 B (17.04 2001) JP
2001 *f 9 312 B (12.09.2001) JP

(71) tamX C*B £ 18 < ±Trof&JEHII-o^Tj: 4=

*t*(***it£tt (CHIIGAI SF.IYAKll KABUSHIKI
KAISHA) [JP/JP]; T 115-8543 X JKSRdt E i*W 5T B
5*1^ Tokyo (JP).

(72) fEBH%; fc<fctf

(75) $EW#/ttiJKA (*BJI=-3 l^TCO^J: ±BK$
(TSUCHIYA.Masayuki) [JP/JP]. A&gljS (OHTOMO,
Tushihiko) [JP/JP]; T412-85I3 » WHHBSBJirtliSlFI I
Tl 135#tfi ^ttKJKIfcitfEttH Shizuoka (JP). fe
E ft 3/» (YABUTA, Naohiro) [JP/JP], ft fflSfT (TSUN-
ODA, Hiruyuki) [JP/JP]. (tffltJj* (OR1TA, Tetsuro)

[JP/JP]; t 300-4101 5?«a*r;&fS*T&tt*?F 153-2 'P

*1-HaH*5t*ttrt Ibaraki (JP).

(74) ttJSA: fi*^*, ^KTAKAGI, Chiyoshi et al.); T
102-0083 XJSffl^FftfflEiaaT— Tg 1 0« Ufa »BTJ£

5¥t'jU Tokyo (JP).

(81) tiSH (111*3): AE, AG, AL, AM, AT, AU, AZ, BA, BB,
BG, BR, BY, BZ, CA, CI I, CN, CO, CR, CU, CZ, DE, DK,
DM, IV., KC, KK, KS, Kl, GB, GD.GE, G11,GM, MR, IIU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG. MR, MN, MW, MX, MZ, NO,
NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) ti*H r'JtWj: ARIPO Wif (GH, GM, KE, LS, MW,
MZ, SD, SL, SZ, TZ, UG, ZW), J.— 7 v7f$l<F (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), 3 — a y sift ft
(AT, BE, C1I, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, TR), OAPI 1#t* (BF, BJ, CP, CU,
CI, CM, GA, GN, GO, GW, ML, MR, KE, SN, I'D, TG).

(54) Title: DEGRADED I PO AGONIST' ANTIBODY
(54) 3£iW<7>*ft: te#T(bTPOT ^- * hijH*

(57) Abstract: A modified antibody containing at least two H chain V domains and al least two L chain V domains of a monoclonal
antibody which transduces a signal into cells by crosslinking a TPO receptor to thereby exert TPO agonism. Because of being usable
as a TPO signal transduction agonist, this modified antibody is useful as a preventive and/or a remedy for blood diseases in which
platelet reduction participates, thrmobopenia following chemotherapy for cancer or leukemia, etc.

(57) gift:

■<

cm

VERIFICATION OF TRANSLATION

I, Shoji MIWA, a patent attorney of c/o Subaru Patent Office
of Kojimachi Koyo Bldg., 10, Kojimachi 1-chome Chiyoda-ku,
Tokyo, Japan, hereby certify that I know well both the Japanese
and English languages, that to the best of my knowledge and belief
the attached English translation is a true translation, made by me
and for which I accept responsibility, of the description, claims,
abstract and drawing of International Application No.
PCT/JPO 1/09259 filed on October 22, 2001, annexed hereto.

Signature of translator: ^Ju^L ~^\Cyr^

Shoji MIWA

Dated this 10th day of March, 2003.

1

DEGRADED TPO AGONIST ANTIBODY

TECHNICAL FIELD

This invention relates to modified antibodies
5 containing two or more H chain V regions and two or more L

chain V regions of an antibody which show TPO agonist
activity by crosslinking TPO receptor. The modified
antibodies have TPO agonist activity of transducing a signal
into cells by crosslinking TPO receptor and are useful as a
10 medicine for various purposes.

BACKGROUND ART

Thrombopoietin (TPO) is a platelet production
regulation factor found in 1994 and is known to be composed

15 of a glycoprotein having a molecular weight of 70-80

thousands produced mainly in liver. Thrombopoietin is a
■cytokine which in bone marrow promotes platelet precursor
cells to survive, proliferate, differentiate and mature,
namely promotes megakaryocytes to differentiate and

20 proliferate. Thrombopoietin (TPO) receptor was identified

earlier than TPO as c-Mpl, a receptor of a specific factor
to regulate platelet production (M . Souyri et al., Cell 63:
1137 (1990)). It was reported that c-Mpl is distributed
mainly in platelet precursor cells, megakayocytes and

25 platelet cells and that the suppression of c-Mpl expression

inhibits selectively megakaryocyte formation (M. Methia et
al . , Blood 82: 1395 (1993)). It was reported that the ligand

2

to c-Mpl is TPO based on the results of proliferation assay
of cells specific to c-Mpl ligand and purification of the
ligand using c-Mpl (F. de Sauvage et al., Nature 369: 533
(1994); TD. Bartley et al . , Cell 77: 1117 (1994)). At
5 present Mpl is called TPO receptor. Therefore TPO and TPO

receptor agonists have been expected to work as a
therapeutic agent for thrombocytopenia, for example, as a
medicine alleviating thrombocytopenia caused by bone marrow
inhibition or bone marrow resection therapy for cancer

10 patients. ,

On the other hand modified antibodies, especially
antibodies with lowered molecular size, for example, single
chain Fvs were developed to improve permeability into
tissues and tumors by lowering molecular size and to produce

15 by a recombinant method. Recently the dimers of single chain

Fvs, especially bispecif ic-dimers have been used for
crosslinking cells. Typical examples of such dimers are
hetero-dimers of single chain Fvs recognizing antigens of
cancer cells and antigens of host cells like NK cells and

20 neutrophils (Kipriyanov et al . , Int. J. Cancer, 77, 9763-

9772, 1998) . They were produced by construction technique of
single chain Fv as modified antibodies, which are more
effective in treating cancers by inducing intercellular
crosslinking. It has been thought that the intercellular

25 crosslinking is induced by antibodies, and their fragments

(e.g. Fab fragment), bispecific modified antibodies and even
dimers of single chain Fvs, which are monospecific.

As antibodies capable of transducing a signal by
crosslinking a cell surface molecule (s ) , there are known an
antibody against EPO receptor involved in cell
differentiation and proliferation (JP-A 2000-95800), an
antibody against MuSK receptor (Xie et al . , Nature Biotech.
15, 768-771, 1997) and others. There are also known an
agonist antibody to TPO receptor, its fragments and single
chain Fvs (W099/17364 ) . However there have been no reports
on single chain Fv dimers and modified antibodies such as
single chain bivalent antibodies having agonist activity.

Noticing that single chain Fv monomers derived
from monoclonal antibodies (antibody MABL-1 and antibody
MABL-2 produced by the inventors) which induce apoptosis of
IAP-containing cells do not induce apoptosis of cells and
that dimers induce apoptosis, the inventors discovered that
dimers crosslink (dimerize) IAP receptor on cell surface,
thereby a signal is transduced into the cells and, as a
result, apoptosis is induced. This suggests that
monospecific single chain Fv dimers crosslink a cell surface
molecule (s) (e.g. receptor) and transduce a signal like a
ligand, thereby serving as an agonist.

Focusing on the intercellular crosslinking, it was
discovered that the above-mentioned single chain Fv dimers
do not cause hemagglutination while the above-mentioned
monoclonal antibodies do. The same result was also observed
with single chain bivalent antibodies (single chain
polypeptides containing two H chain V regions and two L

4

chain V regions) . This suggests that monoclonal antibodies
may form intercellular crosslinking while modified
antibodies like single chain Fv dimers and single chain
bivalent antibodies crosslink a cell surface molecule (s) but
5 do not form intercellular crosslinking.

Based on those observations the inventors have
newly discovered that modified antibodies such as single
chain Fv dimers and single chain bivalent antibodies
crosslink a cell surface molecule (s) or intracellular

10 molecule (s) of the same cell, in addition to known

intercellular crosslinking, and are suitable as a ligand to
the molecule (s) (especially as a ligand which mimics the
action of natural ligand) .

Discovering further that an antibody molecule

15 (whole IgG) can be modified into single chain Fv dimers,

single chain bivalent antibodies and the like which
crosslink a cell surface molecule (s), thereby reducing side
effects caused by intercellular crosslinking and providing
new medicines inducing only desired effect on the cell, the

20 inventors completed the invention. The modified antibodies

of the invention have remarkably high activity compared with
whole antibodies (IgG) having the same V region as the
modified antibodies. They have an improved permeability into
tissues due to the lowered molecular size compared with

25 antibody molecules and the lack of constant regions.

DISCLOSURE OF INVENTION

-5-

It would be advantageous if at least preferred
embodiments of the present invention were to provide low
molecular-sized agonistic modified antibodies which
contain two or more H chain V regions and two or more L
chain V regions of a monoclonal antibody and have TPO
agonist action by crosslinking TPO receptor.

In a first aspect, the present invention provides a
modified antibody comprising two or more H chain V regions
and two or more L chain V regions of antibody and showing
TPO agonist action by crosslinking TPO receptor, wherein
the modified antibody is:

(i) a multimer of single chain Fv comprising an H
chain V region and an L chain V region; or

(ii) a single chain polypeptide comprising two or
more H chain V regions and two or more L chain V regions.

Therefore, this invention relates the modified
antibodies which contain two or more H chain V regions and
two or more L chain V regions, preferably 2 to 6 each,
especially preferably 2 to 4 each, most preferably two
each, and show TPO agonist activity by crosslinking TPO
receptor .

The "modified antibodies" in the specification mean
any substances which contain two or more H chain V regions
and two or more L chain V regions, wherein said V regions
are combined directly or via linker through covalent bond
or non-covalent bond. For example, polypeptides and
compounds produced by combining each V region of antibody
through a peptide linker or a chemical crosslinking agent
and the like. Two or more H chain V regions and two or
more L chain V regions used in the invention can be
derived from the same antibody or from different
antibodies .

Modified antibodies of the invention can be any

-6-

things as long as they comprise two or more H chain v
regions and two or more L chain V regions of antibody,
when the modified antibody is: (i) a multimer of single
chain Fv comprising an H chain V region and an L chain V
region; or (ii) a single chain polypeptide comprising two
or more H chain V regions and two or more L chain V
regions, and specifically recognize and crosslink TPO
receptor and thereby can transduce a signal into cells.
They include modified antibodies produced by further
modifying a part of the amino acid sequence of V region of
the modified antibodies.

The modified antibodies of the invention may be
multimers such as dimers, trimers or tetramers of single
chain Fv containing an H chain V region and an L chain V
region, or single chain polypeptides containing two or
more H chain V regions and two or more L chain V regions.
When the modified antibodies of the invention are
multimers of single chain Fv such as dimers, trimers,
tetramers and the like containing an H chain V region and
an L chain V region, it is preferable that the H chain V
region and L chain V region existing in the same chain are
not associated to form an antigen-binding site.

More preferable examples are dimers of the single
chain Fv which contains an H chain V region and an L chain
V region, or a single chain polypeptide containing two H
chain V regions and two L chain V regions. The H chain V
region and L chain V region are connected preferably
through a linker in the modified antibodies.

The above-mentioned single chain Fv multimer includes
a multimer by non-covalent bond, a multimer by a covalent
bond through a crosslinking radical and a multimer through
a crosslinking reagent (an antibody, an antibody fragment,

-6a-

or bivalent modified antibody) . Conventional crosslinking
radicals used for crosslinking peptides can be used as the
crosslinking radicals to form the multimers. Examples are
disulfide crosslinking by cysteine residue, other
crosslinking radicals such as C4 - C10 alkylene (e.g.
tetramethylene , pentamethylene , hexamethylene ,

heptamethylene and octamethylene, etc.) or C< - Cio
alkenylene (cis/trans -3-butenylene, cis/trans-2-pentenylene,
cis/trans-3-pentenylene, cis/trans-3-hexenylene, etc.).

Moreover, the crosslinking reagent which can combine
with a single chain Fv is, for example, an amino acid
sequence which can optionally be introduced into Fv, for
example, an antibody against FLAG sequence and the like or a
fragment thereof, or a modified antibody originated from the
antibody, for example, single chain Fv.

"TPO agonist action" in the specification means a
biological action occurring in the cell(s) into which a
signal is transduced by crosslinking TPO receptor, for
example, proliferation, differentiation or growth
stimulation of megakaryocytes, or platelet production.

ED50 of the TPO agonist action in the invention is
determined by known methods for measuring agonist action.
Examples for measurement are cell proliferation assay using
TPO sensitive cell lines such as BaF/mpl or UT7/TP0,
measurement of phosphorylation of MPL protein, megakaryocyte
colony assay by differentiation from bone marrow cells, in
vivo mouse platelet recovery synthesis assay, measurement of
expression induction of platelet antigen GPIIbllla (anti
GPIIbllla) using human leukemia megakaryoblastic cell line
(CMK) or measurement of polyploidy induction of
megakaryoblastic cell line (DAMI) . ED50 is a dose needed for
achieving 50% reaction of the maximum activity set as 100%
in the dose-reaction curve.

Preferable modified antibodies of the invention have
TPO agonist action (ED50) equivalent to or better than
that of an antibody having the same antigen-binding region
as the modified antibody, namely the whole antibody
5 (hereinafter "parent antibody") like IgG having the same
pair of H chain V region and L chain V region as the pair
of H chain V region and L chain V region forming antigen-
binding region of the modified antibody. More preferable
are those having TPO agonist action (ED50) more than two
10 times higher than that of parent antibody, further

preferably more than 5 times, most preferably more than 10
times. The invention includes modified antibodies with
TPO agonist action containing H chain V region and L chain
V region forming the same antigen-binding region as the
15 parent antibody which binds to TPO receptor but has no TPO
agonist action to the molecule.

In a second aspect, the present invention provides a
compound comprising two or more H chain V regions and two
or more L chain V regions of monoclonal antibody and
20 showing an equivalent or better agonist action (ED50)
compared with thrombopoietin (TPO) .

The compounds containing two or more H chain V
regions and two or more L chain V regions of the invention
can be any compounds which contain two or more H chain V
25 regions and two or more L chain V regions of antibody and
show TPO agonist action (ED50) equivalent to or better
than that of thrombopoietin (TPO) . Preferable are those
having TPO agonist action (ED50) more than two times
higher than that of TPO, more preferably more than 5
30 times, most preferably more than 10 times.

The "compounds" mentioned here include not only
modified antibodies of the invention but also any
compounds containing two or more, preferably from 2 to 6,

-9-

more preferably from 2 to 4, most preferably 2 antigen-
binding regions such as whole antibodies or F(ab') 2 .

Preferable modified antibodies or compounds of the
invention containing two or more H chain V regions and two
or more L chain V regions of antibody have an
intercellular adhesion action (ED50) not more than 1/10
compared with the parent antibody, more • preferably have no
substantial intercellular adhesion action.

ED50 of the intercellular adhesion action mentioned
in the above is determined by known methods for measuring
intercellular adhesion action, for example, by the
measurement of agglomeration of cells expressing TPO
receptor .

The invention also relates to DNAs which encode for
the modified antibodies or compounds.

In a third aspect, the invention provides a DNA which
encodes the modified antibody of the first aspect, or
compound. of the second aspect.

The invention relates to animal cells or
microorganisms which produce the modified antibodies or
compounds .

In a fourth aspect, the invention provides an animal
cell which produces a modified antibody of the first
aspect, or a compound of the second aspect.

In a fifth aspect, the invention provides a
microorganism which produces a modified antibody of the
first aspect, or a compound of the second aspect.

■ The invention relates to use of the modified antibody
or compound as TPO agonist.

In a sixth aspect, the invention provides use of a
modified antibody of the first aspect, or a compound of
the second aspect, as TPO agonist.

The invention also relates to a method of causing

- 10-

agonist action to cells by crosslinking TPO receptor using
the modified antibody or compound and thereby transducing
a signal into cells.

In a seventh aspect, the invention provides a method
of causing an agonist action to cells by crosslinking TPO
receptor using the modified antibody of the first aspect
or the compound of the second aspect, thereby transducing
a signal into cells.

Examples of agonist action are proliferation,
differentiation-induction or growth stimulation of
megakaryocytes, platelet production, phosphorylation of
TPO receptor protein and the like.

In an eighth aspect, the invention provides a
medicine comprising as active ingredient the modified
antibody of the first aspect or compound of the second
aspect .

The medicine may be for treating thrombocytopenia
etc. containing the modified antibody as active component.

The invention also relates to use of the modified
antibody or compound as a medicine.

In a ninth aspect, the invention provides use of the
modified antibody of the first aspect, or the compound of
the second aspect, as medicine.

In a tenth aspect, the invention provides a method of
screening a modified antibody comprising two or more H
chain V regions and two or more L chain V regions of
antibody and showing an agonist action by crosslinking TPO
receptor, wherein the modified antibody is: (i) a multimer
of single chain Fv comprising an H chain V region and an L
chain V region; or (ii) a single chain polypeptide
comprising two or more H chain V regions and two or more L
chain V regions, that comprises the steps 1) to produce a
modified antibody containing two or more H chain V regions

- 11 -

and two or more L chain V regions of antibody and binding
specifically to TPO receptor, 2) to subject cells
expressing TPO receptor to react with the modified
antibody and 3) to measure TPO agonist action in the cells
caused by crosslinking TPO receptor. The method of
measurement is useful for the quality control in producing
the modified antibodies of the invention as a medicine and
other purposes.

In an eleventh aspect, the invention provides a
method of measuring an agonist action of a modified
antibody comprising two or more H chain V regions and two
or more L chain V regions of antibody and showing an
agonist action by crosslinking TPO receptor, wherein the
modified antibody is: (i) a multimer of single chain Fv
comprising an H chain V region and an L chain V region; or
(ii) a single chain polypeptide comprising two or more H
chain V regions and two or more L chain V regions, which
comprises the steps 1) to produce a modified antibody
comprising two or more H chain V regions and two or more L
chain V regions of antibody and binding specifically to
TPO receptor, 2) to subject cells expressing said TPO
receptor to react with the modified antibody and 3) to
measure TPO agonist action in the cells caused by
crosslinking TPO receptor.

The modified antibodies of the invention can be mono-
specific modified antibodies or multi-specific modified
antibodies like bi-specific modified antibodies.
Preferable are mono-specific modified antibodies.

In one embodiment, the H chain V region and/or L
chain V region is H chain V region derived from human
antibody and/or L chain V region derived from human
antibody. The H chain V region and/or L chain V region
derived from human antibody can be obtained by screening

- 12 -

human monoclonal antibody library as described in
WO99/10494. The H chain V region and L chain V region
derived from human monoclonal antibodies produced by
transgenic mouse and the like are also included.

In another embodiment, the H chain V regions and/or L
chain V regions are humanized H chain V regions and/or
humanized L chain V regions. Specifically, the humanized
modified antibodies consist of the humanized L chain V
region which comprises framework regions (FR) derived from
an L chain V region of human monoclonal antibody and
complementarity determining regions (hereinafter "CDR")
derived from an L chain V region of non-human mammalian
(e.g. mouse, rat, bovine, sheep, ape) monoclonal antibody
and/or the humanized H chain V region which comprises FR
derived from an H chain V region of human monoclonal
antibody and CDR derived from an H chain V region of non-
human mammalian (e.g. mouse, rat, bovine, sheep, ape)
monoclonal antibody. In this case, the amino acid
sequences of CDR and FR may be partially altered, e.g.
deleted, replaced or added.

H chain V regions and/or L chain V regions of the
modified antibodies of. the invention can be H chain V
regions and/or L chain V regions derived from monoclonal
antibodies of animals other than human (such as mouse,
rat, bovine, sheep, ape, chicken and the like) . In this
case, the amino acid sequence of CDR and FR may be
partially altered, e.g. deleted, replaced or added.

Described herein are DNAs encoding the various
modified antibodies as mentioned above and genetic
engineering techniques for producing recombinant vectors
comprising the DNAs.

Described herein are host cells transformed with the
recombinant vectors. Examples of host cells are animal

- 12a-

cells such as human cells, mouse cells or the like and
microorganisms such as E. coli , Bacillu subtilis , yeast or
the like.

Also described herein is a process for producing the
modified antibodies, which comprises culturing the above-
mentioned hosts and extracting the modified antibodies
from the culture thereof.

Also described herein is a process for producing a
dimer of the single chain Fv which comprises culturing
host animal cells producing the single chain Fv in a
serum-free medium to secrete the single chain Fv into the
medium and isolating the dimer of the single chain Fv
formed in the medium.

The present invention also relates to the use of the
modified antibodies as TPO agonist. That is, it relates
to a signal-transduction agonist which comprises as an
active ingredient the modified antibody obtained as
mentioned in the above .

Therefore, pharmaceutical preparations containing TPO
agonist modified antibodies of the invention as an active
ingredient are useful as preventatives and/or

remedies for platelet-reduction-related blood diseases,
thrombocytopenia caused by chemotherapy of cancers or
leukemia, and the like.

The modified antibodies of the present invention
comprise two or more H chain V regions and two or more L
chain V regions derived from antibodies. The structure of
the modified antibodies may be a dimer of single chain Fv
comprising one H chain V region and one L chain V region or
a polypeptide comprising two H chain V regions and two L
chain V regions. In the modified antibodies of the
invention, the V regions of H chain and L chain are
preferably linked through a peptide linker which consists o
one or more amino acids. The resulting modified antibodies
contain variable regions of antibodies and bind to the
antigen with the same specificity as that of the original
monoclonal antibodies.
H chain V region

In the present invention, the H chain V region
derived from an antibody recognizes TPO receptor and
oligomerizes, for example, dimerizes through crosslinking
said molecule, and thereby transduces a signal into the
cells. The H chain V region of the invention includes H
chain V regions derived from a mammal (e.g. human, mouse,
rat, bovine, sheep, ape etc.) and H chain V regions having
partially modified amino acid sequences of the H chain V
regions. More preferable is a humanized H chain V region
containing FR of H chain V region of a human monoclonal

14

antibody and CDR of H chain V region of a mouse monoclonal
antibody. Also preferable is an H chain V region having an
amino acid sequence derived from a human, which can be
produced by recombination technique. The H chain V region of
5 the invention may be a fragment of aforementioned H chain V

region, which fragment preserves the antigen binding
capacity.
L chain V region

In the present invention, the L chain V region

10 recognizes TPO receptor and oligomerizes, for example,

dimerizes through crosslinking said molecule, and thereby
transduces a signal into the cells. The L chain V region of
the invention includes L chain V regions derived from a
mammal (e.g. human, mouse, rat, bovine, sheep, ape etc.) and

15 L chain V regions having partially modified amino acid

sequences of the L chain V regions. More preferable is a
humanized L chain V region containing FR of L chain V region
of human monoclonal antibody and CDR of L chain V region of
mouse monoclonal antibodies. Also preferable is an L chain V

2 0 region having an amino acid sequence derived from a human,

which can be produced by recombination technique. The L
chain V regions of the invention may be fragments of L chain
V region, which fragments preserve the antigen binding
capacity.

25 Complementarity determining region (CDR)

Each V region of L chain and H chain forms an
antigen-binding site. The variable region of the L and H

15

chains is composed of comparatively conserved four common
framework regions linked to three hypervariable regions or
complementarity determining regions (CDR) (Kabat, E.A. et
al . , "Sequences of Protein of Immunological Interest", US
5 Dept. Health and Human Services, 1983) .

Major portions in the four framework regions (FRs)
form p-sheet structures and thus three CDRs form a loop.
CDRs may form a part of the p-sheet structure in certain
cases. The three CDRs are held sterically close position to

10 each other by FR, which contributes to the formation of the

antigen-binding site together with three CDRs.

These CDRs can be identified by comparing the
amino acid sequence of V region of the obtained antibody
with known amino acid sequences of V regions of known

15 antibodies according to the empirical rule in Kabat, E.A. et

al., "Sequences of Protein of Immunological Interest".
Single chain Fv

A single chain Fv is a polypeptide monomer
comprising an H chain V region and an L chain V region

20 linked each other which are derived from antibodies. The

resulting single chain Fvs contain variable regions of the
original antibodies and preserve the complementarity
determining region thereof, and therefore the single chain
Fvs bind to the antigen by the same specificity as that of

25 the original antibodies (JP-Appl. 11-63557) . A part of the

variable region and/or CDR of the single chain Fv of the
invention or a part of the amino acid sequence thereof may

16

be partially altered, for example, deleted, replaced or
added. The H chain V region and L chain V region composing
the single chain Fv of the invention are mentioned before
and may be linked directly or through a linker, preferably a
5 peptide linker. The constitution of the single chain Fv may

be [H chain V region] -[L chain V region] or [L chain V
region] - [H chain V region]. In the present invention, it is
possible to make the single chain Fv to form a dimer, a
trimer or a tetramer, from which the modified antibody of

10 the invention can be formed.

Single chain modified antibody

The single chain modified antibodies of the
present invention comprising two or more H chain V regions
and two or more L chain V regions, preferably each two to

15 four, especially preferable each two, comprise two or more.H

chain V regions and L chain V regions as mentioned above.
Each region of the peptide should be arranged such that the
modified single chain antibody forms a specific steric
structure, concretely mimicking a steric structure formed by

20 the dimer of single chain Fv. For instance, the V regions

are arranged in the order of the following manner:
[H chain V region] - [L chain V region] - [H chain V region] - [L
chain V region] ; or

[L chain V region] - [H chain V region] - [L chain V region] - [H
25 chain V region] ,

wherein these regions are connected through a peptide
linker, respectively.

17

Linker

In this invention, the linkers for the connection
between the H chain V region and the L chain V region may be
any peptide linker which can be introduced by the genetic
5 engineering procedure or any linker chemically synthesized.

For instance, linkers disclosed in literatures, e.g. Protein
Engineering, 9(3), 299-305, 1996 may be used in the
invention. These linkers can be the same or different in
the same molecule. If peptide linkers are required, the
10 following are cited as example linkers:

Ser

Gly-Ser

Gly-Gly-Ser

Ser-Gly-Gly
15 Gly-Gly-Gly-Ser

Ser-Gly-Gly-Gly

Gly-Gly-Gly-Gly-Ser

Ser-Gly-Gly-Gly-Gly

Gly-Gly-Gly-Gly-Gly-Ser
20 Ser-Gly-Gly-Gly-Gly-Gly

Gly-Gly-Gly-Gly-Gly-Gly-Ser

Ser-Gly-Gly-Gly-Gly-Gly-Gly

(Gly-Gly-Gly-Gly-Ser) n and

(Ser-Gly-Gly-Gly-Gly) n
25 wherein n is an integer not less than one . Preferable

length of the linker peptide varies dependent upon the
receptor to be the antigen, in the case of single chain Fvs,

18

the range of 1 to 20 amino acids is normally preferable. In
the case of single chain modified antibodies" comprising two
or more H chain V regions and two or more L chain V regions,
the peptide linkers connecting those forming the same
5 antigen binding site comprising [H chain V region]- (L chain

V region] (or [L chain V region] -[H chain V region]) have
lengths of 1 - 30 amino acids, preferably 1-20 amino
acids, more preferably 3-18 amino acids. The peptide
linkers connecting those not forming the same antigen biding

10 site comprising [H chain V region]-[L chain V region] or ( [L

chain V region] - [H chain V region]) have lengths of 1 - 40
amino acids, preferably 3-30 amino acids, more preferably
5-20 amino acids . The method for introducing those linkers
will be described in the explanation for DNA construction

15 coding for modified antibodies of the invention.

The chemically synthesized linkers, i.e. the
chemical crosslinking agents, according to the invention can
be any linkers conventionally employed for the linkage of
peptides. Examples of the linkers may include N-hydroxy

20 succinimide (NHS) , disuccinimidyl suberate (DSS) ,

bis (sulf osuccinimidyl ) suberate (BS 3 ) , dithiobis (succinimidyl
propionate) (DSP), dithiobis ( sulf osuccinimidyl propionate)
(DTSSP) , ethylene glycolbis ( succinimidyl succinate) (EGS) ,
ethylene glycolbis ( sulf osuccinimidyl succinate) (sulfo-EGS) ,

25 disuccinimidyl tartrate (DST) , disul f osuccinimidyl tartrate

(sulfo-DST) , bis [2- (succinimido oxycarbonyloxy) ethyl] sulfone
(BSOCOES) , bis [2- (sulfosuccinimido oxycarbonyloxy)

ethyl] sulfone (sulfo-BSOCOES) or the like. These are
commercially available. It is preferable for the chemically
synthesized linkers to have the length equivalent to that of
peptide linkers.

To form a dimer of the single chain Fv it is
preferable to select a linker suitable to dimerize in the
solution such as culture medium more than 20%, preferably
more than 50%, more preferably more than 80%, most
preferably more than 90% of the single chain Fv produced in
the host cells. Specifically, preferable is a linker
composed of 2 to 12 amino acids, preferably 3 to 10 amino
acids or other linkers corresponding thereto.
Preparation of modified antibodies

The modified antibodies can be produced by
connecting, through the aforementioned linker, an H chain V
region and an L chain V region derived from known or novel
antibodies specifically binding to TPO receptor. As examples
of the single chain Fvs are cited those having H chain V
region and L chain V region of antibody 12B5 and antibody
12E10 described in WO99/10494. As examples of the modified
antibodies of the invention having two or more H chain V
regions and two or more L chain V regions are cited scl2B5
dimer (linker: 15 amino acids), scl2E10 dimer (linker: 15
amino acids), dbl2B5 dimer (linker: 5 amino acids), dbl2E10
dimer (linker: 5 amino acids), scl2B5sc ( FV) 2 and
scl2E10sc ( FV) 2 which contain H chain V regions and L chain V

20

regions derived from the above-mentioned monoclonal
antibodies .

For the preparation of the modified antibodies, a
signal peptide may be attached to its N-terminal if the
5 polypeptide is desired to be a secretory peptide. A well-

known amino acid sequence useful for the purification of
polypeptide such as the FLAG sequence may be attached for
the efficient purification of the polypeptide. In this case
a dimer can be formed by using anti-FLAG antibody.

10 For the preparation of the modified antibody of

the invention, it is necessary to obtain a DNA, i.e. a DNA
encoding the single chain Fv or a DNA' encoding reconstructed
single chain polypeptide. These DNAs, especially for scl2B5,
dbl2B5, scl2E10 and/or dbl2E10 are obtainable from the DNAs

15 encoding the H chain V regions and the L chain V regions

derived from said Fvs . They are also obtainable by
polymerase chain reaction (PCR) method using those DNAs as a
template and amplifying the part of DNA contained therein
encoding desired amino acid sequence with the aid of a pair

20 of primers corresponding to both ends thereof.

In the case where each V region having partially
modified amino acid sequence is desired, the V regions in
which one or some amino acids are modified, i.e. deleted,
replaced or added can be obtained by a procedure known in

2 5 the art using PCR. A part of the amino acid sequence in the

V region is preferably modified by the PCR known in the art

21

in order to prepare the modified antibody which is
sufficiently active against the specific antigen.

For the determination of primers for the PCR
amplification, the types of H chain and L chain, if a
5 monoclonal antibody is used as a starting material, are

determined by a typing method known in the technical field.

For the amplification of the L chain V regions of
antibody 12B5 and antibody 12E10 by PCR, 5' -end and 3' -end
oligonucleotide primers are decided as aforementioned. In

10 the same manner, 5' -end and 3' -end oligonucleotide primers

are decided for the amplification of the H chain V regions
of antibody 12B5 and antibody 12E10.

In embodiments of the invention, the 5 ' -end
primers which contain a sequence "GANTC" providing the

15 restriction enzyme Hinf I recognition site at the

neighborhood of 5 '-terminal thereof are used and the 3 ' -end
primers which contain a nucleotide sequence "CCCGGG"
providing the Xmal recognition site at the neighborhood of
5' -terminal thereof are used. Other restriction enzyme

20 recognition site may be used instead of these sites as long

as they are used for subcloning a desired DNA fragment into
a cloning vector.

Specifically designed PCR primers are employed to
provide suitable nucleotide sequences at 5 '-end and 3 '-end

25 of the cDNAs encoding the V regions of the antibodies 12B5

and 12E10 so that the cDNAs are readily inserted into an
expression vector and appropriately function in the

22

expression vector (e.g. this invention devises to increase
transcription efficiency by inserting Kozak sequence) . The
V regions of the antibodies 12B5 and 12E10 obtained by
amplifying by PCR using these primers are inserted into HEF
5 expression vector containing the desired human C region (see

W092/197 59) . The cloned DNAs can be sequenced by using any
conventional process, for example, by the automatic DNA
sequencer (Applied Biosystems).

A linker such as a peptide linker can be

10 introduced into the modified antibody of the invention in

the following manner. Primers which have partially
complementary sequence with the primers for the H chain V
regions and the L chain V regions as described above and
which code for the NT-terminal or the C-terminal of the

15 linker are designed. Then, the PCR procedure can be carried

out using these primers to prepare a DNA encoding the
peptide linker having desired amino acid sequence and
length. The DNAs encoding the H chain V region and the L
chain V region can be connected through the resulting DNA to

20 produce the DNA encoding the modified antibody of the

invention which has the desired .peptide linker. Once the
DNA encoding one of the modified antibodies is prepared, the
DNAs encoding the modified antibodies with or without the
desired peptide linker can readily be produced by designing

25 various primers for the linker and then carrying out the PCR

using the primers and the aforementioned DNA as a template.

23

Each V region of the modified antibody of the
present invention can be humanized by using conventional
techniques (e.g. Sato, K. et al . , Cancer Res., 53, 1-6
(1993)) . Once a DNA encoding each of humanized Fvs is
5 prepared, a humanized single chain Fv, a fragment of the

humanized single chain Fv, a humanized monoclonal antibody
and a fragment of the humanized monoclonal antibody can
readily be produced according to conventional methods.
Preferably, amino acid sequences of the V regions thereof

10 may be partially modified, if necessary.

Furthermore, a DNA derived from other mammalian
origin, for example a DNA encoding each of V regions of
human antibody, can be produced in the same manner as used
to produce DNA encoding the H chain V region and the L chain

15 V region derived from mouse by conventional methods as

mentioned in the above. The resulting DNA can be used to
prepare an H chain V region and an L chain V region of other
mammal, especially derived from human antibody, a single
chain Fv derived from human and a fragment thereof, and a

20 monoclonal antibody of human origin and a fragment thereof.

When the modified antibodies of the invention is
bi-specific modified antibodies, they can be produced by
known methods (for example, the method described in
WO9413804) .

2 5 As mentioned above, when the aimed DNAs encoding

the V regions of the modified antibodies and the V regions
of the humanized modified antibodies are prepared, the

24

expression vectors containing them and hosts transformed
with the vectors can be obtained according to conventional
methods. Further, the hosts can be cultured according to a
conventional method to produce the reconstructed single
5 chain Fv, the reconstructed humanized single chain Fv, the

humanized monoclonal antibodies and fragments thereof. They
can be isolated from cells or a medium and can be purified
into a homogeneous mass. For this purpose any isolation and
purification methods conventionally used for proteins, e.g.

10 chromatography, ultra-filtration, salting-out and dialysis,

may be employed in combination, if necessary, without
limitation thereto.

When the reconstructed single chain Fv of the
present invention is produced by culturing an animal cell

15 such as COS7 cells or CHO cells, preferably CHO cells, in a

serum-free medium, the dimer of said single chain Fv formed
in the medium can be stably recovered and purified in a high
yield. Thus purified dimer can be stably preserved for a
long period. The serum-free medium employed in the invention

20 may be any medium conventionally used for the production of

a recombinant protein without limit thereto.

For the production of the modified antibodies of
the present invention, any expression systems can be
employed, for example, eukaryotic cells such as animal

25 cells, e.g., established mammalian cell lines, filamentous

fungi and yeast, and prokaryotic cells such as bacterial
cells e;g., E . coli . Preferably, the modified antibodies of

25

the invention are expressed in mammalian cells, for example
C0S7 cells or CHO cells.

In these cases, conventional promoters useful for
the expression in mammalian cells can be used. Preferably,
5 human cytomegalovirus (HCMV) immediate early promoter is

used. Expression vectors containing the HCMV promoter
include HCMV-VH-HCy 1, HCMV-VL-HCK and the like which are
derived from pSV2neo (W092/19759) .

Additionally, other promoters for gene expression

10 in mammal cell which may be used in the invention include

virus promoters derived form retrovirus, polyoma virus,
adenovirus and simian virus 40 (SV40) and promoters derived
from mammal such as human polypeptide-chain elongation
factor-lot (HEF-la) . SV4 0 promoter can easily be used

15 according to the method of Mulligan, R.C., et al . (Nature

277, 108-114 (1979)) and HEF-la promoter can also be used
according to the methods of Mizushima, S. et al. (Nucleic
Acids Research, 18, 5322 (1990)).

Replication origin (ori) which can be used in the

20 invention includes ori derived from SV40, polyoma virus,

adenovirus, bovine papilloma virus (BPV) and the like. An
expression vector may contain, as a selection marker,
phosphotransferase APH (3') II or I (neo) gene, thymidine
kinase (TK) gene, E. coli xanthine-guanine phosphoribosyl

25 transferase (Ecogpt) gene or dihydrof olate reductase (DHFR)

gene .

26

The antigen-binding activity of the modified
antibody prepared in the above can be evaluated by a
conventional method such as radio immunoassay (RIA) , enzyme-
linked immunosorbent assay (ELISA) or surface plasmon
5 resonance. It can also be evaluated using the binding-

inhibitory ability of original antibody as an index, for
example in terms of the absence or presence of
concentration-dependent inhibition of the binding of said
monoclonal antibody to the antigen.

10 More in detail, animal cells transformed with an

expression vector containing a DNA encoding the modified
antibody of the invention, e.g., COS7 cells or CHO cells,
are cultured. The cultured cells and/or the supernatant of
the medium or the modified antibody purified from them are

15 used to determine the binding to antigen. As a control is

used a supernatant of the culture medium in which cells
transformed only with the expression vector were cultured.
In the case of an antigen, for example, the antibody 12B5
and the antibody 12E10, a test sample of the modified

20 antibody of the invention or a supernatant of the control is

added to Ba/F3 cells expressing human MPL and then an assay
such as the flow cytometry is carried out to evaluate the
antigen-binding activity.

In vitro evaluation of the signal transduction

25 effect (for example, proliferation, differentiation-

induction or growth stimulation of megakaryocyte, platelet
production, or phosphorylation of TPO receptor protein) is

-27-

performed in the following manner. A test sample of the
above-mentioned modified antibody is added to the cells
which are expressing the antibody or cells into which the
gene for the antibody has been introduced, and is
evaluated by the change caused by the signal transduction
(for example, human MPL antigen-specific proliferation,
measurement of protein phosphorylation, or expression of
platelet-specific antigen) using conventional methods.

In vivo evaluation is carried out by
administering a monoclonal antibody recognizing MPL, a
modified antibody of the invention and PBS as control to
mice, and evaluating the strength of the activity by the
change of the amount of platelet in mouse serum.

As mentioned above the modified antibodies of
the invention can be obtained by preparing modified
antibodies which contain two or more H chain V regions and
two or more L chain V regions and specifically bind to TPO
receptor, wherein the modified antibody is: (i) a mul.timer
of single chain Fv comprising an H chain V region and an L
chain V region; or (ii) a single chain polypeptide
comprising two or more H chain V regions and two or more L
chain V regions and screening the modified antibodies by
in vivo or in vitro evaluation as mentioned in the above.

The modified antibodies of the invention, which
comprises two or more H chain V regions and two or more L
chain V regions, preferably each two to four, more
preferably each two, may be a dimer of the single chain Fv
comprising one H chain V region and one L chain V region,
or a single chain polypeptide in which two or more H chain
V regions and two or more L chain V regions are connected.
It is considered that owing to such construction the
peptide

28

mimics three dimensional structure of TPO and therefore
retains an excellent antigen-binding property and TPO
agonist activity.

The modified antibodies of the invention have a
5 remarkably lowered molecular size compared with parent

antibody molecule (e.g. IgG) , and, therefore, have a
superior permeability into tissues and tumors and a higher
activity than parent monoclonal antibody molecule.
Therefore, the modified antibodies of the invention^can

10 efficiently transduce TPO signal into cells. The

pharmaceutical preparations containing them are useful for
treating platelet-reduction-related blood diseases and
thrombocytopenia caused by chemotherapy for cancers or
leukemia. It is further expected that the antibody of the

15 invention can be used as a contrast agent by Rl-labeling.

The effect can be enhanced by attaching to a Rl-compound or
a toxin.

BEST MODE FOR WORKING THE INVENTION

20 The present invention will concretely be

illustrated in reference to the ..following examples, which in
no way limit the scope of the invention.

For illustrating the production process of the
modified antibodies of the invention, examples of producing

25 single chain Fvs are shown below. Mouse antibodies against

human IAP, MABL-1 and MABL-2 were used in the examples of
producing the modified antibodies. Hybridomas MABL-1 and

29

MABL-2 producing them respectively were internationally
deposited as FERM BP-6100 and FERM BP-6101 with the National
Institute of Bioscience and Human Technology, Agency of
Industrial Science and Technology, Minister of International
5 Trade and Industry (1-3 Higasi 1-chome, Tsukuba-shi,

Ibaraki-ken, Japan) , an authorized depository for
microorganisms, on September 11, 1997.
Examples

Example 1 (Cloning of DNAs encoding V region of mouse
10 monoclonal antibodies to human IAP)

DNAs encoding variable regions of the mouse
monoclonal antibodies to human IAP, MABL-1 and MABL-2, were
cloned as follows.

1.1 Preparation of messenger RNA (mRNA)

15 mRNAs of the hybridomas MABL-1 and MABL-2 were

obtained by using mRNA Purification Kit (Pharmacia Biotech) .

1.2 Synthesis of double-stranded cDNA

Double-stranded cDNA was synthesized from about 1
ug of the mRNA using Marathon cDNA Amplification Kit
20 (CLONTECH) and an adapter was linked thereto.

1.3 PCR Amplification of genes encoding variable regions of
an antibody by

PCR was carried out using Thermal Cycler (PERKIN

ELMER) .

2 5 (1) Amplification of a gene coding for L chain V region of

MABL-1

30

Primers used for the PCR method are Adapter
Primer-1 (CLONTECH) shown in SEQ ID No. 1, which hybridizes
to a partial sequence of the adapter, and MKC (Mouse Kappa
Constant) primer (Bio/Technology, 9, 88-89, 1991) shown in
5 SEQ ID No. 2, which hybridizes to the mouse kappa type L

chain V region.

50 ul of the PCR solution contains 5 \il of 10 x
PCR Buffer II, 2 mM MgCl 2 , 0.16 mM dNTPs (dATP, dGTP, dCTP
and dTTP) , 2.5 units of a DNA polymerase, AmpliTaq Gold

10 (PERKIN ELMER), 0.2 uM of the adapter primer of SEQ ID No.

1, 0.2 uM of the MKC primer of SEQ ID No . 2 and 0.1 |a.g of
the double-stranded cDNA derived from MABL-1. The solution
was preheated at 94°C of the initial temperature for 9
minutes and then heated at 94°C for 1 minute, at 60°C for 1

15 minute and at 72°C for 1 minute 20 seconds in order. This

temperature cycle was repeated 35 times and then the
reaction mixture was further heated at 72°C for 10 minutes.
(2) Amplification of cDNA encoding H chain V region of MABL-
1

20 The Adapter Primer-1 shown in SEQ ID No. 1 and

MHC-yl (Mouse Heavy Constant) primer (Bio/Technology, 9, 88-
89, 1991) shown in SEQ ID No. 3 were used as primers for
PCR.

The amplification of cDNA was performed according
25 to the method of the amplification of the L chain V region

gene, which was described in Example 1.3- (1), except for

using 0.2 |oM of the MHC-yl primer instead of 0.2 |oM of the
MKC primer.

[3) Amplification of cDNA encoding L chain V region of MABL-
2

5 The Adapter Primer-1 of SEQ ID No. 1 and the MKC

primer of SEQ ID No. 2 were used as primers for PCR.

The amplification of cDNA was carried out
according to the method of the amplification of the L chain
V region gene of MABL-1 which was described in Example 1.3-
10 except for using 0.1 ug of the double-stranded cDNA

derived from MABL-2 instead of 0.1 ug. of the double-stranded
cDNA from MABL-1.

(4) Amplification of cDNA encoding H chain V region of MABL-
2

15 The Adapter Primer-1 of SEQ ID No. 1 and MHC-y2a -

primer (Bio/Technology, 9, 88-89, 1991) shown in SEQ ID No.
4 were used as primers for PCR.

The amplification of cDNA was performed according
to the method of the amplification of the L chain V region

20 gene, which was described in Example 1.3- (3), except for

using 0.2 uM of the MHC-y2a primer instead of 0.2 uM of the
MKC primer.

1.4 Purification of PCR products

The DNA fragment amplified by PCR as described
25 above was purified using the QIAquick PCR Purification Kit

(QIAGEN) and dissolved in 10 mM Tris-HCl (pH 8.0) containing
1 mM EDTA.

32

1.5 Ligation and Transformation

About 140 ng of the DNA fragment comprising the
gene encoding the mouse kappa type L chain V region derived
from MABL-1 as prepared above was ligated with 50 ng of
5 pGEM-T Easy vector (Promega) in the reaction buffer

comprising 30 mM Tris-HCl (pH 7.8), 10 mM MgCl 2 , 10 mM
dithiothreitol, 1 mM ATP and 3 units of T4 DNA Ligase
(Promega) at 15°C for 3 hours.

Then, 1 ul of the reaction mixture was added to 50

10 |il of coli DH5a competent cells (Toyobo Inc.) and the

cells were stored on ice for 30 minutes, incubated at 42°C
for 1 minute and stored on ice for 2 minutes again. 100
of SOC medium (GIBCO BRL) was added. The cells of E_;_ coli
were plated on LB (Molecular Cloning: A Laboratory Manual,

15 Sambrook et al., Cold Spring Harbor Laboratory Press, 1989)

agar medium containing 100 ug/ml of ampicillin (SIGMA) and
cultured at 37°C overnight to obtain the transformant of E .
coli .

The transformant was cultured in 3 ml of LB medium

20 containing 50 u.g/ml of ampicillin at 37°C overnight and the

plasmid DNA was prepared from the culture using the QIAprep
Spin Miniprep Kit (QIAGEN) .

The resulting plasmid comprising the gene encoding
the mouse kappa type L chain V region derived from the
25 hybridoma MABL-1 was designated as pGEM-MlL.

According to the same manner as described above, a
plasmid comprising the gene encoding the mouse H chain v

33

region derived from the hybridoma MABL-1 was prepared from
the purified DNA fragment and designated as pGEM-MlH .

A plasmid comprising the gene encoding the mouse
kappa type L chain V region derived from the hybridoma MABL-
5 2 was prepared from the purified DNA fragment and designated

as pGEM-M2L.

A plasmid comprising the gene encoding the mouse H
chain V region derived from the hybridoma MABL-2 was
prepared from, the purified DNA fragment and designated as
10 pGEM-M2H .

Example 2 (DNA Sequencing)

The nucleotide sequence of the cDNA encoding
region in the aforementioned plasmids was determined using
15 Auto DNA Sequencer (Applied Biosystem) and ABI PRISM Dye

Terminator Cycle Sequencing Ready Reaction Kit (Applied
Biosystem) according to the manufacturer's protocol.

The nucleotide sequence of the gene encoding the L
chain V region from the mouse antibody MABL-1, which is
20 included in the plasmid pGEM-MIL, is shown in SEQ ID No. 5.

The nucleotide sequence of the gene encoding the H
chain V region from the mouse antibody MABL-1, which is
included in the plasmid pGEM-MlH, is shown in SEQ ID No. 6.

The nucleotide sequence of the gene encoding the L
25 chain V region from the mouse antibody MABL-2, which is

included in the plasmid pGEM-M2L, is shown in SEQ ID No. 7.

34

The nucleotide sequence of the gene encoding the H
chain V region from the mouse antibody MABL-2, which is
included in the plasmid pGEM-M2H, is shown in SEQ ID No. 8.

5 Example 3 (Determination of CDR)

The V regions of L chain and H chain generally
have a similarity in their structures and each four
framework regions therein are linked by three hypervar iable
regions, i.e., complementarity determining regions (CDR). An

10 amino acid sequence of the framework is relatively well

conserved, while an amino acid sequence of CDR has extremely
high variation (Kabat, E.A., et al . , "Sequences of Proteins
of Immunological Interest", US Dept. Health and Human
Services, 1983) .

15 On the basis of these facts, the amino acid

sequences of the variable regions from the mouse monoclonal
antibodies to human IAP were applied to the database of
amino acid sequences of the antibodies made by Kabat et al .
to investigate the homology. The CDR regions were determined

20 based on the homology as shown in Table 1.

Table 1

Plasmid SEQ ID No. CDR ( 1 ) CDR (2) CDR (3)

pGEM-MIL 5 43-58 74-80 113-121

25 pGEM-MlH 6 50-54 69-85 118-125

PGEM-M2L 7 43-58 74-80 113-121

35

pGEM-M2H 8 50-54 69-85 118-125

Example 4 (Identification of Cloned cDNA Expression
(Preparation of Chimera MABL-1 antibody and Chimera MABL-2
5 antibody . )

4.1 Preparation of vectors expressing chimera MABL-1
antibody

cDNA clones, pGEM-MIL and pGEM-MlH, encoding the V
regions of the L chain and the H chain of the mouse antibody

10 MABL-1, respectively, were modified by the PCR method and

introduced into the HEF expression vector (W092/19759) to
prepare vectors expressing chimera MABL-1 antibody.

A forward primer MLS (SEQ ID No. 9) for the L
chain V region and a forward primer MHS (SEQ ID No. 10) for

15 the H chain V region were designed to hybridize to a DNA

encoding the beginning of the leader sequence of each V
region and to contain the Kozak consensus sequence (J. Mol.
Biol., 196, 947-950, 1987) and 'Hindi I I restriction enzyme
site. A reverse primer MLAS (SEQ ID No. 11) for the L chain

20 V region and a reverse primer MHAS (SEQ ID No. 12) for the H

chain V region were designed to ..hybridize to a DNA encoding
the end of the J region and to contain the splice donor
sequence and BamHI restriction enzyme site.

100 \xl of a PCR solution comprising 10 ul of 10 x

25 PCR Buffer II, 2 mM MgCl 2 , 0.16 mM dNTPs (dATP, dGTP, dCTP

and dTTP), 5 units of DNA polymerase AmpliTaq Gold, 0.4 |iM
each of primers and 8 ng of the template DNA (pGEM-Ml L or

36

pGEM-MlH) was preheated at 94°C of the initial temperature
for 9 minutes and then heated at 94°C for 1 minute, at 60°C
for 1 minute and at 72°C for 1 minute 20 seconds in order.
This temperature cycle was repeated 35 times and then the
5 reaction mixture was further heated at 72°C for 10 minutes.

The PCR product was purified using the QIAquick
PCR Purification Kit (QIAGEN) and then digested with Hindi I I
and BamHI . The product from the L chain V region was cloned
into the HEF expression vector, HEF— k. and the product from
10 the H chain V region was cloned into the HEF expression

vector, HEF-y. After DNA sequencing, plasmids containing a
DNA fragment with a correct DNA sequence are designated as
HEF-M1L and HEF-M1H, respectively.

4.2 Preparation of vectors expressing chimera MABL-2
1 5 antibodies

Modification and cloning of cDNA were performed in
the same manner described in Example 4.1 except for using
pGEM-M2L and pGEM-M2H as template DNA instead of pGEM-MIL
and pGEM-MlH. After DNA sequencing, plasmids containing DNA
20 fragments with correct DNA sequences are designated as HEF-

M2L and HEF-M2H, respectively.

4.3 Transfection to COS7 cells

The aforementioned expression vectors were tested
in COS7 cells to observe the transient expression of the
25 chimera MABL-1 and MABL-2 antibodies.

( 1 ) Transfection with genes for the chimera MABL-1 antibody

37

C0S7 cells were co-transformed with the HEF-M1L
and HEF-M1H vectors by electroporation using the Gene Pulser
apparatus (BioRad) . Each DNA (10 \ig) and 0.8 ml of PBS with
1 x 10 7 cells/ml were added to a cuvette. The mixture was
5 treated with pulse at 1.5 kV, 25 jiF of electric capacity.

After the restoration for 10 minutes at a room
temperature, the electroporated cells were transferred into
DMEM culture medium (GIBCO BRL) containing 10% y- globulin-
free fetal bovine serum. After culturing for 72 hours, the
10 supernatant was collected, centrifuged to remove cell

fragments and recovered.

(2) Transfection with genes coding for the chimera MABL-2
antibody

The co-transf ection to COS7 cells with the genes
15 coding for the chimera MABL-2 antibody was carried out in

the same manner as described in Example 4.3- (1) except for
using the HEF-M2L and HEF-M2H vectors instead of the HEF-M1L
and HEF-M1H vectors . The supernatant was recovered in the
same manner.
2 0 4.4 Flow cy tometry

Flow cytometry was performed using the
aforementioned culture supernatant of COS7 cells to measure
binding to the antigen. The culture supernatant of the COS7
cells expressing the chimera MABL-1 antibody or the COS7
25 cells expressing the chimera MABL-2 antibody, or human IgG

antibody (SIGMA) as a control was added to 4 x 10 s cells of
mouse leukemia cell line L1210 expressing human IAP and

38

incubated on ice. After washing, the FITC-labeled anti-human
IgG antibody (Cappel) was added thereto. After incubating
and washing, the fluorescence intensity thereof was measured
using the FACScan apparatus (BECTON DICKINSON) .
5 Since the chimera MABL-1 and MABL-2 antibodies

were specifically bound to L1210 cells expressing human IAP,
it is confirmed that these chimera antibodies have proper
structures of the V regions of the mouse monoclonal
antibodies MABL-1 and MABL-2, respectively (Figs. 1-3).

10

Example 5 (Preparation of reconstructed Single chain Fv

(scFv) of the antibody MABL-1 and antibody MABL-2)

5.1 Preparation of reconstructed single chain Fv of antibody

MABL-1

15 The reconstructed single chain Fv of antibody

MABL-1 was prepared as follows. The H chain V region and the
L chain V of antibody MABL-1 , and a linker were respectively
amplified by the PCR method and were connected to produce
the reconstructed single chain Fv of antibody MABL-1. The

20 production method is illustrated in Fig. 4. Six primers (A-

F) were employed for the production of the single chain Fv
of antibody MABL-1. Primers A, C and E have a sense sequence
and primers B, D and F have an antisense sequence.

The forward primer VHS for the H chain V region

25 (Primer A, SEQ ID No. 13) was designed to hybridize to a DNA

encoding the N-terminal of the H chain V region and to
contain Ncol restriction enzyme recognition site. The

39

reverse primer VHAS for H chain V region (Primer B, SEQ ID
No. 14) was designed to hybridize to a DNA coding the C-
terminal of the H chain V region and to overlap with the
linker .

5 The forward primer LS for the linker (Primer C,

SEQ ID No. 15) was designed to hybridize to a DNA encoding
the N-terminal of the linker and to overlap with a DNA
encoding the C-terminal of the H chain V region. The reverse
primer LAS for the linker (Primer D, SEQ ID No. 16) was

10 designed to hybridize to a DNA encoding the C-terminal of

the linker and to overlap with a DNA encoding the N-terminal
of the L chain V region.

The forward primer VLS for the L chain V region
(Primer E, SEQ ID No. 17) was designed to hybridize to a DNA

15 encoding the C-terminal of the linker and to overlap with a

DNA encoding the N-terminal of the L chain V region. The
reverse primer VLAS-FLAG for L chain V region (Primer F, SEQ
ID No. 18) was designed to hybridize to a DNA encoding the
C-terminal of the L chain V region and to have a sequence

20 encoding the FLAG peptide (Hopp. T. P. et al.,

Bio/Technology, 6, 1204-1210, 1988) , two stop codons and
EcoRI restriction enzyme recognition site.

In the first PCR' step, three reactions, A-B, C-D
and E-F, were carried out and PCR products thereof were

25 purified. Three PCR products obtained from the first PCR

step were assembled by their complementarity. Then, the
primers A and F were added and the full length DNA encoding

40

the reconstructed single chain Fv of antibody MABL-1 was
amplified (Second PCR) . In the first PCR, the plasmid pGEM-
M1H encoding the H chain V region of antibody MABL-1 (see
Example 2) , a plasmid pSC-DPl which comprises a DNA sequence
5 encoding a linker region comprising: Gly Gly Gly Gly Ser Gly

Gly Gly Gly Ser Gly Gly Gly Gly Ser (SEQ ID No. 19) (Huston,
J.S., et al., Proc. Natl. Acad. Sci . USA, 85, 5879-5883,
1988) and the plasmid pGEM-MIL encoding the L chain V region
of antibody MABL-1 (see Example 2) were employed as

10 template, respectively.

50 ul of the solution for the first PCR step
comprises 5 ul of 10 x PCR Buffer II, 2 mM MgCl 2 , 0.16 mM
dNTPs, 2.5 units of DNA polymerase, AmpliTaq Gold (PERK IN
ELMER), 0.4 uM each of primers and 5 ng each of template

15 DNA. The PCR solution was preheated at 94°C of the initial

temperature for 9 minutes and then heated at 94°C for 1
minute, at 65°C for 1 minute and at 72°C for 1 minute and 2 0
seconds in order. This temperature cycle was repeated 35
times and then the reaction mixture was further heated at

20 72°C for 7 minutes.

The PCR products A-B (371bp), C-D (63bp) and E-F
(384bp) were purified using the QIAquick PCR Purification
Kit (QIAGEN) and were assembled in the second PCR. In the
second PCR, 98 ul of a PCR solution comprising 120 ng of the

25 first PCR product A-B, 20 ng of the PCR product C-D and 120

ng of the PCR product E-F, 10 ul of 10 x PCR Buffer II, 2mM
MgCl2, 0.16 mM dNTPs, 5 units of DNA polymerase AmpliTaq

41

Gold (PERKIN ELMER) was preheated at 94°C of the initial
temperature for 8 minutes and then heated at 94°C for 2
minutes, at 65°C for 2 minutes and at 72°C for 2 minutes in
order. This temperature cycle was repeated twice and then
5 0.4 (jM each of primers A and F were added into the reaction,

respectively. The mixture was preheated at 94°C of the
initial temperature for 1 minutes and then heated at 94°C
for 1 minute, at 65°c for 1 minute and at 72°C for 1 minute
and 20 seconds in order. This temperature cycle was repeated

10 35 times and then the reaction mixture was further heated at

72°C for 7 minutes.

A DNA fragment of 843 bp produced by the second
PCR was purified and digested by Ncol and EcoRI . The
resultant DNA fragment was cloned into pSCFVT7 vector. The

15 expression vector pSCFVT7 contains a pelB signal sequence

suitable for coli periplasmic expression system (Lei,
S.P., et al., J. Bacteriology, 169, 4379-4383, 1987). After
the DNA sequencing, the plasmid containing the DNA fragment
encoding correct amino acid sequence of the reconstructed

20 single chain Fv of antibody MABL-1 is designated as "pscMl"

(see Fig. 5) . The nucleotide sequence and the amino acid
sequence of the reconstructed single chain Fv of antibody
MABL-1 contained in the plasmid pscMl are shown in SEQ ID
No. 20.

2 5 The pscMl vector was modified by the PCR method to

prepare a vector expressing the reconstructed single chain
Fv of antibody MABL-1 in mammalian cells. The resultant DNA

42

fragment was introduced into pCHOl expression vector. This
expression vector, pCHOl, was constructed by digesting DHFR-
AE-rvH-PMl-f (W092/19759) with EcoRI and Smal to eliminate
the antibody gene and connecting the EcoRI-Notl-BamHI
Adapter (Takara Shuzo) thereto.

As a forward primer for PCR, Sal-VHS primer shown
in SEQ ID No. 21 was designed to hybridize to a DNA encoding
the N-terminal of the H chain V region and to contain Sail
restriction enzyme recognition site. As a reverse primer for
PCR, FRHlanti primer shown in SEQ ID No. 22 was designed to
hybridize to a DNA encoding the end of the first framework
sequence .

100 \il of PCR solution comprising 10 ul of 10 x
PCR Buffer II, 2 mM MgCl 2 , 0.16 mM dNTPs, 5 units of the DNA
polymerase, AmpliTaq Gold, 0.4 (4.1 M each of primer and 8 ng
of the template DNA (pscMl) was preheated at 95°C of the
initial temperature for 9 minutes and then heated at 95°C
for 1 minute, at 60°C for 1 minute and at 72°C for 1 minute
and 20 seconds in order. This temperature cycle was repeated
35 times and then the reaction mixture was further heated at
72°C for 7 minutes.

The PCR product was purified using the QIAquick
PCR Purification Kit (QIAGEN) and digested by Sail and MboII
to obtain a DNA fragment encoding the N-terminal of the
reconstructed single chain Fv of antibody MABL-1 The pscMl
vector was digested by MboII and EcoRI to obtain a DNA
fragment encoding the C-terminal of the reconstructed single

43

chain Fv of antibody MABL-1. The Sall-MboII DNA fragment and
the Mboll-EcoRl DNA fragment were cloned into pCHOl-Igs
vector. After DNA sequencing, the plasmid comprising the
desired DNA sequence was designated as "pCHOMl" (see Fig.
5 6) . The expression vector, pCHOl-Igs, contains a mouse IgGl

signal sequence suitable for the secretion-expression system
in mammalian cells (Nature, 322, 323-327, 1988) . The
nucleotide sequence and the amino acid sequence of the
reconstructed single chain Fv of antibody MABL-1 contained

10 in the plasmid pCHOMl are shown in SEQ ID No. 23.

5.2 Preparation of reconstructed single chain Fv of
antibody MABL-2

The reconstructed single chain Fv of antibody
MABL-2 was prepared in accordance with the aforementioned

15 Example 5.1. Employed in the first PCR step were plasmid

pGEM-M2H encoding the H chain V region of MABL-2 (see
Example 2) instead of pGEM-MlH and plasmid pGEM-M2L encoding
the L chain V region of MABL-2 (see Example 2) instead of
pGEM-MIL, to obtain a plasmid pscM2 which comprises a DNA

2 0 fragment encoding the desired amino acid sequence of the

single chain Fv of antibody MABL-2. The nucleotide sequence
and the amino acid sequence of the reconstructed single
chain Fv of antibody MABL-2 contained in the plasmid pscM2
are shown in SEQ ID No. 24.

2 5 The pscM2 vector was modified by the PCR method to

prepare a vector, pCHOM2, for the expression in mammalian
cells which contains the DNA fragment encoding the correct

44

amino acid sequence of reconstructed the single chain Fv, of
antibody MABL-2. The nucleotide sequence and the amino acid
sequence of the reconstructed single chain Fv of antibody
MABL-2 contained in the plasmid pCH0M2 are shown in SEQ ID
5 No . 2 5 .

5.3 Transfection to C0S7 cells

The pCH0M2 vector was tested in COS7 cells to
observe the transient expression of the reconstructed single
chain Fv of antibody MABL-2.
10 The C0S7 cells were transformed with the pCHOM2

vector by electroporation using the Gene Pulser apparatus

(BioRad) . The DNA (10 ug) and 0.8 ml of PBS with 1 x 10 7
cells/ml were added to a cuvette. The mixture was treated
with pulse at 1.5 kV, 25 (jF of electric capacity.

15 After the restoration for 10 minutes at a room

temperature, the electroporated cells were transferred into
IMDM culture medium (GIBCO BRL) containing 10% fetal bovine
serum. After culturing for 72 hours, the supernatant was
collected, centrifuged to remove cell fragments and

20 recovered.

5.4 Detection of the reconstructed single chain Fv of
antibody MABL-2 in culture supernatant of COS7 cells

The existence of the single chain Fv of antibody
MABL-2 in the culture supernatant of C0S7 cells which had
25 been transfected with the pCHOM2 vector was confirmed by the

Western Blotting method.

45

The culture supernatant of C0S7 cells transfected
with the pCH0M2 vector and the culture supernatant of C0S7
cells transfected with the pCHOl as a control were subjected
to SDS electrophoresis and transferred to REINFORCED NC
5 membrane (Schleicher & Schuell) . The membrane was blocked

with 5% skim milk (Morinaga Nyu-gyo), washed with 0.05%
Tween 20-PBS and mixed with an anti-FLAG antibody (SIGMA) .
The membrane was incubated at room temperature, washed and
mixed with alkaline phosphatase-conjugated mouse IgG

10 antibody (Zymed) . After incubating and washing at room

temperature, the substrate solution (Kirkegaard Perry
Laboratories) was added to develop color (Fig. 7).

A FLAG-peptide-specif ic protein was detected only
in the culture supernatant of the pCHOM2 vector-introduced

15 COS7 cells and thus it is confirmed that the reconstructed

single chain Fv of antibody MABL-2 was secreted in this
culture supernatant.
5.5 Flow cytometry

Flow cytometry was performed using the

20 aforementioned COS7 cells culture supernatant to measure the

binding to the antigen. The culture supernatant of the COS7
cells expressing the reconstructed single chain Fv of
antibody MABL-2 or the culture supernatant of COS7 cells
transformed with pCHOl vector as a control was added to 2 x

25 10 s cells of the mouse leukemia cell line L1210 expressing

human Integrin Associated Protein (IAP) or the cell line
L1210 transformed with pCOSl as a control. After incubating

46

on ice and washing, the mouse anti-FLAG antibody (SIGMA) was
added. Then the cells were incubated and washed. Then, the
FITC labeled anti-mouse IgG antibody (BECTON DICKINSON) was
added thereto and the cells were incubated and washed again.
5 Subsequently, the fluorescence intensity was measured using

the FACScan apparatus (BECTON DICKINSON) .

Since the single chain Fv of antibody MABL-2 was
specifically bound to L1210 cells expressing human IAP, it
is confirmed that the reconstructed single chain Fv of
10 antibody MABL-2 has an affinity to human Integrin Associated

Protein (IAP) (see Figs. 8-11).
5.6 Competitive ELISA

The binding activity of the reconstructed single
chain Fv of antibody MABL-2 was measured based on the
15 inhibiting activity against the binding of mouse monoclonal

antibodies to the antigen.

The anti-FLAG antibody adjusted to 1 |i.g/ml was
added to each well on 96-well plate and incubated at 37°c
for 2 hours. After washing, blocking was performed with 1%
20 BSA-PBS. After incubating and washing at a room temperature,

the culture supernatant of C0S7 cells into which the
secretion-type human IAP antigen gene (SEQ ID No. 26) had
been introduced was diluted with PBS into twofold volume and
added to each well. After incubating and washing at a room
25 temperature, a mixture of 50 ul of the biotinized MABL-2

antibody adjusted to 100 ng/ml and 50 ul of sequentially
diluted supernatant of the C0S7 cells expressing the

47

reconstructed single chain Fv of antibody MABL-2 were added
into each well. After incubating and washing at a room
temperature, the alkaline phosphatase-conjugated
streptoavidin (Zymed) was added into each well. After
5 incubating and washing at a room temperature, the substrate

solution (SIGMA) was added and absorbance of the reaction
mixture in each well was measured at 405 nm.

The results revealed that the reconstructed single
chain Fv of antibody MABL-2 (MABL2-scFv) evidently inhibited

10 concentration-dependently the binding of the mouse antibody

MABL-2 to human IAP antigen in comparison with the culture
supernatant of the PCHOl-introduced COS7 cells as a control
(Fig. 12) . Accordingly, it is suggested that the
reconstructed single chain Fv of antibody MABL-2 has the

15 correct structure of each of the V regions from the mouse

monoclonal antibody MABL-2.
5.7 Apoptosis-inducing Effect in vitro

An apoptosis-inducing action of the reconstructed
single chain Fv of antibody MABL-2 was examined by Annexin-V

20 staining (Boehringer Mannheim) using the L1210 cells

transfected with human IAP gene, the L1210 cells transfected
with the pCOSl vector as a control and CCRF-CEM cells.

To each 1 x 10 s cells of the above cells was added
the culture supernatant of the COS7 cells expressing the

25 reconstructed single chain Fv of antibody MABL-2 or the

culture supernatant of COS7 cells transfected with the pCHOl
vector as a control at 50% final concentration and the

48

mixtures were cultured for 24 hours. Then, the Annexin-V
staining was performed and the fluorescence intensity was
measured using the FACScan apparatus (BECTON DICKINSON) .

Results of the Annexin-V staining are shown in
Figs. 13-18, respectively. Dots in the left-lower region
represent living cells and dots in the right-lower region
represent cells at the early stage of apoptosis and dots in
the right-upper region represent cells at the late stage of
apoptosis. The results show that the reconstructed single
chain Fv of antibody MABL-2 (MABL2-scFv) remarkably induced
cell death of L1210 cells specific to human IAP antigen
(Figs. 13-16) and that the reconstructed single chain Fv
also induced remarkable cell death of CCRF-CEM cells in
comparison with the control (Figs. 17-18).
5.8 Expression of MABL-2 derived single chain Fv in CHO
cells

CHO cells were transfected with the pCH0M2 vector
to establish a CHO cell line which constantly expresses the
single chain Fv (polypeptide) derived from the antibody
MABL-2 .

CHO cells were transformed with the pCH0M2 vector
by the electroporation using the Gene Pulser apparatus
(BioRad) . A mixture of DNA (10 ^g) and 0.7 ml of PBS with
CHO cells (1 x 10 7 cells/ml) was added to a cuvette. The
mixture was treated with pulse at 1.5 kV, 25 ^F of electric
capacity. After the restoration for 10 minutes at a room
temperature, the electroporated cells were transferred into

49

nucleic acid free ct-MEM medium (GIBCO. BRL) containing 10%
fetal bovine serum and cultured. The expression of desired
protein in the resultant clones was confirmed by SDS-PAGE
and a clone with a high expression level was selected as a
5 cell line producing the single chain Fv derived from the

antibody MABL-2 . The cell line was cultured in serum-free
medium CHO-S-SFM II (GIBCO BRL) containing 10 nM
methotrexate (SIGMA) . Then, the culture supernatant was
collected, centrifuged to remove cell fragments and

10 recovered.

5.9 Purification of MABL-2 derived single chain Fv produced
in CHO cells

The culture supernatant of the CHO cell line
expressing the single chain Fv obtained in Example 5.8 was

15 concentrated up to twenty times using a cartridge for the

artificial dialysis (PAN130SF, AS AH I MEDICALS) . The

concentrated solution was stored at -20°C and thawed on
purification.

Purification of the single chain Fv from the
20 culture supernatant of the CHO cells was performed using

three kinds of chromatography, i.e., Blue-sepharose, a
hydroxyapatite and a gel filtration.
( 1 ) Blue-sepharose column chromatography

The concentrated supernatant was diluted to ten
25 times with 20 mM acetate buffer (pH 6.0) and centrifuged to

remove insoluble materials (10000 x rpm, 30 minutes) . The
supernatant was applied onto a Blue-sepharose column (20 ml)

50

equilibrated with the same buffer. After washing the column
with the same buffer, proteins adsorbed in the column were
eluted by a stepwise gradient of NaCl in the same buffer,
0.1, 0.2, 0.3, 0.5 and up to 1.0 M. The pass-through
5 fraction and each eluted fraction were analyzed by SDS-PAGE.

The fractions in which the single chain Fv were confirmed
(the fractions eluted at 0.1 to 0.3M NaCl) were pooled and
concentrated up to approximately 20 times using CentriPrep-
10 (AMICON) .

10 (2) Hydroxyapatite

The concentrated solution obtained in (1) was
diluted to 10 times with 10 mM phosphate buffer (pH 7.0) and
applied onto the hydroxyapatite column (20 ml, BIORAD) . The
column was washed with 60 ml of 10 mM phosphate buffer (pH

15 7.0) . Then, proteins adsorbed in the column were eluted by a

linear gradient of sodium phosphate buffer up to 200 mM (see
Fig. 19) . The analysis of each fraction by SDS-PAGE
confirmed the single chain Fv in fraction A and fraction B.
(3) Gel filtration

20 Each of fractions A and B in (2) was separately

concentrated with CentriPrep-10 and applied onto TSKgel
G3000SWG column (21.5 x 600 mm) equilibrated with 20 mM
acetate buffer (pH 6.0) containing 0.15 M NaCl.
Chromatograms are shown in Fig. 20. The analysis of the

2 5 fractions by SDS-PAGE confirmed that both major peaks (AI

and BI) are of desired single chain Fv. In the gel
filtration analysis, the fraction A was eluted at 36 kDa of

51

^ apparent molecular weight and the fraction B was eluted at

O

O 76 kDa. The purified single chain Fvs (AI, BI) were analyzed

03

o

with 15% SDS polyacrylamide gel. Samples were treated in the
absence or presence of a reductant and the electrophoresis

O

r— i 5 was carried out in accordance with the Laemmli's method.

Then the protein was stained with Coomassie Brilliant Blue.

As shown in Fig. 21, both AI and BI gave a single band at 35

kDa of apparent molecular weight, regardless of the absence

CN or presence of the reductant. From the above, it is

O

^ LO concluded that AI is a monomer of the single chain Fv and BI

is a non-covalently bound dimer of the single chain Fv. The
gel filtration analysis of the fractions AI and BI with
TSKgel G3000SW column (7.5 x 60 mm) revealed that a. peak of
the monomer is detected only in the fraction AI and a peak
15 of the dimer is detected only in the fraction BI (Fig. 22).

The dimer fraction (fraction BI) accounted for 4 percent
(%) of total single chain Fvs. More than 90% of the dimer
in the dimer fraction was stably preserved for more than a
month at 4°C.

20 5.10 Construction of vector expressing single chain Fv

derived from antibody MABL-2 in E. coli cell

The pscM2 vector was modified by the PCR method to
prepare a vector effectively expressing the single chain Fv
from the antibody MABL-2 in E_;_ coli cells. The resultant DNA
25 fragment was introduced into pSCFVT7 expression vector.

As a forward primer for PCR, Nde-VHSm02 primer
shown in SEQ ID No. 27 was designed to hybridize to a DNA

52

encoding the N-terminal of the H chain V region and to
contain a start codon and Ndel restriction enzyme
recognition site. As a reverse primer for PCR, VLAS primer
shown in SEQ ID No. 28 was designed to hybridize to a DNA
5 encoding the C-terminal of the L chain V region and to

contain two stop codons and EcoRI restriction enzyme
recognition site. The forward primer, Nde-VHSm02, comprises
five point mutations in the part hybridizing to the DNA
encoding the N-terminal of the H chain V region for the

10 effective expression in coli .

100 ul of a PCR solution comprising 10 jil of 10 x
PCR Buffer #1, 1 mM MgCl 2 , 0.2 mM dNTPs, 5 units of KOD DNA
polymerase (all from TOYOBO) , 1 fjM of each primer and 100 ng
of a template DNA (pscM2) was heated at 98°C for 15 seconds,

15 at 65°C for 2 seconds and at 74°C for 30 seconds in order.

This temperature cycle was repeated 25 times.

The PCR product was purified using the QIAquick
PCR Purification Kit (QIAGEN) and digested by Ndel and
EcoRI, and then the resulting DNA fragment was cloned into

20 pSCFVT7 vector, from which pelB signal sequence had been

eliminated by the digestion with Ndel and EcoRI. After DNA
sequencing, the resulting plasmid comprising a DNA fragment
with the desired DNA sequence is designated as "pscM2DEm02"
(see Fig. 23) . The nucleotide sequence and the amino acid

25 sequence of the single chain Fv derived from the antibody

MABL-2 contained in the plasmid pscM2DEm02 are shown in SEQ
ID No. 29.

53

5.11 Expression of single chain Fv derived from antibody
MABL-2 in E. coli cells

E^ coli BL21 (DE3)pLysS (STRATAGENE) was
transformed with pscM2DEm02 vector to obtain a strain of E .
coli expressing the single chain Fv derived from antibody
MABL-2. The resulting clones were examined for the
expression of the desired protein using SDS-PAGE, and a
clone with a high expression level was selected as a strain
producing the single chain Fv derived from antibody MABL-2.

5.12 Purification of single chain Fv derived from antibody
MABL-2 produced in E.coli

A single colony of E_^ coli obtained by the
transformation was cultured in 3 ml of LB medium at 28°C for
7 hours and then in 70 ml of LB medium at 28°C overnight.
This pre-culture was transplanted to 7 L of LB medium and
cultured at 28°C with stirring at 300 rpm using the Jar-
fermenter. When an absorbance of the medium reached
O.D.=l.5, the bacteria were induced with 1 mM IPTG and then
cultured for 3 hours.

The culture medium was centrifuged < 10000 x g, 10
minutes) and the precipitated bacteria were recovered. To
the bacteria was added 50 mM Tris-HCl buffer (pH 8.0)
containing 5 mM EDTA, 0.1 M NaCl and 1% Triton X-100 and the
bacteria were disrupted by ultrasonication (out put: 4, duty
cycle: 70%, 1 minute x 10 times) . The suspension of
disrupted bacteria was centrifuged (12000 x g, 10 minutes)
to precipitate inclusion body. Isolated inclusion body was

54

mixed with 50 mM Tris-HCl buffer (pH 8.0) containing 5 mM
EDTA, 0.1 M NaCl and 4% Triton X-100,. treated by
ultrasonication (out put: 4, duty cycle: 50%, 30 seconds x 2
times) again and centrifuged (12000 x g, 10 minutes) to
5 isolate the desired protein as precipitate and to remove

containment proteins included in the supernatant.

The inclusion body comprising the desired protein
was lysed in 50 mM Tris-HCl buffer (pH 8.0) containing 6 M
Urea, 5 mM EDTA and 0.1 M NaCl and applied onto Sephacryl S-

10 300 gel filtration column (5 x 90 cm, Amersharm Pharmacia)

equilibrated with 50 mM Tris-HCl buffer (pH 8.0) containing
4M Urea, 5 mM EDTA, 0.1 M NaCl and 10 mM mercaptoethanol at
a flow rate of 5 ml/minutes to remove associated single
chain Fvs with high-molecular weight. The obtained fractions

15 were analyzed with SDS-PAGE and the fractions with high

purity of the protein were diluted with the buffer used in
the gel filtration up to O. D28o=0 . 25 . Then, the fractions
were dialyzed three times against 50 mM Tris-HCl buffer (pH
8.0) containing 5 mM EDTA, 0.1 M NaCl, 0.5 M Arg, 2 mM

20 glutathione in the reduced form and 0.2 mM glutathione in

the oxidized form in order for the protein to be refolded.
Further, the fraction was dialyzed three times against 20 mM
acetate buffer (pH 6.0) containing 0.15 M NaCl to exchange
the buffer.

25 The dialysate product was applied onto Superdex

200 pg gel filtration column (2.6 x 60 cm, Amersharm
Pharmacia) equilibrated with 20 mM acetate buffer (pH 6.0)

55

containing 0.15 M NaCl to remove a small amount of high
molecular weight protein which was intermolecularly
crosslinked by S-S bonds. As shown in Fig. 24, two peaks,
major and sub peaks, were eluted after broad peaks which are
5 expectedly attributed to an aggregate with a high molecular
weight. The analysis by SDS-PAGE (see Fig. 21) and the
elution positions of the two peaks in the gel filtration
analysis suggest that the major peak is of the monomer of
the single chain Fv and the sub peak is of the non-
10 covalently bound dimer of the single chain Fv. The non-
covalently bound dimer accounted for 4 percent of total
single chain Fvs .

5.13 Apoptosis-inducing activity in vitro of single chain Fv
derived from antibody MABL-2

15 An apoptosis-inducing action of the single chain

Fv from antibody MABL-2 (MABL2-scFv) produced by the CHO
cells and E_^ coli was examined according to two protocols by
Annexin-V staining (Boehringer Mannheim) using the L1210
cells (hIAP/L1210) into which human IAP gene had been

20 introduced.

In the first protocol sample antibodies at the
final concentration of 3 ug/ml were added to 5 x 10 4 cells
of hIAP/L1210 cell line and cultured for 24 hours. Sample
antibodies, i.e., the monomer and the dimer of the single

25 chain Fv of MABL-2 from the CHO cells obtained in Example

5.9, the monomer and the dimer of the single chain Fv of
MABL-2 from E_^ coli obtained in Example 5.12, and the mouse

IgG antibody as a control were analyzed. After culturing,
the Annexin-V staining was carried out and the fluorescence
intensity thereof was measured using the FACScan apparatus
(BECTON DICKINSON) .

In the second protocol sample antibodies at the
final concentration of 3 ng/ml were added to 5 x 10 4 cells
of hIAP/L1210 cell line, cultured for 2 hours and mixed with
anti-FLAG antibody (SIGMA) at the final concentration of 15

ug/ml and further cultured for 22 hours. Sample antibodies
of the monomer of the single chain Fv of MABL-2 from the CHO
cells obtained in Example 5.9 and the mouse IgG antibody as
a control were analyzed. After culturing, the Annexin-V
staining was carried out and the fluorescence intensity
thereof was measured using the FACScan apparatus.

Results of the analysis by the Annexin-V staining
are shown in Figs. 25-31. The results show that the dimers
of the single chain Fv polypeptide of MABL-2 produced in the
CHO cells and E_^ coli remarkably induced cell death (Figs.
26, 27) in comparison with the control (Fig. 25), while no
apoptosis-inducing action was observed in the monomers of
the single chain Fv polypeptide of MABL-2 produced in the
CHO cells and coli (Figs. 28, 29) . When anti-FLAG
antibody was used together, the monomer of the single chain
Fv polypeptide derived from antibody MABL-2 produced in the
CHO cells induced remarkably cell death (Fig. 31) in
comparison with the control (Fig. 30) .

57

5.14 Antitumor effect of the monomer and the dimer of
scFv/CHO polypeptide with a model mouse of human myeloma

(1) Quantitative measurement of human IgG in mouse serum

Measurement of human IgG (M protein) produced by
human myeloma cell and contained in mouse serum was carried
out by the following ELISA. 100 uL of goat anti-human IgG
antibody (BIOSOURCE, Lot#7 902) diluted to 1 ng/mL with 0.1%
bicarbonate buffer (pH 9.6) was added to each well on 96
wells plate (Nunc) and incubated at 4°C overnight so that
the antibody was immobilized. After blocking, 100 \iL of the.
stepwisely diluted mouse serum or human IgG (CAPPEL,
Lot#00915) as a standard was added to each well and
incubated for 2 hours at a room temperature. After washing,
100 uL of alkaline phosphatase-labeled anti-human IgG
antibody (BIOSOURCE, Lot#6202) which had been diluted to
5000 times was added, and incubation was carried out for 1
hour at a room temperature. After washing, a substrate
solution was added. After incubation, absorbance at 405 nm
was measured using the M I CROPLATE READER Model 3550
(BioRad) . The concentration of human IgG in the mouse serum
was calculated based on the calibration curve obtained from
the absorbance values of human IgG as the standard.

(2) Preparation of antibodies for administration

The monomer and the dimer of the scFv/CHO
polypeptide were respectively diluted to 0.4 mg/ml or 0.25
mg/mL with sterile filtered PBS(-) on the day of
administration to prepare samples for the administration.

58

(3) Preparation of a mouse model of human myeloma

A mouse model of human myeloma was prepared as
follows. KPMM2 cells passaged in vivo (JP-Appl. 7-2364 75) by
SCID mouse (Japan Clare) were suspended in RPMI1640 medium
5 (GIBCO-BRL) containing 10% fetal bovine serum (GIBCO-BRL)

and adjusted to 3 x 10 7 cells/mL. 200 uL of the KPMM2 cell
suspension (6 x 10 s cells/mouse) was transplanted to the
SCID mouse (male, 6 week-old) via caudal vein thereof, which
had been subcutaneously injected with the asialo GM1
10 antibody (WAKO JUNYAKU, 1 vial dissolved in 5 mL) a day

before the transplantation.

(4) Administration of antibodies

The samples of the antibodies prepared in (2), the
monomer (250 uL) and the dimer (400 ^L) , were administered

15 to the model mice of human myeloma prepared in (3) via

caudal vein thereof. The administration was started from
three days after the transplantation of KPMM2 cells and was
carried out twice a day for three days. As a control, 200 uX,
of sterile filtered PBS(-) was likewise administered twice a

20 day for three days via caudal vein. Each group consisted of

seven mice.

(5) Evaluation of antitumor effect of the monomer and the
dimer of scFv/CHO polypeptide with the model mouse of human
myeloma

25 The antitumor effect of the monomer and the dimer

of scFv/CHO polypeptide with the model mice of human myeloma
was evaluated in terms of the change of human IgG (M

59

protein) concentration in the mouse serum and survival time
of the mice. The change of human igG concentration was
determined by measuring it in the mouse serum collected at
24 days after the transplantation of KPMM2 cells by ELISA
5 described in the above (1) . The amount of serum human IgG (M

protein) in the serum of the PBS (-) -administered group
(control) increased to about 8500 ng/mL, whereas the amount
of human IgG of the scFv/CHO dimer-administered group was
remarkably low, that is, as low as one-tenth or less than

10 that of the control group. Thus, the results show that the

dimer of scFv/CHO strongly inhibits the growth of the KPMM2
cells (Fig. 32) . As shown in Fig. 33, a remarkable
elongation of the survival time was observed in the scFv/CHO
dimer-administered group in comparison with the PBS(-)-

15 administered group.

From the above, it is confirmed that the dimer of
scFv/CHO has an antitumor effect for the human myeloma model
mice. It is considered that the antitumor effect of the
dimer of scFv/CHO, the modified antibody of the invention,

20 results from the apoptosis-inducing action of the modified

antibody.

5.15 Hemagglutination Test

Hemagglutination test and determination of
hemagglutination were carried out in accordance with
25 "Immuno-Biochemical Investigation", Zoku-Seikagaku Jikken

Koza, edited by the Biochemical Society of Japan, published
by Tokyo Kagaku Dojin.

60

Blood was taken from a healthy donor using
heparin-treated syringes and washed with PBS (-) three times,
and then erythrocyte suspension with a final concentration
of 2% in PBS(-) was prepared. Test samples were the antibody
MABL-2, the monomer and the dimer of the single chain Fv
polypeptide produced by the CHO cells, and the monomer and
the dimer of the single chain Fv polypeptide produced by E.
coli, and the control was mouse IgG { ZYMED) . For the
investigation of the hemagglutination effect, round bottom
96-well plates available from Falcon were used. 50 uL per
well of the aforementioned antibody samples and 50 |aL of the
2% erythrocyte suspension were added and mixed in the well.
After incubation for 2 hours at 37°C, the reaction mixtures
were stored at 4°C overnight and the hemagglutination
thereof was determined. As a control, 50 jj.L per well of
PBS (-) was used and the hemagglutination test was carried
out in the same manner. The mouse IgG and antibody MABL-2
were employed at 0.01, 0.1, 1.0, 10.0 or 100.0 ug/mL of the
final concentration of the antibodies. The single chain Fvs
were employed at 0.004, 0.04, 0.4, 4.0, 40.0 or 80.0 u.g/mL
of the final concentration and further at 160.0 ug/mL only
in the case of the dimer of the polypeptide produced by E .
coli . Results are shown in the Table 2. In the case of
antibody MABL-2, the hemagglutination was observed at a
concentration of more than 0.1 |ig/mL, whereas no
hemagglutination was observed for both the monomer and the
dimer of the single chain Fv.

61

Table 2 Hemagglutination Test

Control 0.01 0.1 1 10 100 ^g/mL
mlgG - - - -

/ M f B h" 2 - - + +++ +++ ++
(intact)

Control 0.004 0.04 0.4 4 40 80 fig/mL

scFv/CHO

monomer

scFv/CHO

dimer ~ " " "

Control 0.004 0.04 0.4 4 40 80 160 ng/mL

scFv/E.coli
monomer
scFv/E.coli
dimer

Example 6 Modified antibody sc(Fv) 2 comprising two H chain V
regions and two L chain V regions and antibody MABL-2 scFvs
having linkers with different length

6.1 Construction of plasmid expressing antibody MABL-2
sc (Fv) 2

For the preparation of a plasmid expressing the
modified antibody [sc(Fv) 2 ] which comprises two H chain V
regions and two L chain V regions derived from the antibody
MABL-2, the aforementioned pCHOM2, which comprises the DNA
encoding scFv derived from the MABL-2 described above, was
modified by the PCR method as mentioned below and the
resulting DNA fragment was introduced into pCH0M2 .

Primers employed for the PCR are EF1 primer (SEQ
ID NO: 30) as a sense primer, which is designed to hybridize
to a DNA encoding EFla, and an antisense primer (SEQ ID NO:
19), which is designed to hybridize to the DNA encoding C-
terminal of the L chain V region and to contain a DNA

62

sequence coding for a linker region, and VLLAS primer
containing Sail restriction enzyme recognition site (SEQ ID
NO 31) .

100 jil of the PCR solution comprises 10 [il of 10 x
PCR Buffer #1, 1 mM MgCl 2 , 0.2 mM dNTPs (dATP, dGTP , dCTP
and dTTP) , 5 units of KOD DNA polymerase (Toyobo, Inc.), 1
uM of each primer and 100 ng of the template DNA (pCHOM2) .
The PCR solution was heated at 94°C for 30 seconds, at 50°C
for 30 seconds and at 74°C for 1 minute in order. This
temperature cycle was repeated 30 times.

The PCR product was purified using the QIAquick
PCR Purification Kit (QIAGEN) and digested by Sail. The
resultant DNA fragment was cloned into pBluescript KS +
vector (Toyobo, Inc.). After DNA sequencing, a plasmid
comprising the desired DNA sequence was digested by Sail and
the obtained DNA fragment was connected using Rapid DNA
Ligation Kit (BOEHRINGER MANNHEIM) to pCHOM2 digested by
Sail. After DNA sequencing, a plasmid comprising the desired
DNA sequence is designated as "pCHOM2 (Fv) 2 " (see Fig. 34).
The nucleotide sequence and the amino acid sequence of the
antibody MABL-2 sc(Fv) 2 region contained in the plasmid
pCHOM2(Fv) 2 are shown in SEQ ID No. 32.

6.2 Preparation of Plasmid expressing antibody MABL-2 scFvs
having linkers with various length

The scFvs containing linkers with different length
and the V regions which are designed in the order of [H
chain] - [ L chain] (hereinafter "HL" ) or [L chain] - [H chain]

63

(hereinafter "LH") were prepared using, as a template, cDNAs
encoding the H chain and the L chain derived from the MABL-2
as mentioned below.

To construct HL type scFv the PCR procedure was
5 carried out using pCHOM2(Fv)2 as a template. In the PCR

step, a pair of CFHL-F1 primer (SEW ID NO: 33) and CFHL-R2
primer (SEQ ID NO: 34) or a pair of CFHL-F2 primer (SEQ ID
NO: 35) and CFHL-R1 primer (SEQ ID NO: 36) and KOD
polymerase were employed. The PCR procedure was carried out

10 by repeating 30 times the temperature cycle consisting of

94°C for 30 seconds, 60°C for 30 seconds and 72°C for 1
minute in order to produce a cDNA for the H chain containing
a leader sequence at 5 '-end or a cDNA for the L chain
containing FLAG sequence at 3 ' -end thereof. The resultant

15 cDNAs for the H chain and the L chain were mixed and PCR was

carried out by repeating 5 times the temperature cycle
consisting of 94°C for 30 seconds, 60°C for 30 seconds and
72°C for 1 minute in order using the mixture as templates
and the KOD polymerase. To the reaction mixture were added

20 CFHL-F1 and CFHL-R1 primers and then the PCR reaction was

performed by repeating 30 times of the aforementioned
temperature cycle to produce a cDNA for HL-0 type without a
linker.

To construct LH type scFv, the PCR reaction was
25 carried out using, as a template, pGEM-M2L and pGEM-M2H

which contain cDNAs encoding the L chain V region and the H
chain V region from the antibody MABL-2, respectively (see

64

JP- Appl. 11-63557). A pair of T7 primer (SEQ ID NO: 37) and
CFLH-R2 primer (SEQ ID NO: 38) or a pair of CFLH-F2 primer
(SEQ ID NO: 39) and CFLH-R1 (SEQ ID NO: 40) and the KOD
polymerase (Toyobo Inc.) were employed. The PCR reaction was
performed by repeating 30 times the temperature cycle
consisting of 94°C for 30 seconds, 60°C for 30 seconds and
72°C for 1 minute in sequential order to produce a cDNA of
an L chain containing a leader sequence at 5 '-end or a cDNA
of an H chain containing FLAG sequence at 3 ' -end thereof.
The resultant cDNAs of the L chain and the H chain were
mixed and PCR was carried out using this mixture as
templates and the KOD polymerase by repeating 5 times the
temperature cycle consisting of 94°C for 30 seconds, 60°C
for 30 seconds and 72°C for 1 minute in order. To the
reaction mixture were added T7 and CFLH-R1 primers and the
reaction was performed by repeating 30 times of the
aforementioned temperature cycle. The reaction product was
used as a template and PCR was carried out using a pair of
CFLH-F4 primer (SEQ ID NO: 41) and CFLH-R1 primer by
repeating 30 times the temperature cycle consisting of 94°C
for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in
order to produce a cDNA of LH-0 type without a linker.

The resultant cDNAs of LH-0 and HL-0 types were
digested by EcoRI and BamHI restriction enzymes (Takara
Shuzo) and the digested cDNAs were introduced into an
expression plasmid INPEP4 for mammalian cells using Ligation
High (Toyobo Inc.), respectively. Competent E_;_ coli JM109

65

(Nippon Gene) was transformed with each plasmid and the
desired plasmids were isolated from the transformed coli
using QIAGEN Plasmid Maxi Kit (QUIAGEN) . Thus plasmids
PCF2LH-0 and pCF2HL-0 were prepared.

To construct the expression plasmids of HL type
containing linkers with different size, pCF2HL-0, as a
template, and CFHL-X3 (SEQ ID NO: 42), CFHL-X4 (SEQ ID NO:
43), CFHL-X5 (SEQ ID NO: 44), CFHL-X6 (SEQ ID NO: 45) or
CFHL-X7 (SEQ ID NO: 46), as a sense primer, and BGH-1 (SEQ
ID NO: 47) primer, as an antisense primer, which is
complementary with the vector sequence were employed. PCR
reaction was carried out using the KOD polymerase by
repeating 30 times the temperature cycle consisting of 94°C
for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute in
order and the reaction products were digested by restriction
enzymes Xhol and BamHI (Takara Shuzo) . The digested
fragments were introduced between Xhol and BamHI sites in
the pCF2HL-0 using Ligation High (Toyobo Inc.),
respectively. Competent E^ coli JM109 was transformed with
each plasmid and the desired plasmids were isolated from the
transformed coli by using Qiagen Plasmid Maxi kit. Thus
expression plasmids pCF2HL-3, pCF2HL-4, pCF2HL-5, pCF2HL-6
and pCF2HL-7 were prepared.

To construct expression plasmid for the transient
expression in COS7 cells the plasmids pCF2HL-0, pCF2HL-3,
PCF2HL-4, pCF2HL-5, pCF2HL-6 and pCF2HL-7 were digested by
restriction enzymes EcoRI and BamHI (Takara Shuzo) and the

66

resultant fragments of approximately 800 bp were purified
with agarose gel electrophoresis. The obtained fragments
were introduced between EcoRI and BamHI sites in an
expression plasmid pCOSl for the expression in mammalian
5 cells by using Ligation High (Toyobo Inc.), respectively.

Competent E^ coli DH5a (Toyobo Inc.) was transformed with
each plasmid and the desired plasmids were isolated from the
transformed E_^ coli using Qiagen Plasmid Maxi kit. Thus the
expression plasmids CF2HL-0/pCOSl, CF2HL-3/pCOSl, CF2HL-
10 4/pCOSl, CF2HL-5/pCOSl, CF2HL-6/pCOSl and CF2HL-7/pCOSl were

prepared .

As a typical example of these plasmids, the
construction of the plasmid CF2HL-0/pCOSl is illustrated in
Fig. 35 and the nucleotide sequence and the amino acid

15 sequence of MABL2-scFv <HL-0> contained in the plasmid are

shown in SEQ ID No. 48. Nucleotide sequences and amino acid
sequences of the linker regions in these plasmids are also
shown in Fig. 36.

To construct the expression plasmids of LH type

20 containing linkers with different size, pCF2LH-0, as a

template, and CFLH-X3 (SEQ ID NO: 49), CFLH-X4 (SEQ ID NO:
50), CFLH-X5 (SEQ ID NO: 51), CFLH-X6, (SEQ ID NO: 52) or
CFLH-X7 (SEQ ID NO: 53), as a sense primer, and BGH-1
primer, as an antisense primer, which is complementary with

25 the vector sequence were employed. PCR reaction was carried

out using the KOD polymerase by repeating 30 times the
temperature cycle consisting of 94°C for 30 seconds, 60°C

67

for 30 seconds and 72°C for 1 minute in order and the
reaction products were digested by restriction enzymes Xhol
and BamHI . The digested fragments were introduced into the
pCF2LH-0 between Xhol and BamHI sites using Ligation High,
5 respectively. Competent coli DH5ce (Toyobo Inc.) was

transformed with each plasmid and the desired plasmids were
isolated from the transformed coli using Qiagen Plasmid
Maxi kit. Thus expression plasmids pCF2LH-3, pCF2LH-4,
pCF2LH-5, pCF2LH-6 and pCF2LH-7 were prepared.

10 To construct expression plasmid for the transient

expression in COS7 cells the plasmids pCF2LH-0, pCF2LH-3,
pCF2LH-4, pCF2LH-5, pCF2LH-6 and pCF2LH-7 were digested by
restriction enzymes EcoRI and BamHI (Takara Shuzo) and the
resultant fragments of approximately 800 bp were purified

15 with agarose gel electrophoresis. The obtained fragments

were introduced between Xhol and BamHI sites in an
expression plasmid pCOSl for the expression in mammalian
cells by using the Ligation High, respectively. Competent E .
coli DH5a (Toyobo Inc. ) was transformed with each plasmid

20 and the desired plasmids were isolated from the transformed

E . coli using the Qiagen Plasmid Maxi kit. Consequently, the
expression plasmids CF2LH-0/pCOSl , CF2LH-3/pCOSl , CF2LH-
4/pCOSl, CF2LH-5/pCOSl, CF2LH-6/pCQSl and CF2LH-7/pC0Sl were
prepared.

25 As a typical example of these plasmids, the

construction of the plasmid CF2LH-0/pCOSl is illustrated in
Fig. 37 and the nucleotide sequence and the amino acid

68

sequence of MABL2-scFv <LH-0> contained in the plasmid are
shown in SEQ ID No. 54. Nucleotide sequences and amino acid
sequences of the linker regions in these plasmids are also
shown in Fig. 38.

6.3 Expression of scFvs and sc(Fv) 2 in COS! cells
(1) Preparation of culture supernatant using serum-
containing culture medium

The HL type and LH type of scFvs and sc(Fv) 2 were
transiently expressed in C0S7 cells (JCRB9127, Japan Health
Sciences Foundation) . C0S7 cells were subcultured in DMEM
media (GIBCO BRL) containing 10% fetal bovine serum
(HyClone) at 37°C in carbon dioxide atmosphere incubator.
The COS7 cells were transfected with CF2HL-0, 3 ~ 7/pCOSl,
or CF2LH-0, 3 ~ 7/pCOSl prepared in Example 6.2 or
pCHOM2(Fv) 2 vectors by electroporation using the Gene Pulser
apparatus (BioRad) . The DNA (10 \ig) and 0.25 ml of 2 x 10 7
cells/ml in DMEM culture medium containing 10% FBS and 5 mM
BES (SIGMA) were added to a cuvette. After standing for 10
minutes the mixtures were treated with pulse at 0.17kV,
950uF of electric capacity. After the restoration for 10
minutes at room temperature, the electroporated cells were
transferred into the DMEM culture medium (10%FBS) in 75 cm 3
flask. After culturing for 72 hours, the culture supernatant
was collected and centrifuged to remove cell fragments. The
culture supernatant was subjected to the filtration using
0.22 urn bottle top filter (FALCON) to obtain the culture
supernatant (hereinafter "CM").

69

(2) Preparation of culture supernatant using serum-free
culture medium

Cells transfected in the same manner as (1) were
transferred to the DMEM medium (10% FBS) in 75 cm 3 flask and
5 cultured overnight. After the culture, the supernatant was

discarded and the cells were washed with PBS and then added
to CHO-S-SFM II medium (GIBCO BRL) . After culturing for 72
hours, the culture supernatant was collected, centrifuged to
remove cell fragments and filtered using 0.22 urn bottle top

10 filter (FALCON) to obtain CM.

6.4 Detection of scFvs and sc(Fv) 2 in CM of C0S7

The various MABL2-scFVs and sc(Fv) 2 in CM of COS7
prepared in the aforementioned Example 6.3 (2) were detected
by Western Blotting method.

15 Each CM of COS7 was subjected to SDS-PAGE

electrophoresis and transferred to REINFORCED NC membrane
(Schleicher & Schuell) . The membrane was blocked with 5%
skim milk (Morinaga Nyu-gyo) and washed with TBS. Then an
anti-FLAG antibody (SIGMA) was added thereto. The membrane

20 was incubated at room temperature and washed. A peroxidase

labeled mouse IgG antibody (Jackson immuno Research) was
added. After incubating and washing at room temperature, the
substrate solution (Kirkegaard Perry Laboratories) was added
to develop color (Fig. 39) .

25 6.5 Flow cytometry

Flow cytometry was performed using the culture
supernatants of COS7 cells prepared in Example 6.3 (1) to

measure the binding of the MABL2-scFV$ and sc(Fv) 2 to human
Integrin Associated Protein (LAP) antigen. The culture
supernatants to be tested or a culture supernatant of C0S7
cells as a control was added to 2 x 10 5 cells of the mouse
leukemia cell line L1210 expressing human IAP. After
incubating on ice and washing, 10 ng/mL of the mouse anti-
FLAG antibody (SIGMA) was added and then the cells were
incubated and washed. Then, the FITC labeled anti-mouse IgG
antibody (BECTON DICKINSON) was added thereto and the cells
were incubated and washed again. The fluorescence intensity
was measured using the FACScan apparatus (BECTON DICKINSON) .
The results of the flow cytometry show that the MABL2-scFvs
having linkers with different length and the sc(Fv) 2 in the
culture supernatants of COS7 have high affinity to human IAP
(see Figs. 40a and 40b).
6.6 Apoptos is- inducing Effect in vitro

An apoptosis-inducing action of the culture
supernatants of COS7 prepared in Example 6.3 (1) was
examined by Annexin-V staining (Boehringer Mannheim) using
the L1210 cells transfected with human IAP gene
(hIAP/L1210) .

To 5 x 10" cells of the hIAP/L1210 cells were
added the culture supernatants of COS7 cells transfected
with each vectors or a culture supernatant of COS7 cells as
a control at 10% of the final concentration and the mixtures
were cultured for 24 hours. Then, the Annexin-V/ PI staining
was performed and the fluorescence intensity was measured

71

using the FACScan apparatus (BECTON DICKINSON) . The results
revealed that scFvs <HL3, 4, 6, 7, LH3, 4, 6, 7> and sc(Fv) 2
in CM of C0S7 induced remarkable cell death of hIAP/L1210
cells. These results are shown in Fig. 41.
5 6.7 Construction of vectors for the expression of scFvs and

sc(Fv) 2 in CHO cells

To isolate and purify MABL2-scFvs and sc{Fv) 2 from
culture supernatant, the expression vectors for expressing
in CHO cells were constructed as below.

10 The EcoRI-BamHI fragments of pCF2HL-0, 3 ~ 7, and

PCF2LH-0, 3 ~ 7 prepared in Example 6.2 were introduced
between EcoRI and BamHI sites in an expression vector pCHOl
for CHO cells using the Ligation High. Competent coli
DH5a was transformed with them. The plasmids were isolated

15 from the transformed E_^ coli using QIAGEN Plasmid Midi kit

(QIAGEN) to prepare expression plasmids pCHOM2HL-0, 3-7,
and pCHOM2LH-0, 3-7.

6.8 Production of CHO cells expressing MABL2-scFvs <HL-0, 3
~ 7>, MABL2-scFvs <LH-0, 3 ~ 7> and sc(Fv) 2 and preparation

20 of the culture supernatants thereof

CHO cells were transformed with each of the
expression plasmids pCHOM2HL-0, 3-7, and pCHOM2LH-0, 3 -
7, constructed in Example 6.7 and pCHOM2(Fv) 2 vector to
prepare the CHO cells constantly expressing each modified

25 antibody. As a typical example thereof, the production of

the CHO cells constantly expressing MABL2-scFv <HL-5> or
sc(Fv) 2 is illustrated as follows.

72

The expression plasmids pCH0M2HL-5 and pCHOM2(Fv) 2
were linearized by digesting with a restriction enzyme Pvul
and subjected to transfection to CHO cells by
electroporation using Gene Pulser apparatus (BioRad) . The
5 DNA (10 \iq) and 0.75 ml of PBS with 1 x 10 7 cells/ml were

added to a cuvette and treated with pulse at 1.5 kV, 25 uF
of electric capacity. After the restoration for 10 minutes
at room temperature, the electroporated cells were
transferred into nucleic acid-containing a-MEM culture

10 medium (GIBCO BRL) containing 10% fetal bovine serum and

cultured. After culturing overnight, the supernatant was
discarded. The cells were washed with PBS and added to
nucleic acid-free a-MEM culture medium (GIBCO BRL)
containing 10% fetal bovine serum. After culturing for two

15 weeks, the cells were cultured in a medium containing 10 nM

(final concentration) methotrexate (SIGMA), then 50 nM and
100 nM methotrexate. The resultant cells were cultured in
serum-free CHO-S-SFM II medium (GIBCO BRL) in a roller
bottle. The culture supernatant was collected, centrifuged

20 to remove cell fragments and filtered using a filter with

0.22 \m of pore size to obtain CM, respectively.

According to the above, CHO cells which constantly
express MABL2-scFvs <HL-0, -3, -4, -6, -7> and <LH-0, -3, -
4, -5, -6, -7> and CMs thereof were obtained.

2 5 6.9 Purification of dimer of MABL2-scFv <HL-5> and sc(Fv) 2

73

The MABL2-scFv <HL-5> and the sc(Fv) 2 were
purified from CMs prepared in Example 6.8 by two types of
purification method as below.
<Purif ication Method 1>
5 HL-5 and sc(Fv) 2 were purified by the anti-FLAG

antibody affinity column chromatography utilizing the FLAG
sequence located at C-terminal of the polypeptides and by
gel filtration. One liter of CM as obtained in 6.8 was
applied onto a column (7.9ml) prepared with anti-FLAG M2

10 Affinity gel (SIGMA) equilibrated with 50 mM Tris-HCl buffer

(TBS, pH 7.5) containing 150 mM NaCl . After washing the
column with TBS, the scFv was eluted by 0.1 M glycine-HCl
buffer, pH 3.5. The resultant fractions were analyzed by
SDS-PAGE and the elution of the scFv was confirmed. The scFv

15 fraction was mixed with Tween 20 up to 0.01% of the final

concentration and concentrated using Centricon-10
(MILIPORE) . The concentrate was applied onto TSKgel G3000SWG
column (7.5 x 600 mm) equilibrated with 20 mM acetate buffer
(pH 6.0) containing 150 mM NaCl and 0.01% Tween 20. At 0.4

20 mL/minute of the flow rate, the scFv was detected by the

absorption at 280 nm. The HL-5 was eluted as the major
fraction in the position of the dimer' and the sc(Fv)2 was
eluted in the position of the monomer.
Purification Method 2>

25 HL-5 and sc(Fv) 2 were purified using three steps

comprising ion exchange chromatography, hydroxyapatite and
gel filtration. In the ion exchange chromatography, Q

74

sepharose fast flow column (Pharmacia) was employed for HL-5
and SP-sepharose fast flow column was employed for sc(Fv) 2 .
In and after the second step, HL-5 and sc(Fv) 2 were
processed by the same procedure.
5 First step for HL-5

CM of HL-5 was diluted to two times with 20 mM
Tris-HCl buffer (pH 9.0) containing 0.02% Tween 20 and then
the pH was adjusted to 9.0 with 1 M Tris. The solution was
applied onto Q Sepharose fast flow column equilibrated with

10 20 mM Tris-HCl buffer (pH 8.5) containing 0.02% Tween 20. A

polypeptide adsorbed to the column was eluted by a linear
gradient of NaCl in the same buffer, from 0.1 to 0.55 M.
Monitoring the eluted fractions by SDS-PAGE, the fractions
containing HL-5 were collected and subjected to

15 hydroxyapatite of the second step.

First step for sc(Fv) 2

CM of the sc(Fv) 2 was diluted to two times with
20mM acetate buffer (pH 5.5) containing 0.02% Tween 20 and
its pH was adjusted to 5.5 with 1 M acetic acid. The

20 solution was applied onto a SP-Sepharose fast flow column

equilibrated with 20 mM acetate buffer (pH 5.5) containing
0.02% Tween 20. A polypeptide adsorbed to the column was
eluted by a linear gradient of NaCl in the buffer, from 0 to
0.5 M. Monitoring the eluted fractions by SDS-PAGE, the

25 fractions containing the sc(Fv) 2 were collected and

subjected to hydroxyapatite of the second step.

75

Second step: Hydroxyapatite chromatography of HL-5 and

SC (FV) 2

The fractions of HL-5 and sc(Fv)2 obtained in the
first step were separately applied onto the hydroxyapatite
5 column (Type I, BIORAD) equilibrated with 10 mM phosphate

buffer containing 0.02% Tween 20, pH 7.0. After washing the
column with the same buffer, polypeptides adsorbed to the
column were eluted by a linear gradient of the phosphate
buffer up to 0.5 M. Monitoring the eluted fractions by SDS-
10 PAGE, the fractions containing the desired polypeptides were

collected.

Third step: Gel filtration of HL-5 and sc(Fv) 2

Each fraction obtained at the second step was
separately concentrated with CentriPrep-10 (MILIPORE) and

15 applied onto a Superdex 200 column (2.6 x 60 cm, Pharmacia)

equilibrated with 20 mM acetate buffer (pH 6.0) containing
0.02% Tween 20 and 0.15 M NaCl. HL-5 was eluted in the
position of the dimer, and sc(Fv)HL-5 and sc(Fv) 2 were
eluted in the position of the monomer as a major peek

20 respectively.

Since the monomer of HL-5 was hardly detected by
both purification methods, it is proved that the dimers of
single chain Fvs are formed in high yields when the linker
for the single chain Fv contains around 5 amino acids.

25 Furthermore, the dimer of HL-5 and the sc(Fv) 2 were stably

preserved for a month at 4°C after the purification.

76

6.10 Evaluation of the binding activity of purified dimer of
scFv <HL-5> and sc(Fv) 2 against antigen

Flow cytometry was performed using the purified
dimer of MABL2-scFv <HL-5> and the purified sc(Fv)2 in order
5 to evaluate the binding to human Integrin Associated Protein

(IAP) antigen. lOug/ml of the purified dimer of MABL2-scFv
<HL-5>, the purified sc(Fv) 2 , the antibody MABL-2 as a
positive control or a mouse IgG (Zymed) as a negative

control was added to 2 x 10 5 cells of the mouse leukemia
10 cell line L1210 expressing human IAP (hIAP/L1210) or the

cell line L1210 transformed with pCOSl (pCOSl/L1210) as a

control. After incubating on ice and washing, 10u,g/mL of the
mouse anti-FLAG antibody (SIGMA) was added and then the
cells were incubated and washed. FITC labeled anti-mouse IgG
15 antibody (BECTON DICKINSON) was added thereto and the cells

were incubated and washed again. Then the fluorescence
intensity was measured using the FACScan apparatus (BECTON
DICKINSON) .

Since the purified dimer of MABL2-scFv <HL-5> and
20 the purified sc(Fv) 2 were specifically bound to hIAP/L1210

cells, it is confirmed that the dimer of scFv <HL-5> and the
sc(Fv) z have high affinity to human IAP (see Fig. 42).

6.11 Apoptosis-inducing activity in vitro of purified dimer
of scFv <HL-5> and sc(Fv) 2

25 An apoptosis-inducing action of the purified dimer

of MABL2-scFv <HL-5> and the purified sc(Fv) 2 were examined
by Annexin-V staining (Boehringer Mannheim) using the L1210

77

cells (hIAP/L1210) in which human IAP gene had been
introduced and cells of human leukemic cell line CCRF-CEM.

Different concentrations of the purified dimer of
MABL2-scFv <HL-5>, the purified MABL2-sc (Fv) 2 , the antibody
5 MABL-2 as a positive control or a mouse IgG as a negative

control were added to 5 x 10" cells of hIAP/L1210 cell line
or 1 x 10 5 cells of CCRF-CEM cell line. After culturing for
2 4 hours, the Annexin-V staining was carried out and the
fluorescence intensity thereof was measured using the

10 FACScan apparatus (BECTON DICKINSON) . As a result the dimer

of MABL2-scFv <HL-5> and the MABL2-sc ( Fv) 2 remarkably
induced cell death of hHIAP/L1210 and CCRF-CEM in
concentration-dependent manner (see Fig. 43) . As a result it
was shown that the dimer of MABL2-scFv <HL-5> and MABL2-

15 sc(Fv) 2/ had improved efficacy of inducing apoptosis

compared with original antibody MABL-2.

6.12 Hemagglutination Test of the purified dimer of scFv

<HL-5> and the sc(Fv);

Hemagglutination test was carried out using
20 different concentrations of the purified dimer of scFv <HL-

5> and the purified sc(Fv) 2 in accordance with Example 5.15.
The hemagglutination was observed with the

antibody MABL-2 as a positive control, whereas no

hemagglutination was observed with both the single chain
25 antibody MABL2-SC ( Fv) 2 and the MABL2-scFv <HL-5>. Further,

there was no substantial difference in the hemagglutination

78

between two buffers employed with the antibody MABL-2. These
results are shown in Table 3.

79

e
y.

CO
UJ

m

o

W

o
o

o

s

o
o

CM
CO
CM
O

O
O

o

a?

CM
CM

o

.CD

ra

E

CD

CO

m

Q.

0>

co
o

O

m

CM

CO

m

CM
CM

co

CM

3f
m £

o
o
o

3
s

CO

o
o

CO

s

o"

35
o

o

8

CM

o

o

CO
00

o

CO

co

co"

o

8

o
o

CO

o
o

o"

co

o
o

co
o
o

CO

r—
o
o

co
8

CO
CD

CO
CM
CO

O

CO
CM

CO
CM

CM

8

3 > A
g u. 3
S "o" 3:
S in v

+1

+

o
o
o

CO

o
o

CO

o
o

co
r—
o
o"

CO

CO

o"

CO
CM
CO

o

a.

CO
CM

+

+
+

+

+

i

CO

8 +

9 +

<u
o

2^

it

o

CP

E

80

6.13 Antitumor effect of the purified dimer of scFv <HL-5>
and the sc ( Fv) 2 for a model mouse of human myeloma

The antitumor effects were tested for the dimer of
scFv <HL-5> and the sc(Fv) 2 prepared and purified in
5 Examples 6.8 and 6.9. The test was performed by using the

mouse model for human myeloma produced in Example 5.1 and
determining the amount of M protein produced by human
myeloma cells in the mouse serum using ELISA and examining
survival time of the mice. Then, the antitumor effects of

10 the dimer of scFv <HL-5> and the sc(Fv) 2 were evaluated in

terms of the change of the amount of M protein in the mouse
serum and the survival time of the mice.

In the test, the HL-5 and the sc(Fv) 2 were
employed as a solution at 0.01, 0.1 or 1 mg/mL in vehicle

15 consisting of 150 mM NaCl, 0.02% Tween and 20 mM acetate

buffer, pH 6.0 and administered to the mice at 0.1, 1 or 10
mg/kg of dosage. Control group of mice were administered
only with the vehicle.

The mouse serum was gathered 2 6 days after the

20 transplantation of the human myeloma cells and the amount of

M protein in the serum was measured using ELISA according to
Example 5.14. As a result, the amount of M protein in the
serum of both mice groups administered with HL-5, the dimer
and the sc(Fv) z decreased in dose-dependent manner (see Fig.

25 44) . Furthermore, a significant elongation of the survival

time was observed in both groups administered with the HL-5
(Fig. 45) and with the sc(Fv) 2 (Fig. 46) in comparison with

81

the control group administered with the vehicle. These
results show that the HL-5 and the sc{Fv) 2 of the invention
have excellent antitumor effect in vivo .
Example 7

Single chain Fv comprising H chain V region and L chain V
region of human antibody 12B5 against human MPL

A DNA encoding V regions of human monoclonal antibody
12B5 against human MPL was constructed as follows:
7.1 Construction of a gene encoding H chain V region of 12B5

The gene encoding H chain V region of human antibody
12B5 binding to human MPL was designed by connecting the
nucleotide sequence of the gene thereof (SEQ ID NO: 55) at
the 5 '-end to the leader sequence (SEQ ID NO: 56) originated
from human antibody gene (Eur. J. Immunol. 1996; 26: 63-69).
The designed nucleotide sequence was divided into four
oligonucleotides having overlapping sequences of 15 bp each
(12B5VH-1, 12B5VH-2, 12B5VH-3, 12B5VH-4) . 12B5VH-1 (SEQ ID
NO: 57) and 12B5VH-3 (SEQ ID NO: 59) were synthesized in the
sense direction, and 12B5VH-2 (SEQ ID NO: 58) and 12B5VH-4
(SEQ ID NO: 60) in the antisense direction, respectively.
After assembling each synthesized oligonucleotide by
respective complementarity, the outside primers (12B5VH-S
and 12B5VH-A) were added to amplify the full length of the
gene. 12B5VH-S (SEQ ID NO: 61) was designed to hybridize to
5' -end of the leader sequence by the forward primer and to
have Hind III restriction enzyme recognition site and Kozak
sequence, and 12B5VH-A (SEQ ID NO: 62) was designed to

82

hybridize to the nucleotide sequence encoding C-terminal of
H chain V region by the reverse primer and to have a splice
donor sequence and BamHI restriction enzyme recognition site,
respectively.

5 lOOjil of the PCR solution containing 10^1 of 10 x PCR

Gold Buffer II, 1 . 5mM MgCl 2 , 0.08mM dNTPs (dATP, dGT-P , dCTP,
dTTP) , 5 units of DNA-polymerase AmpliTaq Gold (all by
PERKIN ELMER) and each 2.5 p mole of each synthesized
oligonucleotide (12B5VH-1 to -4) was heated at 94°C of the

10 initial temperature for 9 minutes, at 94°C for 2 minutes, at

55°C for 2 minutes and 72°C for 2 minutes. After repeating
the cycle two times each 100 pmole of external primer
12B5VH-S and 12B5VH-A was added. The mixture was subjected
to the cycle consisting of at 94°C for 30 seconds, at 55°C

15 for 30 seconds and 72°C for 1 minute 35 times and heated at

72°C for further 5 minutes.

The PCR product was purified by 1.5% low-melting-
temperature agarose gel (Sigma) , digested by restriction
enzymes BamHI and Hind III, and cloned into expression

20 vector HEF-gyl for human H chain. After determining the DNA

sequence the plasmid containing the correct DNA sequence was
named HEF-12B5H-gyl .

The HEF-12B5H-gyl was digested by restriction enzymes
EcoRI and BamHI to produce the gene encoding 12B5VH which

25 was then cloned into an expression vector pCOS-Fd for human

Fab H chain to produce pFd-12B5H. The expression vector for
human Fab H chain was constructed by amplifying the DNA (SEQ

83

ID NO: 63) containing the intron region existing between the
genes encoding human antibody H chain V region and the
constant region, and the gene encoding a part of the
constant region of human H chain by PCR, and inserting the
5 PCR product into animal cell expression vector pCOSl. The

human H chain constant region was amplified for the gene
under the same conditions mentioned above using as the
template HEF-gyl, as the forward primer G1CH1-S (SEQ ID NO:
64) which was designed to hybridize to 5' -end sequence of

10 intron 1 and to have restriction enzyme recognition sites

EcoRI and BamHI and as the reverse primer G1CH1-A (SEQ ID
NO: 65) which was designed to hybridize to 3' -end DNA of
human H chain constant region CHI domain and to have a
sequence encoding a part of hinge region, two stop codons

15 and restriction enzyme recognition site Bgl II.

The nucleotide sequence and amino acid sequence of the
reconstructed 12B5H chain variable region which were
included in plasmids HE F- 12B5H-gyl and pFd-12B5H are shown
in SEQ ID NO: 66.

20 7.2 Construction of the gene encoding 12B5 L chain V region

The gene encoding L chain V region of human antibody
12B5 binding to human MPL was designed by connecting the
nucleotide sequence of gene (SEQ ID NO: 67) at the 5' -end to
the leader sequence (SEQ ID NO: 68) originated from human

25 antibody gene 3D6 (Nuc. Acid Res. 1990: 18; 4927) . In the

same way as mentioned above the designed nucleotide sequence
was divided into four oligonucleotides having overlapping

84

sequences of 15 bp each (12B5VL-1, 12B5VL-2, 12B5VL-3,
12B5VL-4) and synthesized respectively. 12B5VL-1 (SEQ ID
NO: 69) and 12B5VL-3 (SEQ ID NO: 71) had sense sequences,
and 12B5VL-2 (SEQ ID NO: 70) and 12B5VL-4 (SEQ ID NO: 72)
5 had antisense sequences, respectively. Each of the

synthesized oligonucleotides was assembled by respective
complementarity and mixed with the external primer (12B5VL-S
and 12B5VL-A) to amplify the full length of the gene.
12B5VL-S (SEQ ID NO: 73) was designed to hybridize to 5' -end

10 of the leader sequence by the forward primer and to have

Hind III restriction enzyme recognition site and Kozak
sequence. 12B5VL-A (SEQ ID NO: 74) was designed to
hybridize to the nucleotide sequence encoding C- terminal of
L chain V region by the reverse primer and to have a splice

15 donor sequence and BamHI restriction enzyme recognition site.

Performing the PCR as mentioned above, the PCR product
was purified by 1.5% low-melting-temperature agarose gel
(Sigma), digested by restriction enzymes BamHI and Hind III,
and cloned into an expression vector HEF-gx for human L

20 chain. After determining the DNA sequence the plasmid

containing the correct DNA sequence was named HEF-12B5L-gK.
The nucleotide sequence and amino acid sequence of the
reconstructed 12B5 L chain V region which were included in
plasmid HEF-12B5L-gic are shown in SEQ ID NO: 75.

25 7.3 Production of reconstructed 12B5 single chain Fv (scFv)

The reconstructed 12B5 antibody single chain Fv was
designed to be in the order of 12B5VH-linker-12B5VL and to

85

have FLAG sequence (SEQ ID NO: 76) at C-terminal to
facilitate the detection and purification. The
reconstructed 12B5 single chain Fv (scl2B5) was constructed
using a linker sequence consisting of 15 amino acids
represented by (Gly4Ser)3.

(1) Production of the reconstructed 12B5 single chain Fv
using the linker sequence consisting of 15 amino acids

The gene encoding the reconstructed 12B5 antibody
single chain Fv, which contained the linker sequence
consisting of 15 amino acids, was constructed by connecting
12B5 H chain V region, linker region and 12B5 L chain V
region which was amplified by PCR respectively. This method
is schematically shown in Fig. 47. Six PCR primers (A-F)
were used for production of the reconstructed 12B5 single
chain Fv. Primers A, C, and E had sense sequences, and
primers B, D, and F had antisense sequences.

The forward primer 12B5-S (Primer A, SEQ ID NO: 77)
for H chain V region was designed to hybridize to 5' -end of
H chain leader sequence and to have EcoRI restriction enzyme
recognition site. The reverse primer HuVHJ3 (Primer B, SEQ
ID NO: 78) for H chain V region was designed to hybridize to
DNA encoding C-terminal of H chain V region.

The forward primer RHuJH3 (Primer C, SEQ ID NO: 79)
for the linker was designed to hybridize to DNA encoding the
N-terminal of the linker and to overlap DNA encoding the C-
terminal of H chain V region. The reverse primer RHuVKl
(Primer D, SEQ ID NO: 80) for the linker was designed to

86

hybridize to DNA encoding the C-terminal of the linker and
overlap DNA encoding the N-terminal of L chain V region.

The forward primer HuVK1.2 (Primer E, SEQ ID NO: 81)
for L chain V region was designed to hybridize to DNA
5 encoding the N-terminal of L chain V region. The reverse

primer 12B5F-A for L chain V region (Primer F, SEQ ID NO:
82) was designed to hybridize to DNA encoding C-terminal of
L chain V region and to have the sequence encoding FLAG
peptide (Hopp, T. P. et al., Bio/Technology, 6, 1204-1210,

10 1988), two transcription stop codons and NotI restriction

enzyme recognition site.

In the first PCR step, three reactions A-B, C-D, and
E-F were performed, and the three PCR products obtained from
the first step PCR were assembled by respective

15 complementarity. After adding primers A and F the full

length DNA encoding the reconstructed 12B5 single chain Fv
having the linker consisting of 15 amino acids was amplified
(the second PCR) . In the first step PCR, the plasmid HEF-
12B5H-gyl (see Example 7. 1) encoding the reconstructed 12B5

20 H chain V region, pSCFVT7-hM21 (humanized 0NS-M21 antibody)

(Ohtomo et al . , Anticancer Res. 18 (1998), 4311-4316)
containing DNA (SEQ ID NO: 83) encoding the linker region
consisting of Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly Ser (Huston et al., Proc. Natl. Acad. Sci . USA,

25 85, 5879-5883, 1988) and the plasmid HE F- 1 2 B 5I>— gjc (see

Example 7. 2) encoding the reconstructed 12B5 L chain V
region were used as templates, respectively.

87

50ul of PCR solution for the first step contained 5ul
of 10 x PCR Gold Buffer II, 1 . 5mM MgClz, 0.08mM dNTPs, 5
units of DNA polymerase AmpliTaq Gold (all by PERKIN ELMER) ,
each 100 pmole of each primer and lOOng of each template DNA.
5 The PCR solution was heated at 94°C of the initial

temperature for 9 minutes, at 94 for 30 seconds, 55°C for 30
seconds and 72°C for 1 minute. After repeating the cycle 35
times the reaction mixture was further heated 72°C for 5
minutes .

10 The PCR products A-B, C-D, and E-F were assembled by

the second PCR. PCR mixture solution for the second step of
98ul containing as the template lul of the first PCR product
A-B, 0.5ul of PCR product C-D and lul of PCR product E-F,
lOjil of 10 x PCR Gold Buffer II, 1 . 5mM MgCl 2 , 0.08mM dNTPs,

15 5 units of DNA polymerase AmpliTaq Gold (all by PERKIN

ELMER) was heated at 94°C of the initial temperature for 9
minutes, at 94°C for 2 minutes, at 65°C for 2 minutes and
72°C for 2 minutes. After repeating the cycle two times,
each 100 pmole of each of primers A and F were added. After

20 repeating the cycle consisting of at 94°C for 30 seconds,

55°C for 30 seconds and 72°C for 1 minute 35 times, the
reaction mixture was heated at 72°C for 5 minutes.

The DNA fragments produced by the second PCR were
purified using 1.5% low-melting-temperature agarose gel,

25 digested by EcoRI and Not I, and cloned into pCHOl vector and

pCOSl vector (Japanese Patent Application No. 8-255196) .
The expression vector pCHOl was a vector constructed by

88

deleting the antibody gene from DHFR-AE-rvH-PMl-f (see
W092/19759) by EcoRI and Smal digestion, and connecting to
EcoRI-Notl-BamHI Adaptor (TAKARA SHUZO) . After determining
the DNA sequence the plasmids containing the DNA fragment
5 encoding the correct amino acid sequence of reconstructed

12B5 single chain Fv were named pCHO-scl2B5 and pCOS-scl2B5.
The nucleotide sequence and amino acid sequence of the
reconstructed 12B5 single chain Fv included in the plasmids
pCHO-scl2B5 and pCOS-scl2B5 are shown in SEQ ID NO: 84.
10 7.4 Expression of antibody 12B5 (IgG, Fab) and single chain

Fv polypeptide by animal cell

Antibody 12B5 (IgG, Fab) and single chain Fv derived
from antibody 12B5 were expressed by using COS-7 cells or
CHO cells.

15 The transient expression using COS-7 cells was

performed as follows. The transfection was performed by
electroporation method using Gene Pulser equipment (BioRad) .
For the expression of antibody 12B5 (IgG) each 10u.g of the
above-mentioned expression vector HE F-12B5H-gyl and HEF-12

20 B5L-gK were added, for the expression of 12B5Fab fragment

each 10ng of pFd-12B5H and HEF-12B5L-gK were added and for
the expression of single chain Fv 10|ag of pCOS-scl2B5 was
added to COS-7 cells (lxlO 7 cells/ml) suspended in 0.8ml of
PBS. The mixture kept in a cuvette was treated by pulse at

25 the capacity of 1.5kV, 25uFD. After recovering for 10

minutes in a room temperature the electroporated cells were
added to DMEM culture medium (GIBCO BRL) containing 10%

89

bovine fetal serum cultivated. After cultivating overnight
the cells were washed once by PBS, added to serum- free
medium CHO-S-SFM II and cultivated for 2 days. The culture
medium was centrifuged to remove cell debris and filtered
5 with 0.22jun filter to prepare the culture supernatant.

To establish a stable expression CHO cell line for the
single chain Fv (polypeptide) derived from antibody 12B5,
the expression vector pCHO-scl2B5 was introduced into CHO
cells as follows.

10 The expression vector was introduced into CHO cells by

electroporation method using Gene Pulser equipment (BioRad) .
Linearized DNA (100|jg) obtained by digestion with
restriction enzyme Pvul and CHO cells (lxlO 7 cells /ml)
suspended in 0.8 ml of PBS were mixed in a cuvette, left

15 stationary on ice for 10 minutes and treated with pulse at

the capacity of 1.5kV, 25p.FD. After recovering for 10
minutes at a room temperature the electroporated cells were
added to CHO-S-SFM II (GIBCO BRL) containing 10% bovine
fetal serum and cultivated. After cultivating for 2 days

20 the cultivation was continued in CHO-S-SFM II (GIBCO BRL)

containing 5nM methotrexate (SIGMA) and 10% bovine fetal
serum. From thus obtained clones a clone with high
expression rate was selected as the production cell line for
12B5 single chain Fv. After cultivating in serum-free

25 medium CHO-S-SFM II (GIBCO BRL) containing 5nM methotrexate

(SIGMA) , the culture supernatant was obtained by centrifugal
separation of cell debris.

90

7.5 Purification of single chain Fv derived from 12B5
produced by CHO cells

The culture supernatant of CHO cell line expressing
12B5 single chain Fv obtained in 7.4 was purified by anti-
5 FLAG antibody column and gel filtration column.

(1) Ant i- FLAG antibody column
The culture supernatant was added to anti-FLAG M2 affinity
gel (SIGMA) equilibrated by PBS. After washing the column
by the same buffer the proteins adsorbed to the column were

10 eluted by 0.1M glycine-HCl buffer (pH 3.5). The eluted

fractions were immediately neutralized by adding 1M Tris-HCl
buffer (pH 8.0). The eluted fractions were analyzed by SDS-
PAGE and the fraction which was confirmed to contain the
single chain Fv was concentrated using Centricon-10

15 (MILLIPORE) .

(2) Gel filtration

The concentrated solution obtained in (1) was added to
Superdex200 column (10x300mm, AMERSHAM PHARMACIA)
equilibrated by PBS containing 0.01% Tween20.

20 The product scl2B5 was eluted in two peaks (A, B) (see Fig.

48) . The fractions A and B were analyzed using the 14%-SDS-
polyacrylamide gel. The sample was processed by
electrophoresis in the presence and absence of a reducing
agent according to Laemmli method, and stained by Coomassie

25 Brilliant Blue after the electrophoresis. As shown in Fig.

49 the fractions A and B, regardless of the presence of the.
reducing agent or its absence, produced a single band having

91

an apparent molecular weight of about 31 kD. When the
fractions A and B were analyzed by gel filtration using
Superdex200 PC 3.2/30 (3.2x300mm, AMERSHAM PHARMACIA), the
fraction A produced an eluted product at an apparent
5 molecular weight of about 44 kD and the fraction B produced

at 22kD (see Fig. 50a and b) . The -results show that the
fraction A is the non-covalent bond dimer of scl2B5 single
chain Fv, and B is the monomer.

7.6 Measurement of TPO-like agonist activity of various

10 single chain Fvs

The TPO-like activity of anti-MPL single chain antibody was
evaluated by measuring the proliferation activity to Ba/F3
cells (BaF/mpl) expressing human TPO receptor (MPL) . After
washing BaF/Mpl cells two times by RPMI1640 culture medium

15 (GIBCO) containing 10% bovine fetal serum (GIBCO) , the cells

were suspended in the culture medium at cell density of
5x10 s cells/ml. The anti-MPL single chain antibody and
human TPO (R&D Systems) was diluted with the culture medium,
respectively. 50ul of the cell suspension and 50ul of the

20 diluted antibody or human TPO were added in 96-well

microplate (flat bottom) (Falcon), and cultivated in C0 Z
incubator (C0 2 concentration: 5%) for 24 hours. After the
incubation 10ul of WST-8 reagent (reagent for measuring the
number of raw cells SF: Nacalai Tesque) was added and the

25 absorbance was immediately measured at measurement

wavelength of 450nm and at refference wavelength of 620nm
using fluorescence absorbency photometer SPECTRA Fluor

92

(TECAN) . After incubating in C0 2 incubator (COz
concentration: 5%) for 2 hours, the absorbance at 450nm of
measurement wavelength and 620nm of refference wavelength
was again measured using SPECTRA Fluor. Since WST-8 reagent
developed the color reaction depending upon the number of
live cells at wavelength of 450nm, the proliferation
activity of BaF/Mpl based on the change of absorbance in 2
hours was evaluated by ED 50 calculated as follows. In the
proliferation reaction curve wherein the absorbance was
plotted on the ordinate against the antibody concentration
on the abscissa, the absorbance at the plateau was set 100%
reaction rate. Obtaining an approximation formula by
straight line approximation method based on the plotted
values close to 50% reaction rate, the antibody
concentration of 50% reaction rate was calculated and
adopted as ED 50.

The results of the agonist activity to MPL measured by using
culture supernatants of COS-7 cells expressing various 12B5
antibody molecules showed as illustrated in Fig. 51 that
12B5lgG having bivalent antigen-binding site increased the
absorbance in concentration-dependent manner and had TPO-
like agonist activity (ED50; 29nM) , while the agonist
activity of 12B5Fab having monovalent antigen-biding site
was very weak (ED50; 34,724nM). On the contrary the single
chain Fv (scl2B5) having monovalent antigen-binding site
like Fab showed strong agonist activity at a level that ED50
was 75nM. However it has been known that variable regions

93

of H chain and L chain of the single chain Fv are associated
through non-covalent bond and, therefore, each variable
region is dissociated in a solution and can be associated
with variable region of other molecule to form multimers
5 like dimers. When the molecular weight of scl2B5 purified

by gel filtration was measured, it was confirmed that that
there were molecules recognized to be monomer and dimer (see
Fig. 48) . Then monomer scl2B5 and dimer scl2B5 were
isolated (see Fig. 50) and measured for the agonist activity

10 to MPL. As shown in Figs. 51 and 52, ED50 of scl2B5 monomer

was 4438. 7nM, which confirmed that the agonist activity was
reduced compared with the result using culture supernatant
of COS-7 cells. On the contrary single chain Fv (scl2B5
dimer) having bivalent antigen-binding site showed about

15 400-fold stronger agonist activity (ED50; lO.lnM) compared

with monovalent scl2B5. Furthermore, the bivalent single
chain Fv showed the agonist activity equivalent to or higher
than the agonist activity of human TPO and 12B5IgG.
Example 8

20 Construction of a gene encoding the variable region of human

antibody 12E10 against human MPL

A DNA encoding variable region of human monoclonal
antibody 12E10 against human MPL was constructed as follows:
8.1 Construction of a gene encoding 12E10 H chain V region

25 The nucleotide sequence SEQ ID NO: 86 was designed as a

gene encoding H chain V region of human antibody 12E10
binding to human MPL on the basis of the amino acid sequence

94

described in WO99/10494 (SEQ ID NO: 85) . The full length of
nucleotide sequence was designed by connecting to its 5' -end
the leader sequence (SEQ ID NO: 87) derived from human
antibody gene (GenBank accession No. AF062252) . The designed
5 nucleotide sequence was divided into four oligonucleotides

having overlapping sequences of 15 bp each (12E10VH1,
12E10VH2, 12E10VH3, 12E10VH4). 12E10VH1 (SEQ ID NO: 88) and
12E10VH3 (SEQ ID NO: 90) were synthesized in the sense
direction, and 12E10VH2 (SEQ ID NO: 89) and 12E10VH4 (SEQ ID

10 NO: 91) in the antisense direction, respectively. After

assembling each synthesized oligonucleotide by respective
complementarity, the external primers (12E10VHS and
12E10VHA) were added to amplify the full length of the gene.
12E10VHS (SEQ ID NO: 92) was designed to hybridize to 5' -end

15 of the leader sequence by the forward primer and to have

Hind III restriction enzyme recognition site and Kozak
sequence, and 12E10VHA (SEQ ID NO: 93) was designed to
hybridize to the nucleotide sequence encoding C-terminal of
H chain V region by the reverse primer and to have a splice

20 donor sequence and BamHI restriction enzyme recognition site,

respectively.

lOOjul of the PCR solution containing 10^1 of 10 x.PCR
Gold Buffer II, 1 . 5mM MgCl 2 , 0.08mM dNTPs (dATP, dGTP, dCTP,
dTTP) , 5 units of DNA-polymerase AmpliTaq Gold (all by
2 5 PERKIN ELMER) and each 2.5pmole of each synthesized

oligonucleotide (12E5VH-1 to -4) was .heated at 94°C of the

initial temperature for 9 minutes, at 94°C for 2 minutes, at

95

55°C for 2 minutes and 72°C for 2 minutes. After repeating
the cycle two times each 100 pmole of external primer
12E10VHS and 12E10VHA were added. The mixture was subjected
to the cycle consisting of at 94°C for 30 seconds, at 55°C
5 for 30 seconds and 72°C for 1 minute 35 times and heated at

72°C for further 5 minutes.

The PCR product was purified by 1.5% low-melting-
temperature agarose gel (Sigma) , digested by restriction
enzymes BamHI and Hind III, and cloned into a human H chain

10 expression vector HEF-gyl. After determining the DNA

sequence the plasmid containing the correct DNA sequence was

named HEF-12E10H-gyl .

The HEF-12E10H-gyl was digested by restriction enzymes
EcoRI and BamHI to produce the gene encoding 12E10VH and

15 then cloned into a human Fab H chain expression vector pCOS-

Fd to produce pFd-12E10H. The human Fab H chain expression
vector was constructed by amplifying the DNA (SEQ ID NO: 63)
containing the intron region existing between the genes
encoding human antibody H chain V region and the constant

20 region, and the gene encoding a part of the human H chain

constant region by PCR, and inserting the PCR product into
animal cell expression vector pCOSl. The human H chain
constant region was amplified for the gene under the same
conditions mentioned above using as the template HEF-gyl, as

25 the forward primer G1CH1-S (SEQ ID NO: 64) which was

designed to hybridize to 5' -end sequence of intron 1 and to
have restriction enzyme recognition sites EcoRI and BamHI

96

and as the reverse primer G1CH1-A (SEQ ID NO: 65) which was
designed to hybridize to 3' -end DNA of human H chain
constant region CHI domain and to have a sequence encoding a
part of hinge region, two stop codons and restriction enzyme
5 recognition site Bgl II.

The nucleotide sequence and amino acid sequence of the
reconstructed 12E10 H chain variable region which were
included in plasmids HEF-12E1 OH-gyl and pFd-12E10H are shown
in SEQ ID NO: 94.

10 8.2 Construction of a gene encoding 12E10 L chain V region

The nucleotide sequence SEQ ID NO: 96 was designed as a
gene encoding L chain V region of human antibody 12E10
binding to human MPL on the basis of the amino acid sequence
described in WO99/10494 (SEQ ID NO: 95). It was further

15 designed by connecting to its 5' -end the leader sequence

(SEQ ID NO: 97) derived from human antibody gene (Mol .
Immunol. 1992; 29: 1515-1518). In the same way as mentioned
above the designed nucleotide sequence was divided into four
oligonucleotides having overlapping sequences of 15 bp each

20 (12E10VL1, 12E10VL2, 12E10VL3, 12E10VL4) and synthesized

respectively. 12E10VL1 (SEQ ID NO: 98) and 12E10VL3 (SEQ ID
NO: 100) had sense sequences, and 12E10VL2 (SEQ ID NO: 99)
and 12E10VL4 (SEQ ID NO: 101) had antisense sequences,
respectively. Each of the synthesized oligonucleotides was

25 assembled by respective complementarity and mixed with the

external primers (12E10VLS and 12E10VLA) to amplify the full
length of the gene. 12E10VLS (SEQ ID NO: 102) was designed

97

to hybridize to 5' -end of the leader sequence by the forward
primer and to have EcoRI restriction enzyme recognition site
and Kozak sequence. 12E10VLA (SEQ ID NO: 103) was designed
to hybridize to the nucleotide sequence encoding C-terminal
5 of L chain V region by the reverse primer and to have a Blnl

restriction enzyme recognition site.

Performing the PCR as mentioned above, the PCR product
was purified by 1.5% low-melting-temperature agarose gel
(Sigma) , digested by restriction enzymes EcoRI and Blnl, and

10 cloned into pUC19 containing a gene for human lambda chain

constant region. After determining the DNA sequence the
plasmid containing the correct DNA sequence was digested by
EcoRI to produce a gene encoding 12E10 L chain V region and
human lambda chain constant region and then inserted in

15 expression vector pCOSl. The plasmid having 12E10 L chain

gene (SEQ ID NO: 104) was named pCOS-12E10L
8.3 Production of reconstructed 12E10 single chain Fv

The reconstructed 12E10 antibody single chain Fv was
designed to be in the order of 12E10VH-linker-12E10VL and to

20 have FLAG sequence (SEQ ID NO: 105) at C-terminal to

facilitate the detection and purification. The reconstructed
12E10 chain Fvs (scl2E10 and dbl2E10) were constructed using
a linker sequence consisting of 15 amino acids represented
by (Gly 4 Ser) 3 or 5 amino acids represented by (Gly4Ser)i.

25 (1) Production of the reconstructed 12E10 single chain Fv

using the linker sequence consisting of 5 amino acids

98

The gene encoding the reconstructed 12E10 single chain
Fv, which contained the linker sequence consisting of 5
amino acids, was constructed by introducing the nucleotide
sequence for the linker (Gly4Ser)i to 3' -end of the gene
5 encoding 12E10 H chain V region and to 5' -end of the gene

encoding 12E10 L chain V region, amplifying thus -obtained
respective gene by PCR and connecting the amplified genes.
Four PCR primers (A-D) were used to produce the
reconstructed 12E10 single chain Fv. Primers A and C had

10 sense sequences, and primers B and D had antisense sequences.

The forward primer for H chain V region was 12E10S
(Primer A, SEQ ID NO: 106) . The reverse primer DB2 (Primer B,
SEQ ID NO: 107) for H chain V region was designed to
hybridize to DNA encoding C-terminal of H chain V region and

15 to have the nucleotide sequence encoding the linker

(Gly^SerJi and the nucleotide sequence encoding N-terminal
of L chain V region.

The forward primer DB1 (Primer C, SEQ ID NO: 108) for
L chain V region was designed to hybridize to DNA encoding

20 the N-terminal of L chain V region and to have the

nucleotide sequence encoding the linker (Gly<Ser)i and the
nucleotide sequence encoding C-terminal of H chain V region.
The reverse primer 12E10FA (Primer D, SEQ ID NO: 109) for L
chain V region was designed to hybridize to DNA encoding the

25 C-terminal of L chain V region and to have the nucleotide

sequence encoding FLAG and NotI restriction enzyme
recognition site.

99

In the first PCR step, two reactions A-B and C-D were
performed, and the two PCR products obtained from the first
step PCR were assembledby respective complementarity.
After adding primers A and D the full length DNA encoding
5 the reconstructed 12E10 single chain Fv having the linker

consisting of 5 amino acids was amplified (the second PCR) .
In the first step PCR, the plasmid HEF-12E10H-gyl ■ (see .
Example 8. 1) encoding the reconstructed 12E10 H chain V
: region and pCOS-12E10L (see Example 8.2) encoding the
10 reconstructed 12E10 L chain V region were used as templates,

respectively.

50ul of the first step PCR solution contained 5ul of 10
x PCR Gold Buffer II, 1 . 5mM MgCl 2 , O.OBmM dNTPs, 5 units of
DNA polymerase AmpliTaq Gold (by PERKIN ELMER), each 100

.15 pmole of each primer and lOOng of each template DNA. The PCR

solution was heated at 94°C of the initial temperature for 9
minutes, at 94 for 30 seconds, 55°C for 30 seconds and 72°C
for 1 minute. After repeating . the cycle 35 times the
reaction mixture was further heated at 72°c for 5 minutes.

20 The PCR products A-B (429bp) and C-D (395bp) were

assembled by the second PCR. The second step PCR mixture
solution (98u.l) containing lul each of the first PCR product
A-B and C-D as templates, 100 pmole each of each primer,
10ul of 10 x PCR Gold Buffer II, 1 . 5mM MgCl z , 0.08mM dNTPs

25 and 5 units of DNA polymerase AmpliTaq Gold (by PERKIN

ELMER) was reacted under the same conditions as mentioned
above .

100

The DNA fragment of 795bp produced by the second PCR
was purified using 1.5% low-melting- temperature agarose gel,
digested by EcoRI and Not I, and cloned into pCHOl vector or
pCOSl vector. The expression vector pCHOl was a vector
constructed by deleting the antibody gene from DHFR-AE-RVH-
PMl-f (see W092/19759) by EcoRI and Smal digestion, and
connecting to EcoRI-Notl-BamHI Adaptor (TAKARA SHUZO) .
After determining the DNA sequence the plasmids containing
the DNA fragment encoding the correct amino acid sequence of
reconstructed 12E10 single chain Fv were named pCHO-dbl2E10'
and pCOS-dbl2E10 . The nucleotide sequence and amino acid
sequence of the reconstructed 12E10 single chain Fv included
in the plasmids pCHO-dbl2E10 and pCOS-dbl2E10 are shown in
SEQ ID NO: 110.

(2) Production of the reconstructed 12E10 single chain Fv
using the linker sequence consisting of 15 amino acids

The gene encoding the reconstructed 12E10 antibody
single chain Fv, which contained the linker sequence
consisting of 15 amino acids, was constructed by introducing
the nucleotide sequence for the linker (Gly4Ser) 3 to 3' -end
of the gene encoding 12E10 H chain V region and to 5' -end of
the gene encoding 12E10 L chain V region, amplifying thus
obtained respective gene by PCR and connecting the amplified
genes. Four PCR primers (A-D) were used for production of
the reconstructed 12E10 single chain Fv. Primers A and C had
sense sequences, and primers B and D had antisense sequences.

101

10

The forward primer for H chain V region was 12E10S
(Primer A, SEQ ID NO: 106). The reverse primer sc4.3 (Primer
B, SEQ ID NO: 111) for H chain V region was designed to
hybridize to DNA encoding C-terminal of H chain V region and
to have the nucleotide sequence encoding the linker
(GlV4Ser) 3 and the nucleotide sequence encoding N-terminal

of L chain V region.

The forward primer scl.3 (Primer C, SEQ ID NO: 112)
for L chain V region was designed to hybridize to DNA
encoding the N-terminal of L chain V region and to have the
nucleotide sequence encoding the linker (Gly 4 Ser) 3 and the
nucleotide sequence encoding c-terminal of H chain V region.
The reverse primer 12E10FA (Primer .D, SEQ ID NO: 109) for 1<
chain V region was designed to hybridize to DNA encoding the
15 c-terminal of L chain V region and to have the nucleotide

sequence encoding FLAG and NotI restriction enzyme

recognition site.

In the first PCR step, two reactions A-B and. C-D were

performed, and the two PCR products obtained from the first
2 0 step PCR were assembled by respective complementarity.

After adding primers A and D the full length- DNA encoding

the reconstructed 12E10 single chain Fv having the linker

consisting of 15 amino acids was amplified (the second PCR) .

In the first step PCR, the plasmid P COS-dbl2E10 (see Example
25 8. 3(1)) encoding the reconstructed 121E10 single chain Fv:

was used as template.

102

50(11 of the first step PCR solution contained 5|il of 10
x ExTaq Buffer, 0.4mM dNTPs, 2.5 units of DNA polymerase
TaKaRa ExTaq (by TAKARA) , each 100 pmole of each primer and
lOng of each template DNA. The PCR solution was heated at
94°C of the initial temperature for 30 seconds, at 94 for 15
seconds and 72°C for 2 minute, and the cycle was repeated 5
times. After repeating 28 times the cycle of at 94°C for 15
seconds and at 70°C for 2 minutes, the reaction mixture was
further heated at 72°C for 5 minutes.

The PCR products A-B (477bp) and C-D (447bp) were
assembled by the second PCR. The second step PCR mixture
solution (98ul) containing each of the first PCR

products A-B and C-D as templates, 100 pmole each of each
primer A and D, 5ul of 10 x ExTaq Buffer, 0 . 4mM dNTPs, 2.5
units of DNA polymerase TaKaRa ExTaq (by TAKARA) was reacted
under the same conditions as mentioned above.

The DNA fragment of 825bp produced by the second PCR
was purified using 1.0% low-melting-temperature agarose gel,
digested by EcoRI and Notl. Thus obtained DNA fragment was
cloned into pCHOl vector or pCOSl vector. After determining
the DNA sequence the plasmids containing the DNA fragment
encoding the correct amino acid sequence of reconstructed
12E10 single chain Fv were named pCHO-scl2E10 and pCOS-
scl2E10. The nucleotide sequence and amino acid sequence of
the reconstructed 12E10 single chain Fv included in the
plasmids pCHO-scl2E10 and pCOS-scl2E10 are shown in SEQ ID
NO: 113.

103

8.4 Expression of antibody 12E10 (IgG, Fab) and single
chain Fv polypeptide by animal cell

Antibody 12E10 (IgG, Fab) and single chain Fv derived
from antibody 12E10 (linker sequence 5 amino acids, 15 amino
5 acids) were expressed by using COS-7 cells or CHO cells.

The transient expression using COS-7 cells was
performed as follows. The transfection was performed by
electroporation method using Gene Pulser II equipment
(BioRad) . For the expression of antibody 12E10 (IgG) each

10 l°pq of the above-mentioned expression vector HEF-12E10H-gyl

and pCOS-12E10L were added, for the expression of 12E10Fab

fragment each lOug of pFd-12E10H and pCOS-12E10L were added
and for the expression of single chain Fv of pCOS-scl2E10
(10ng) or pCOS-dbl2E10 (10ng) was added to COS-7 cells
15 (lxlO 7 cells/ml) suspended in 0.8ml of PBS. The mixture

kept in a cuvette was treated by pulse at the capacity of

1.5kV, 25^FD. After recovering for 10 minutes in a room
temperature the electroporated cells were added to DMEM
medium (GIBCO BRL) containing 10% bovine fetal serum and

20 cultivated. After cultivating overnight the cells were

washed once by PBS, added to serum-free medium CHO-S-SFM II
(GIBCO BRL) and cultivated for 3 days. The culture
supernatant was centrifuged to remove cell debris and
filtered with 0.22nm filter.

25 To establish a stable expression CHO cell line for the

single chain Fv (polypeptide) derived from antibody 12E10,

104

the expression vector pCHO-scl2E10 or pCHO-dsl2E10 was
introduced into CHO cells respectively.

Each expression vector was introduced into CHO cells
by electroporation method using Gene Pulser II equipment
5 (BioRad) . Linearized DNA (lOO^g) obtained by digestion with

restriction enzyme Pvul and CHO cells -(lxlO 7 cells /ml)
suspended in 0.8 ml of PBS were mixed in a cuvette, left
stationary on ice for 10 minutes and treated with pulse at
the capacity of 1.5kV, 25nFD. After recovering for 10

10 minutes at a room temperature the electroporated cells were

added to CHO-S-SFM II medium (GIBCO BRL) containing 10%
dialyzed bovine fetal serum and nucleic acid and cultivated.
After cultivating for 2 days the cultivation was continued
in nucleic acid-free CHO-S-SFM II medium (GIBCO BRL)

15 containing 10% dialyzed bovine fetal serum. From thus

obtained clones a clone with high expression rate was
selected as the production cell line for 12E10 single chain
Fv. After cultivating in serum-free CHO-S-SFM II medium
(GIBCO BRL), the culture supernatant was centrifuged to

20 remove cell debris and filtered with 0.22(im filter.

8.5 Purification of single chain Fv derived from 12E10
produced by CHO cells

The culture supernatants produced by CHO cell lines
expressing 12E10 single chain Fvs (scl2E10, dbl2E10)

25 obtained in Example 8.4 were purified by anti-FLAG antibody

column and gel filtration column respectively to produce
purified single chain Fvs.

105

(1) Purification with anti-FLAG antibody column
Each culture supernatant (scl2E10, dbl2E10) was added to
anti-FLAG M2 affinity gel column (SIGMA.) equilibrated by
50mM Tris-HCl buffer <pH7.4) containing 150mM NaCl. After
5 washing the column by the same buffer the proteins adsorbed

to the column were eluted by lOOmM glycine buffer (pH 3.5).
The eluted fractions were immediately neutralized by adding
1M Tris-HCl buffer (pH 8.0) and analyzed by SDS-PAGE. The
fraction which was confirmed to contain the single chain Fv
10 was pooled and concentrated about 20-fold using Centricon-10

(AMICON) .

(2) Gel filtration

The concentrated solution obtained in (1) was added to
Superdex200 column HR (10x300mm, AMERSHAM PHARMACIA)

15 equilibrated by PBS containing 0.01% Tween20. Chlomatograms

were shown in Fig. 53 and 54. The product scl2E10 was eluted
in two peaks (A, B) (see Fig. 53) . The product dbl2E10 was
eluted in two peaks (C, D) (see Fig. 54) . Each peak
fraction was collected, treated in the presence and absence

20 of a reducing agent, processed by electrophoresis according

to Laemmli method and stained by Coomassie Brilliant Blue
after the electrophoresis. As shown in Fig. 55 the all of
fractions A, B, C and D, regardless of the presence or
absence of the reducing agent, produced a single band having

25 an apparent molecular weight of about 31 kD. When these

fractions were analyzed by gel filtration using Superdex200
HR, the fraction A produced a product eluted at an apparent

molecular weight of about 42 kD, the fraction B at 20kD (see '
Fig. 56), fraction C at 69kD and fraction D at 41kD (see Fig.
57) . The results suggest that scl2E10-derived fraction A is
the non-covalent bond dimer of single chain Fv and the
fraction B is the monomer of single chain Fv, and the
dbl2E10-derived fraction C is the non-covalent bond trimer
of single chain Fv and D is non-covalent bond dimer of
single chain Fv.

8 . 6 Measurement of TPQ-like agonist activity of various
single chain Fvs

The TPO-like activity of anti-mpl single chain
antibody was evaluated by measuring the proliferation
activity to Ba/F3 cells- (BaF/mpl) expressing human TPO
receptor (MPL) .

After washing BaF/mpl cells two times by RPMI1640
medium (GIBCO) containing 1% bovine fetal serum (GIBCO) , the
cells were suspended in the medium at cell density of 5xl0 5
cells/mL. The ant i -MPL single chain antibody or human TPO
(R&D Systems) was diluted with the medium, respectively.
50nl of the cell suspension and 50ul of the diluted antibody
or human TPO were added in 96-well microplate (flat bottom)
(Corning) , and cultivated in C0 2 incubator (C0 2
concentration: 5%) for 24 hours. After the incubation lOjil
of WST-8 reagent (reagent for measuring the number of raw
cells SF: Nacalai Tesque) was added and the absorbance was
immediately measured at measurement wavelength of 4 50nm and
at reference wavelength of 655nm using absorbency photometer

107

Benchmark Plus (BioRad) . After incubating in C0 2 incubator
(C0 2 concentration: 5%) for 2 hours, the absorbance at 450nm
of measurement wavelength and 655nm of reference wavelength
was again measured using Benchmark Plus. Since WST-8 reagent
5 developed the color reaction depending upon the number of

live cells at wavelength of 450nm, the proliferation
activity of BaF/mpl was evaluated based on the change of
absorbance in 2 hours.

The agonist activity to MPL measured by using

10 culture supernatants of COS-7 cells expressing various 12E1P

antibody molecules are shown in Fig. 58. Single chain Fvs
having the 5-amino-acid-linker (dsl2E10) and the 15-amino-
acid-linker (scl2E10) increased the absorbance in
concentration-dependent manner, showing TPO-like agonist

15 activity (ED50; 9pM and 51pM respectively) , while 12E10IgG

and 12E10Fab had no activity.

It has been known that H chain and L chain of the
single chain Fv are associated not only within a molecule
but also between molecules to form multimers such as dimer.

2 0 When the culture supernatants of CHO cells expressing single

chain Fvs of 12E10 were gel filtrated and tested for agonist
activity on MPL. The results were shown in Fig. 59. The
dimer, which was contained in scl2E10 in a small amount,
showed about 5000-fold stronger TPO-like agonist activity

25 (scl2E10 dimer, ED50; 1.9pM) compared with the monomer

(scl2E10 monomer, ED50; >10nM) . The activity was higher than
that of TPO (ED50; 27pM) . The dimer of dbl2E10 (dbl2E10

108

dimer, ED50;2.0pM) showed strong activity comparable to that
of scl2E10 dimer. dbl2E10 trimer (ED50; 7.4pM), which was
presumed to be a trimer from molecular weight obtained by
gel filtration, showed a high activity which is lower than
5 that of dbl2E10 dimer. Those results suggest that it is

important for the activity of agonist antibody 12E10 that
the antigen-binding site is bivalent (dimer) . Considering
the fact that 12E10 IgG had no activity, other factors than
being bivalent are presumed to be important such as the

10 location of antigen-binding site, the distance or the angle.

EXPLANATION OF DRAWINGS

Fig. 1 shows the result of flow cytometry,
illustrating that human IgG antibody does not bind to L1210
cells expressing human IAP (hIAP/L1210) .

15 Fig. 2 shows the result of flow cytometry,

illustrating that the chimera MABL-1 antibody specifically
binds to L1210 cells expressing human IAP (hIAP/L1210) .

Fig. 3 shows the result of flow cytometry,
illustrating that the chimera MABL-2 antibody specifically

20 binds to L1210 cells expressing human IAP (hIAP/L1210) .

Fig. 4 schematically illustrates the process for
producing the single chain Fv according to the present
invention .

Fig. 5 illustrates a structure of an expression
2 5 plasmid which can be used to express a DNA encoding the

single chain Fv of the invention in E. coli .

109

Fig. 6 illustrates a structure of an expression
plasmid which is used to express a DNA encoding the single
chain Fv of the invention in mammalian cells.

Fig. 7 shows the result of western blotting in
5 Example 5.4. From the left, a molecular weight marker (which

indicates 97.4, 66, 45, 31, 21.5 and 14.5 "kDa from the top),
the culture supernatant of pCHOl- introduced C0S7 cells and
the culture supernatant of pCHOM2-introduced COS7 cells. It
illustrates that the reconstructed single chain Fv of the
10 antibody MABL-2 (arrow) is contained in the culture

supernatant of the pCHOM2-introduced cells.

Fig. 8 shows the result of flow cytometry,
illustrating that an antibody in the culture supernatant of
pCH01/COS7 cell as a control does not bind to pCOSl/L1210
15 cell as a control.

Fig. 9 shows the result of flow cytometry,
illustrating that an antibody in the culture supernatant of
MABL2-scFv/COS7 cells does not bind to pCOSl/L1210 cells as
a control.

20 Fig. 10 shows the result of flow cytometry,

illustrating that an antibody in the culture supernatant of
pC0Sl/C0S7 cells as a control does not bind to hIAP/L1210
cells .

Fig. 11 shows the result of flow cytometry,
25 illustrating that an antibody in the culture supernatant of

MABL2-scFv/COS7 cells specifically binds to hIAP/L1210
cells.

110

Fig. 12 shows the result of the competitive EL ISA
in Example 5.6, wherein the binding activity of the single
chain Fv of the invention (MABL2-scFv) to the antigen is
demonstrated in terms of the inhibition of binding of the
5 mouse monoclonal antibody MABL-2 to the antigen as an index,

in comparison with the culture supernatant of pCH01/C0S7
cells as a control.

Fig. 13 shows the results of the apoptosis-
inducing effect in Example 5.7, illustrating that the
10 antibody in the culture supernatant of pCH01/COS7 cells as a

control does not induce the apoptosis of pCOSl/L1210 cells
as a control.

Fig. 14 shows the results of the apoptosis-
inducing effect in Example 5.7, illustrating that the
15 antibody in the culture supernatant of MABL2-scFv/COS7 cells

does not induce apoptosis of pCOSl/L1210 cells as a control.

Fig. 15 shows the results of the apoptosis-
inducing effect in Example 5.7, illustrating that the
antibody in the culture supernatant of pCH01/COS7 cells as a
20 control does not induce apoptosis of hIAP/L1210 cells.

Fig. 16 shows the results of the apoptosis-
inducing effect in Example 5.7, illustrating that the
antibody in the culture supernatant of MABL2-scFv/COS7 cells
specifically induces apoptosis of hIAP/L1210 cells.
25 Fig. 17 shows the results of the apoptosis-

inducing effect in Example 5.7, illustrating that the
antibody in the culture supernatant of pCHO!/COS7 cells as a

Ill

control does not induce apoptosis of PCRF-CEM cells (at 50%
of the final concentration) .

Fig. 18 shows the results of the apoptosis-
inducing effect in Example 5.7, illustrating that the
5 antibody in the culture supernatant of MABL2-scFv/COS7 cells

specifically induces apoptosis of CCRF-CEM cells (at 50% of
the final concentration) .

Fig. 19 shows the chroma to gram obtained in the
purification of the single chain Fv derived form the

10 antibody MABL-2 produced by the CHO cells in Example 5.9,

illustrating that fraction A and fraction B were obtained as
the major peaks when the fraction from Blue-sepharose
column was purified with hydroxyapat ite column.

Fig. 20 shows the results of purification by gel

15 filtration of fraction A and fraction B obtained in Example

5.9- (2), illustrating that the major peaks (AI and BI,
respectively) were eluted from fraction A at approximately
3 6 kD of the apparent molecular weight and from fraction B
at approximately 7 6 kD.

20 Fig. 21 is the analysis on SDS-PAGE of the

fractions obtained in the purification of the single chain
Fv derived from the antibody MABL-2 produced by the CHO
cells in Example 5.9, illustrating that a single band of
approximately 35 kD of molecular weight was observed in both

25 fractions.

Fig. 22 shows the results of analysis of fractions
AI and BI obtained by gel filtration in the purification of

112

the single chain Fv derived from the antibody MABL-2
produced by the CHO cells, wherein fraction AI comprises
monomer and fraction BI comprises dimer.

Fig. 23 illustrates a structure of an expression
5 plasmid which can be used to express a DNA encoding the

single chain Fv of the invention in E. coli .

Fig. 2'4 shows the results of purification on the
gel filtration column of crude products of the single chain
Fv polypeptide derived from the antibody MABL-2 produced by
10 E. coli obtained in Example 5.12, wherein each peak

indicates monomer or dimer, respectively, of the single
chain Fv produced by E. coli .

Fig. 25 shows the results of the apoptosis-
inducing effect in Example 5.13, illustrating that mouse IgG
15 antibody as a control does not induce apoptosis of

hIAP/L1210 cells (the final concentration of 3 ug/ml) .

Fig. 2 6 shows the results of the apoptosis-
inducing effect in Example 5.13, illustrating that the dimer
of MABL2-scFv produced by the CHO cells remarkably induces
20 apoptosis of hIAP/L1210 cells (the final concentration of 3

ug/ml) .

Fig. 27 shows the results of the apoptosis-
inducing effect in Example 5.13, illustrating that the dimer
of MABL2-scFv produced by E. coli remarkably induces
25 apoptosis of hIAP/L1210 cells (the final concentration of 3

ug/ml) .

113

Fig. 28 shows the results of the apoptosis-
inducing effect in Example 5.13, illustrating that apoptosis
induction to hIAP/L1210 cells by the MABL2-scFv monomer
produced by the CHO cells is the same level as that of the

5 control (the final concentration of 3 ug/ml) .

Fig. 29 shows the results of the apoptosis-
inducing effect in Example 5.13, illustrating that apoptosis
induction to hIAP/L1210 cells of the MABL2-scFv monomer
produced by E. coli is the same level, as that of control
10 (the final concentration of 3 ug/ml) .

Fig. 30 shows the results of the apoptosis-
inducing effect in Example 5.13, illustrating that mouse IgG
antibody used as a control does not induce apoptosis of
hIAP/L1210 cells even when anti-FLAG antibody is added (the.
15 final concentration of 3 ug/ml) .

Fig. 31 shows the results of the apoptosis-
inducing effect in Example 5.13, illustrating that MABL2-
scFv. monomer produced by the CHO cells remarkably induces
apoptosis of hIAP/L1210 cells when anti-FLAG antibody is
20 added (the final concentration of 3 ug/ml) .

Fig. 32 shows the results of quantitative
measurement of human IgG in the serum of a human myeloma
cell line KPMM2^transplanted mouse, indicating amounts of
human IgG produced by the human myeloma cells in the mouse.
25 It illustrates that the dimer of scFv/CHO remarkably

inhibited growth of the KPMM2 cells.

114

Fig. 33 shows the survival time of the mouse after
the transplantation of tumor, illustrating that the scFv/CHO
dimer-administered group elongated remarkably the survival
time.

5 Fig. 34 illustrates a structure of an expression

plasmid which expresses a modified antibody [sc(Fv)2]
comprising two H chain V regions and two L chain V regions
derived from the antibody MABL-2 .

Fig. 35 illustrates a structure of a plasmid which
10 expresses a scFv (HL type) wherein the V regions are linked

in the manner of [H chain] - [L chain] without a peptide
linker .

Fig. 36 illustrates a structure of the HL-type
polypeptide and amino acid sequences of peptide linkers.
15 Fig. 37 illustrates a structure of a plasmid which

expresses a scFv (LH type) wherein the V regions are linked
in the manner of [L chain] - [H chain] without a peptide
linker .

Fig. 38 illustrates a structure of the LH-type
2 0 polypeptide and amino acid sequences of peptide linkers.

Fig. 39 shows the results of the western blotting
in Example 6.4, illustrating that the modified antibody
sc(FV) 2 comprising two H chain V regions and two L chain V
regions, and the MABL2-scFv having peptide linkers with
25 different length are expressed.

Figs. 4 0a and 40b show the results of flow
cytometry using the culture supernatant of COS7 cells

prepared in Example 6.3 (1), illustrating that the MABL2-
scFv and sc(Fv) 2 having peptide linkers with different
length have high affinities against human IAP .

Fig. 41a and 41b shows the results of the . apoptosis
inducing effect in Example 6.6, illustrating that trie scFv
<HL3, 4, 6, 7, LH3, 4, 6 and 7> and the sc(Fv) 2 remarkably
induce cell death of hIAP/L1210 cells.

Fig. 42 shows the results of the evaluation of
antigen binding capacity in Example 6.10, illustrating that
the dimer of scFv <HL5> and sc(Fv) 2 have high affinities
against human IAP.

Fig-. 43 shows the results of the in vitro
apoptosis-inducing effect in Example 6.11, illustrating that
the dimer of scFv <HL5> and the sc(Fv) 2 induce apoptosis of
hIAP/L1210 cells and CCRF-CEM cells in concentration-
dependent manner .

Fig. 44 shows the results of the quantitative
measurement of M protein produced by a human myeloma cell
line KPMM2 in the serum of the human myeloma cell-
transplanted mouse. It illustrates that the dimer of scFv
<HL5> and the sc(Fv) 2 remarkably inhibited growth of the
KPMM2 cells .

Fig. 4 5 shows the survival time (days) of mice
after the transplantation of tumor, illustrating that the
survival time of the scFv <HL5> administrated- group was
remarkably prolonged.

116

Fig. 46 shows the survival time (days) of mice
after the transplantation of tumor, illustrating that the
survival time of the sc(Fv>2 administrated-group was
remarkably prolonged.
5 Fig. 47 is a scheme showing the method for

constructing DMA fragment encoding the reconstructed 12B5
single chain Fv containing the linker sequence consisting of
15 amino acids and the structure thereof.

Fig. 48 shows the purification result of each 12B5
10 single chain Fv by gel filtration obtained in Example 7. 5

(1), illustrating that scl2B5 was divided into two peaks
(fractions A and B) .

Fig. 49 shows the analytical result of each
fraction A and B by SDS-PAGE performed in Example 7. 5 (2) .
15 Fig. 50 shows the analytical result of each

fraction A and B by Superdex200 column performed in Example
7. 5 (2), illustrating that the major peak of fraction A was
eluted at an apparent molecular weight of about 44 kD shown
in (a) and that the major peak of fraction B was eluted at
20 an apparent molecular weight of about 22kD shown in (b) .

Fig. 51 shows the measurement result of the TPO-
like agonist activity of scl2B5 and antibody 12B5 (IgG, Fab) ,
illustrating that 12B5IgG and monovalent single chain Fv
(scl2B5) showed TPO-like agonist activity in concentration-
25 dependent manner.

Fig. 52 shows the measurement result of TOP-like
agonist activity of scl2B5 monomer and dimer, illustrating

- 117 -

that .single chain Fv (scl2B5 dimer) having bivalent
antigen-binding site had agonist activity about " 400-fold
higher than monovalent scl2B5 and that the efficacy is
equivalent to or higher than human TPO.

Fig. 53 shows the purification result of obtained
scl2E10 single chain antibody by gel filtration
chromatography using Superdex200HR column, illustrating that
SC12E1Q was divided into two peaks (fractions A and B) .

Fig. 54 shows the purification result of obtained
dbl2E10 single chain antibody by gel filtration
chromatography using Superdex200HR column, illustrating
that dbl2E10 was divided into peaks (fractions C and D) .

Fig. 55 shows SDS-PAGE analysis of fractions A and B
(scl2E10) and fractions C and D (dbl2E10) under the
reductive or non-reductive condition.

Fig. 56 shows the analytical result of fractions A
and B by gel filtration chromatography using Superdex200HR
column,, illustrating (1) the major peak of fraction A was
eluted at an apparent molecular weight of about 42 kD and
(2) the major peak of fraction B was eluted at an apparent
molecular weight of about 20kD.

Fig. 57 shows the analytical result of fractions C
and D by gel filtration chromatography using Superdex200HR
column, illustrating (1) the major peak of fraction C was
eluted at an apparent molecular weight of about 69 kD and
(2) the major peak of fraction D was eluted at an apparent
molecular weight of about 41kD.

118

Fig. 58 is a graph showing the agonist activity of
various 12E10 antibody molecules on MPL, illustrating that
single chain Fvs (scl2E10, dbl2ElO) showed TPO-like agonist
activity while 12E10 IgG and 12E10 Fab did not.
5 Fig. 59 is a graph showing the agonist activity of

monomer and dimer of scl2E10 and dimer and trimer of dbl2ElO
on MPL, illustrating that dimer of scl2E10 and dimer and
trimer of dbl2E10 showed higher TPO-like agonist activity
than TPO.

10

INDUSTRIAL APPLICABILITY

The modified antibodies of the invention have an
agonist action capable of transducing a signal into cells by
crosslinking a cell surface molecule (s) and are advantageous

15 in that the permeability to tissues and tumors is high due

to the lowered molecular size compared with antibody
molecule (whole IgG) . This invention provides the modified
antibodies with an agonist activity remarkably higher than
TPO or parent antibodies (whole IgG) . Especially even parent

20 antibodies without agonist activity can be altered into the

modified antibodies with an agonist activity higher than
TPO. Therefore the modified antibodies can be used as
signal-transducing agonists. The modification of antibody
molecule results in the reduction of side effects caused by

25 intercellular crosslinking and provides novel medicines

inducing only required action by crosslinking a cell surface
molecule (s). Medical preparations containing as active

-119-

ingredient the modified antibodies of the invention are
useful as preventives and/or remedies for platelet-
related-blood diseases, thrombocytopenia caused by
chemotherapy for cancers or leukemia and the like.

In the claims which follow and in the preceding
description of the invention, except where the context
requires otherwise due to express language or necessary
implication, the word "comprise" or variations such as
"comprises" or "comprising" is used in an inclusive sense,
i.e. to specify the presence of the stated features but
not to preclude the presence or addition of further
features in various embodiments of the invention.

It is to be understood that a reference herein to a
prior art document does not constitute an admission that
the document forms part of the common general knowledge in
the art in Australia or any other country.

- 120-

CLAIMS

1. A modified antibody comprising two or more H chain V
regions and two or more L chain V regions of antibody and
showing TPO agonist action by crosslinking TPO receptor,
wherein the modified antibody is:

(i) a multimer of single chain Fv comprising an H
chain V region and an L chain V region; or

(ii) a single chain polypeptide comprising two or
more H chain V regions and two or more L chain V regions.

2. The modified antibody of claim 1, wherein the H chain
V region and the L chain V region are connected through a
linker .

3. The modified antibody of claim 2, wherein the linker
is a peptide linker comprising at least one amino acid.

4. The modified antibody of any one of claims 1 to 3,
wherein the modified antibody is composed of tetramer,
trimer or dimer of single chain Fv .

5. The modified antibody of claim 4, wherein the
modified antibody is composed of dimer of single chain Fv .

6. The modified antibody of any one of claims 1 to 5,
wherein the H chain V region and the L chain V region
existing in the same chain are not associated to form an
antigen-binding site.

7. The modified antibody of any one of claims 1 to 3,
wherein the modified antibody is a single chain

- 121 -

polypeptide comprising two H chain V regions and two L
chain V regions .

8. The modified antibody of any one of claims 1 to 7,
wherein the modified antibody further comprises an amino
acid sequence (s) for peptide purification.

9. The modified antibody of any one of claims 1 to 8,
wherein the modified antibody has been purified.

10. The modified antibody of any one of claims 1 to 9,
wherein H chain V region and/or L chain V region is H
chain V region and/or L chain V region derived from a
human antibody.

11. The modified antibody of any one of claims 1 to 9,
wherein H chain V region and/or L chain V region is
humanized H chain V region and/or L chain V region.

12. The modified antibody of any one of claims 1 to 11,
wherein the modified antibody is mono-specific modified
antibody .

13. The modified antibody of any one of claims 1 to 11,
wherein the modified antibody is multi-specific modified
antibody .

14. The modified antibody of claim 13, wherein the
modified antibody is bi-specific modified antibody.

15. The modified antibody of claim 12, wherein the L
chain V region and the H chain V region are from the same
monoclonal antibody.

- 122 -

16. The modified antibody of any one of claims 1 to 15
which shows an equivalent or better agonist action (ED50)
compared with the parent monoclonal antibody.

17. The modified antibody of claim 16 which shows at
least 2-fold agonist action (ED50) compared with the
parent monoclonal antibody.

18. The modified antibody of claim 17 which shows at
least 10-fold agonist action (ED50) compared with the
parent monoclonal antibody.

19. The modified antibody of any one of claims 1 to 15
which is derived from a parent antibody having
substantially no agonist action.

20. A compound comprising two or more H chain V regions
and two or more L chain V regions of monoclonal antibody
and showing an equivalent or better agonist action (ED50)
compared with thrombopoietin (TPO) .

21. The compound of claim 20 which shows at least 2-fold
agonist action (ED50) compared with TPO.

22. The compound of claim 21 which' shows at least 10-fold
agonist action (ED50) compared with TPO.

23. The modified antibody or compound of any one of
claims 1-22 which has ED50 of TPO agonist activity not
more than 20pM.

24. The modified antibody or compound of claim 23 which

-123-

has ED50 of TPO agonist activity not more than 10 pM.

25. The modified antibody or compound of claim 24 which
has ED50 of TPO agonist activity not more than 2pM.

26. The modified antibody or compound of any one of
claims 1 to 25 which has intercellular adhesion action
(ED50) not more than 1/10 compared with the parent
antibody .

27. The modified antibody or compound of any one of
claims 1 to 25 which has substantially no intercellular
adhesion action.

28. A DNA which encodes the modified antibody or compound
of any one of claims 1 to 27 .

29. An animal cell which produces the modified antibody
or compound of any one of claims 1 to 27 .

30. A microorganism which produces the modified antibody
or compound of any one of claims 1 to 27.

31. Use of the modified antibody or compound of any one
of claims 1 to 27 as TPO agonist.

32. A method of causing an agonist action to cells by
crosslinking TPO receptor using the modified antibody or
compound of any one of claims 1 to 27 thereby transducing
a signal into cells .

33. The method of claim 32 wherein the agonist action is
proliferation, differentiation-induction or growth

- 124-

stimulation of megakaryocytes, platelet production or
phosphorylation of TPO receptor protein.

34. A medicine comprising as active ingredient the
modified antibody or compound of any one of claims 1 to
27 .

35. The medicine of claim 34 which is for the treatment
of thrombocytopenia .

36. Use of the modified antibody or compound of any one
of claims 1 to 27 as medicine.

37. A method of screening a modified antibody comprising
two or more H chain V regions and two or more L chain V
regions of antibody and showing an agonist action by
crosslinking TPO receptor, wherein the modified antibody
is :

(i) a multimer of single chain Fv comprising an H chain V
region and an L chain V region; or

(ii) a single chain polypeptide comprising two or more H
chain V regions and two or more L chain V regions, which
comprises the steps

(1) to produce a modified antibody comprising two or more
H chain V regions and two or more L chain V regions of
antibody and binding specifically to TPO receptor,

(2) to subject cells expressing said TPO receptor to react
with the modified antibody and

(3) to measure TPO agonist action in the cells caused by
crosslinking TPO receptor.

38. A method of measuring an agonist action of a modified
antibody comprising two or more H chain V regions and two

- 125 -

or more L chain V regions of antibody and showing an
agonist action by crosslinking TPO receptor, wherein the
modified antibody is:

(i) a multimer of single chain Fv comprising an H chain V
region and an L chain V region; or

(ii) a single chain polypeptide comprising two or more H
chain V regions and two or more L chain V regions, which
comprises the steps

(1) to produce a modified antibody comprising two or more
H chain V regions and two or more L chain V regions of
antibody and binding specifically to TPO receptor,

(2) to subject cells expressing said TPO receptor to react
with the modified antibody and

(3) to measure TPO agonist action in the cells caused by
crosslinking TPO receptor.

39. A modified antibody according to claim 1
substantially as hereinbefore described with reference to
any one of the Examples.

40. A compound according to claim 20 substantially as
hereinbefore described with reference to any one of the
Examples .

41. A DNA according to claim 28 substantially as
hereinbefore described with reference to any one of the
Examples .

42. An animal cell according to claim 29 substantially as
hereinbefore described with reference to any one of the
Examples .

43. A microorganism according to claim 30 substantially

- 126-

as hereinbefore described with reference to any one of the
Examples .

44. A use according to claim 31, substantially as
hereinbefore described with reference to any one of the
Examples .

45. A method according to claim 32 substantially as
hereinbefore described with reference to any one of the
Examples .

46. A medicine according to claim 34 substantially as
hereinbefore described with reference to any one of the
Examples .

47. A use according to claim 36, substantially as
hereinbefore described with reference to any one of the
Examples .

48. A method according to claim 37 substantially as
hereinbefore described with reference to any one of the
Examples .

49. A method according to claim 38 substantially as
hereinbefore described with reference to any one of the
Examples .

Dated this 9th day of March 2006
CHUGAI SEIYAKU KABUSHIKI KAISHA
By Their Patent Attorneys
GRIFFITH HACK

1 / 50

Fig. 1

o 980727.004

iu-
FL1 FFTC

Fig. 2

o 980727.006

o -

CM _

FL1 FITC.

2 / 50

Fig. 3

3 / 50

a

LL
(A

K
- o
o
IU

■c

o -

u

IU

-J
>

O
-H
+J
(0
C
•H
-Q

e
o
u
<u

«
o

Fig. 5

4 / 50

pelB

T7 promoter

Ori

(Giy4Ser)3

FLAG

T7 terminator

5 / 50

Fig . 6

6 / 50

Fig. 7

marker

7 / 50

Fig. 8

FL1 RTC

Fig. 9

Fig. 10

6 / 50

o 990128.057

R.1 RTC

Fig. 11

FL1 FtTC

Fig. 12

9 / 50

Fig. 13

Competitive EL/SA

0.001 0.01 0.1

Dilution ratio of CM

pCH01/COS7 CM
-• MABL2-3CFV/C0S7 CM

CD
O -

■s

a.
o

o -

990209.001

4.57%

5.38%

10^

i in — i — r i i 1 1 ii i —

1 2

10 10^

i t — rm

AnnexJn V-FITC

10 v

' 1 1 "f

10 H

12 / 50

Fig. 18

13 / 50

14 / 50

Fig. 20

edition time (min)

15 / 50

Fig. 21

SDS-PAGE analysis of MABL2-scFv

<CHO>

03

E

kOa
97.4-
66-

31 -»

21J5-
14.5-

£
o
c
o

£

lliilii

JL

E

0>

£
o
c
o
£

+2ME -2ME

<E. coli>

£

o

CD

E

c
o

.§

IrDa iriv.t— u-.S

£

"a

-45-*-|

31-

£
o
c
o
£

21.5-

14.5-

+2ME -2ME

Fig. 22

16 / 50

TSK gel G3000SW

20 mM Acetate buffer, 0.15 M NaCI, pH 6.0

cd

monomer §

dimer

cd cd
QQ
J*.

CD CO

I

17/50

Fig. 23

Amp'

18 / 50

Fig. 25

19 / 50

990819.004

o _

"O
I

H3

— ~r: — > — ' ■
10 w 10*

AnneM'n V-FITC

10

3.80%

2.76%

10"

Fig. 26

990819.024

Annexin V-FITC

Fig. 27

20 / 50

990810.024

Annexin V-FITC

Fig. 28

21 / 50

Fig. 29

22 / 50

Fig. 30

Fig. 31

990925.036

10 v

10" 1c£ io°

Annejdn V-RTC

10

23 / 50

Fig. 32

Effect of MABL-2 (scFv) on serum hlgG
in KPMM2 l.v. SCJD mice

** : p<0.01

24 / 50

Fig. 33

Effect of MABL-2 (scFv) on survival
of KPMM2 Lv. SC1D mice

100

75

]_

>
>

La

3

W 25

10 20 30 40

Days after cell inoculation

scFv/CHO Dimer **

scFv/CHO Monomer
PBS(-)

i

50

** ;• P<0.01 by t-test

Fig. 34

25 / 50

26 / 50

Fig. 35

27 / 50

Fig. 36

Base Sequence and Amino Acid Sequence of Linker for HL Type

Heavy chain

Light chain

gtc teg agt

V s s

linier

gac gtc gtg ■••
D V V

FLAG

Plasmid

Number of
linker amino acid

linier .

CF2HL-0/pCOSl

0

gtc teg agt

gac gtc gtg

V S S

D V V

CF2HL-3/pCOSl

3

gtc teg agt ggt ggt tec

gac gtc gtg

V S S G G S

D V V

CF2HL-4/pCOSl

4

gtc teg agt ggt ggt ggt tec

gac gtc gtg

V S S G G G S

'D V V

CF2HL-5/pCOSl

5

gtc teg- agt ggt ggt ggt ggt tec

gac gtc gtg

VSSGGGGS

D V V

CF2HL-6/pCOSl

6

gtc teg agt gt ggt ggt ggt ggt tec

gac gtc gtg

VSSGGGGGS

D V V

CF2HL-7/pCOSl

7 •

gtc teg agt ggt ggt ggt ggt ggt ggt tec gac gtc gtg

VSSGGGGGG

S D V V

Fig. 37

28 / 50

Pvu I

29 / 50

Fig. 38

Base Sequence and Amino Acid Sequence of Linker for LH Type

Li?ht chain

Heavy chain

gag ata aaa
E I K

linker

cag gtc caa
Q V Q

FLAG

Plasmid

Number of
linker amino acid

linker

CF2LH-0/pCOSl

0

gag ata aaa

cag gtc caa

E IK

Q V Q

CF2LH-3/pCOSl

3

gag ata aaa tec gga ggc

cag gtc caa

E I K S G G

Q V Q

CF2LH-4/pCOSl

4

gag ata aaa tec gga ggt ggc

cag gtc caa

E I K S G G G

Q V Q

CF2LH-5/pCOSl

5

gag ata aaa tec gga ggt ggt ggc

cag gtc caa

E IZSGGGG

Q V Q

CF2LH-6/pCOSl

6

gag ata aaa tec gga ggt -ggt ggt ggc

cag gtc caa

E IKSG GGGG

Q V Q

CF2LH-7/pCOSl

7

gag ata aaa tec gga ggt ggt ggt ggt ggc

cag gtc caa

E IKSGGGGGG

Q V Q

30 / 50

Fig. 39

CO

CO

CO

CO

CO

CO

CO

CO

CO

CO

CO

CO

O

O

O

O

O

O

O

o

o

O

O

O

O

o

O

O

o

O

O

O

o

o

O

o

>

.g.

_g.

,g.

Q.

Q.

Q.

-5*

.a.

Q.

.a.

,g.

a.

LL^

o

CO

*r

Lea

o

CO

CO
l

CM

i

_l

Jj

Jj

Jj

Jj

_J

1

X

1

X

i

X

i

X

X

X

X

X

X

X

X

X

_l

_J

-I

_J

_!

_I

O

CM

CN

CM

Of

<M

CN

CNJ

CM

CM

X

LL

ll

LL

LL

LL

LL

LL

2!

LL

CF

LL

a

O

O

O

O

O

o

O

O

o

O

o

a.

^^li|ip^P^P#fe9 J — sc(Fv)2

31 / 50

Fig. 40a

32 / 50

Fig. 40b

pCHOM2(Fv)j COS7 CM

©

<N .

v» -

FTTC

CF2LH-4/pCOS1 COS7 CM

o

CM

RTC

CF2LH-6/pC0S1 C0S7 CM

p

CF2LH-0/pCOS1 COS7 CM £H

8- - j

33 / 50

'spipoi^jnipidojd

apipo]

?un|p|dojd

Fig. 41b

34 / 50

CF2HL-4/pCOS1 COS7 CM CF2LH-4/pCOS1 COS7 CM

Annexin V-FITC Annexin V-FITC

CF2HL-€/pCOS1 COS7 CM

CF2LH-6/pCOS1 COS7 CM

u ^»:

': . •

'. .' 24.95%

4i- 36.53%

10 v

10 10' 10

Annexin V-FITC

10

3 ^—
Q.

Q_ O -

o
o

■

' . s * * , •

> * *. - '
'* * *

,? : =' * -•• 27.74%

.••v^>. : "

■ i^m

V.\. '• ■ 34.46%

10

10' 10' 10"
Annexin V-FITC

10

CF2HL-7/pCOS1 C0S7 CM CF2LH-7/pCOS1 COS7 CM

Annexin V-FITC Annexin V-FITC

35 / 50

Fig. 42

(A) pCOS1/L1210 cells (B) hlAP/L1210 cells

Fig. 43

36 / 50

(A) hIAP/L1210 cells

Binding Sites (nM).

100

100

(B) CCRF-CEM cells

1 10

Binding Sites (nM)

100

control migG
Intact MABL-2
MABL2-SCFV <HL-5>
MABL2-sc(Fv) 2

37 / 50

.g. 44

2500 5000 7500

Serum M protein (ug/mL)

10000

38 / 50

Fig. 45

100

75

50

25

0

■HL-5 10mg/kg *
HL-5 1mg/kg
HL-5 0.1mg/kg
Vehicle

20 40 60 80 100

Number of Days after Transplantation

39 / 50

Fig. 46

en
c

<

<

rt

100

75

50

25

sc(Fv)2 10mg/kg •
sc(Fv)2 1mg/kg
sc(Fv)2 0.1mg/kg
Vehicle

20

40

60

Number of Days after Transplantati

ion

40 / 50

41 / 50

Fig. 48

s c 1 2 B 5

290 142 67
T T T

mAO

1000

32
T

12.4
T

5.0

10. 0

A

15 .0

20 . 0

ml

42 / 50

49

M 1 2 M 1 2

With Reducing Agent Without Reducing Agent

M : MW marker

1 :sd 2B5 fractionA

2:sc1 2B5 fractionB

43 / 50

50

290 142 67 32 12.4 kD

g (a) sc 12B5peakA f II I I

o

44 / 50

Fig. 51

1.2 r

< 0.0001 0.001 0.01 0.1 1 10 100

Concentration (nM)

Fig. 52

1.5 r

0.00001 0.0001 0.001 0.01 0.1 1 10 100 1000

Concentration (nM)

45 / 50

o

o
o

o

©

•H

1 2

o
o

o
o
o

o
o

46 / 50

47 / 50

Fig. 5 5

Reductive condition Non-reductive condition
M1234 M1234

2: sc12E10 fraction B
3: db12E10 fraction C
4: db12E10 fraction D

48 / 50

Fig. 56

SC3 peak A

SC3 peak B

o

00
CM

0
C

n
Xi
u
o

0)

2

o

GO
CM

O
C
as
X)
M
O
10

5

(scl2E10)

mAU
5.0

4.0

3.0

2.0

1.0

0.0

-1.0

42kD
I

37.17

i!

0:67

\

0.0

10.0 20.0 30.0

Retention time (minute)

40.0

min

mAU

60.0
40.0
20.0
0.0

20kD
I

41.24

\

0.0

10.0

20.0

30.0

40.0

Retention time (minute)

49 / 50

Pig. 57

db3 peak C

db3 Peak D

o

CO

<0

o
c

(4
J3
M
O
m

3

o
co

CM

<B
O
C
rt

O

10

5

(dbl2E10 )

69 kD

mAU
80
60
40
20
0

0.0 10.0 20.0 30.0

Retention, time (minute)

40.0

mAU
30.0
20.0
10.0
0.0

41kD
I

\

\

0.0

10.0

20.0

30.0

40.0

min

Retention time (minute)

50 / 50

Fig. 5 8

0.00001 0.0001 0.001 0.01 0.1 1 10

Concentration (nM)

Fig. 5 9

Concentration (nM)

1/74

SEQUENCE LISTING

<110> CHUGAI SEIYAKU KABUSHIKI KAISHA

<120> DEGRADED AGONIST ANTIBODY

<130> FP1033
<141> 2001-10-22
<150> JP2000-321821
<151> 2000-10-20
<150> PCT/JPO 1/03288
<151> 2001-04-17
<150> JP2001-277314
<151> 2001-09-12

<160> 113

<210> 1
<211> 27
<212> DNA

<213> Artificial Sequence

<220>

<223> PCR primer
<400> 1

ccatcctaat acgactcact atagggc 27

<210> 2
<211> 27
<212> DNA

<213> Artificial Sequence

2/74

<220>

<223> PCR primer
<400> 2

ggatcccggg tggatggtgg gaagatg 27

<210> 3
<211> 28
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 3

ggatcccggg ccagtggata gacagatg 28

<210> 4
<211> 26
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 4

ggatcccggg agtggataga ccgatg 26

<210> 5
<211> 394
<212> DNA
<213> Mus
<220>

3/74

<221> CDS

<222> (1). . . (393)

<223> pGEM-MlL. 1-57; signal peptide, 58-394 Iraature peptide
<400> 5

atg aag ttg cct gtt agg ctg ttg gtg ctg atg ttc tgg att cct gcg 48
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp He Pro Ala

1 5 10 15

tec age agt gat gtt gtg atg ace caa act cca etc tec ctg cct gtc 96
Ser Ser Ser Asp Val Val Met Thr Gin Thr Pro Leu Ser Leu Pro Val

20 25 30

agt ctt gga gat caa gec tec ate tct tgc aga tct agt cag age ctt 144
Ser Leu Gly Asp Gin Ala Ser He Ser Cys Arg Ser Ser Gin Ser Leu

35 40 45

eta cac agt aaa gga aac acc tat tta caa tgg tac eta cag aag cca 192
Leu His Ser Lys Gly Asn Thr Tyr Leu Gin Trp Tyr Leu Gin Lys Pro

50 55 60

ggc cag tct cca aag etc ctg ate tac aaa gtt tec aac cga ttt tct 240
Gly Gin Ser Pro Lys Leu Leu He Tyr Lys Val Ser Asn Arg Phe Ser
65 70 75 80

ggg gtc cca gac agg ttc agt ggc agt gga tea ggg aca gat ttc aca 288
Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr

85 90 95

etc aag ate age aga gtg gag get gag gat ctg gga gtt tat ttc tgc 336
Leu Lys He Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys

100 105 110

tct caa agt aca cat gtt ccg tac acg tec gga ggg ggg acc aag ctg 384
Ser Gin Ser Thr His Val Pro Tyr Thr Ser Gly Gly Gly Thr Lys Leu
115 120 125

4/74

gaa ata aaa c 394
Glu He Lys
130

<210> 6

<211> 409

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (408)

<223> pGEM-MlH. 1-57; signal peptide, 58-409 ;mature peptide
<400> 6

atg gaa tgg age tgg ata ttt etc ttc etc ctg tea gga act gca ggt 48
Met Glu Trp Ser Trp He Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly

1 5 10 15

gtc cac tec cag gtc cag ctg cag cag tct gga cct gac ctg gta aag 96
Val His Ser Gin Val Gin Leu Gin Gin Ser Gly Pro Asp Leu Val Lys •

20 25 30

cct ggg get tea gtg aag atg tec tgc aag get tct gga tac acc ttc 144
Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe

35 40 45

gtt aac cat gtt atg cac tgg gtg aag cag aag cca ggg cag ggc ctt 192
Val Asn His Val Met His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu

50 55 60

gag tgg att gga tat att tat cct tac aat gat ggt act aag tac aat 240
Glu Trp He Gly Tyr He Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn
65 70 75 80

5/74

gag aag ttc aag ggc aag gcc aca ctg act tea gag aaa tec tec age 288
Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Glu Lys Ser Ser Ser

85 90 95

gca gcc tac atg gag etc age age ctg gcc tct gag gac tct gcg gtc 336
Ala Ala Tyr Met Glu Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val

100 105 110

tac tac tgt gca aga ggg ggt tac tat agt tac gac gac tgg ggc caa 384
Tyr Tyr Cys Ala Are Gly Gly Tyr Tyr Ser Tyr Asp Asp Trp Gly Gin

115 120 125

ggc acc act etc aca gtc tec tea g 409
Gly Thr Thr Leu Thr Val Ser Ser
130 135

<210> 7

<211> 394

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1). . . (393)

<223> pGEM-M2L. l-57;signal peptide, 58-394;mature peptide
<400> 7

atg aag ttg cct gtt agg ctg ttg gtg ctg atg ttc tgg att cct ggt 48
Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp He Pro Gly

1 5 10 15

tec age agt gat gtt gtg atg acc caa agt cca etc tec ctg cct gtc 96
Ser Ser Ser Asp Val Val Met Thr Gin Ser Pro Leu Ser Leu Pro Val
20 25 30

6/74

agt ctt gga gat caa gcc
Ser Leu Gly Asp Gin Ala
35

gtg cac agt aat gga aag
Val His Ser Asn Gly Lys
50

ggc cag tct cca aaa etc
Gly Gin Ser Pro Lys Leu
65 70
ggg gtc cca gac agg ttc
Gly Val Pro Asp Arg Phe
85

etc atg ate age aga gtg
Leu Met lie Ser Arg Val
100

tct caa agt aca cat gtt
Ser Gin Ser Thr His Val
115

gaa ata aaa c
Glu lie Lys
130

tec ate tct tgo aga
Ser He Ser Cys Arg
40

ace tat tta cat tgg
Thr Tyr Leu His Trp
55

ctg ate tac aaa gtt
Leu lie Tyr Lys Val
75

agt ggc agt gga tea
Ser Gly Ser Gly Ser
90

gag get gag gat ctg
Glu Ala Glu Asp Leu
105

ccg tac acg ttc gga
Pro Tyr Thr Phe Gly
120

tea agt cag age ctt 144
Ser Ser Gin Ser Leu
45

tac ctg cag aag cca 192
Tyr Leu Gin Lys Pro
60

tec aac cga ttt tct 240
Ser Asn Arg Phe Ser
80

gtg aca gat ttc aca 288
Val Thr Asp Phe Thr
95

gga gtt tat ttc tgc 336
Gly Val Tyr Phe Cys
110

ggg ggg acc aag ctg 384
Gly Gly Thr Lys Leu
125

394

<210> 8
<211> 409
<212> DNA
<213> Mus
<220>
<221> CDS

7/74

<222> (1). . . (408)

<223> pGEM-M2H. 1-57; signal peptide, 58-409;iriature peptide
<400> 8

atg gaa tgg age tgg ata ttt etc ttc etc ctg tea gga act gca ggt 48

Met Glu Trp Ser Trp He Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly

15 10 15

gtc cac tec cag gtc cag ctg cag cag tct gga cct gaa ctg gta aag 96

Val His Ser Gin Val Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Lys

20 25 30

cct ggg get tea gtg aag atg tec tgc aag get tct gga tac acc ttc 144

Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe

35 40 45

get aac cat gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt 192

Ala Asn His Val He His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu

50 55 60

gag tgg att gga tat att tat cct tac aat gat ggt act aag tat aat 240

Glu Trp He Gly Tyr He Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn

65 70 75 80

gag aag ttc aag gac aag gec act ctg act tea gac aaa tec tec acc 288

Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr

85 90 95

aca gec tac atg gac etc age age ctg gec tct gag gac tct gcg gtc 336

Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val

100 105 110

tat tac tgt gca aga ggg ggt tac tat act tac gac gac tgg ggc caa 384

Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp Gly Gin

115 120 125

ggc acc act etc aca gtc tec tea g 409

8/74

Gly Thr Thr Leu Thr Val Ser Ser
130 135

<210> 9
<211> 32
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 9

cccaagcttc caccatgaag ttgcctgtta gg 32

<210> 10
<211> 32
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 10

cccaagcttc caccatggaa tggagctgga ta 32

<210> 11
<211> 34
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 11

9/74

cgcggatcca ctcacgtttt atttccagct tggt 34

<210> 12
<211> 34
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 12

cgcggatcca ctcacctgag gagactgtga gagt 34

<210> 13
<211> 30
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 13

catgccatgg cgcaggtcca gctgcagcag 30

<210> 14

<211> 27

<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer

<400> 14

accaccacct gaggagactg tgagagt 27

10/74

<210> 15
<211> 27
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 15

gtctcctcag gtggtggtgg ttcgggt 27

<210> 16
<211> 27
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 16

cacaacatcc gatccgccac cacccga 27

<210> 17
<211> 27
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 17

ggcggatcgg atgttgtgat gacccaa 27

11/74

<210> 18
<211> 57
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 18

ccggaattct cattatttat cgtcatcgtc tttgtagtct tttatttcca gcttggt 57

<210> 19
<211> 45
<212> DNA

<213> Artificial Sequence
<220>

<223> Linker amino acid sequence and nucleotide sequence
<400> 19

ggt ggt ggt ggt teg ggt ggt ggt ggt teg ggt ggt ggc gga teg 45
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
5 10 15

<210> 20

<211> 828

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1). . . (822)

<223> pscMl. MABLl-scFv

12/74

<400> 20

atg aaa tac eta ttg cct acg gca gec get gga ttg tta tta etc get 48
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala

1 5 10 15

gec caa cca gee atg gcg cag gtc cag ctg cag cag tct gga cct gac 96
Ala Gin Pro Ala Met Ala Gin Val Gin Leu Gin Gin Ser Gly Pro Asp

20 25 30

ctg gta aag cct ggg get tea gtg aag atg tec tgc aag get tct gga 144
Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly

35 40 45

tac acc ttc gtt aac cat gtt atg cac tgg gtg aag cag aag cca ggg 192
Tyr Thr Phe Val Asn His Val Met His Trp Val Lys Gin Lys Pro Gly

50 55 60

cag ggc ctt gag tgg att gga tat att tat cct tac aat gat ggt act 240
Gin Gly Leu Glu Trp lie Gly Tyr He Tyr Pro Tyr Asn Asp Gly Thr
65 70 75 80

aag tac aat gag aag ttc aag ggc aag gec aca ctg act tea gag aaa 288
Lys Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Glu Lys

85 90 95

tec tec age gca gec tac atg gag etc age age ctg gec tct gag gac 336
Ser Ser Ser Ala Ala Tyr Met Glu Leu Ser Ser Leu Ala Ser Glu Asp

100 105 110

tct gcg gtc tac tac tgt gca aga ggg ggt tac tat agt tac gac gac 384
Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Ser Tyr Asp Asp

115 120 125

tgg ggc caa ggc acc act etc aca gtc tec tea ggt ggt ggt ggt teg 432
Trp Gly Gin Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser
130 135 140

13/74

ggt ggt ggt ggt
Gly Gly Gly Gly
145

act cca etc tec
Thr Pro Leu Ser

tgc aga tct agt
Cys Arg Ser Ser
180

caa tgg tac eta
Gin Trp Tyr Leu
195

aaa gtt tec aac
Lys Val Ser Asn
210

gga tea ggg aca
Gly Ser Gly Thr
225

gat ctg gga gtt
Asp Leu Gly Val

tec gga ggg ggg
Ser Gly Gly Gly
260

gat aaa taatga
Asp Lys

teg ggt ggt ggc
Ser Gly Gly Gly
150

ctg cct gtc agt
Leu Pro Val Ser
165

cag age ctt eta
Gin Ser Leu Leu

cag aag cca ggc
Gin Lys Pro Gly
200

cga ttt tct ggg
Arg Phe Ser Gly
215

gat ttc aca etc
Asp Phe Thr Leu
230

tat ttc tgc tct
Tyr Phe Cys Ser
245

acc aag ctg gaa
Thr Lys Leu Glu

gga teg gat gtt gtg
Gly Ser Asp Val Val
155

ctt gga gat caa gec
Leu Gly Asp Gin Ala
170

cac agt aaa gga aac
His Ser Lys Gly Asn
185

cag tct cca aag etc
Gin Ser Pro Lys Leu
205

gtc cca gac agg ttc
Val Pro Asp Arg Phe
220

aag ate age aga gtg
Lys lie Ser Arg Val
235

caa agt aca cat gtt
Gin Ser Thr His Val
250

ata aaa gac tac aaa
lie Lys Asp Tyr Lys
265

atg acc caa 480
Met Thr Gin
160

tec ate tct 528
Ser lie Ser
175

acc tat tta 576
Thr Tyr Leu
190

ctg ate tac 624
Leu lie Tyr

agt ggc agt 672
Ser Gly Ser

gag get gag 720
Glu Ala Glu
240

ccg tac acg 768
Pro Tyr Thr
255

gac gat gac 816
Asp Asp Asp
270

828

<210> 21

14/74

<211> 31
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 21

acgcgtcgac tcccaggtcc agetgeagea g 31

<210> 22
<211> 18
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 22

gaaggtgtat ccagaagc 18

<210> 23

<211> 819

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1). . . (813)

<223> pCHOMl. MABLl-scFv

<400> 23

atg gga tgg age tgt ate ate etc ttc ttg gta gca aca get aca ggt 48
Met Gly Trp Ser Cys lie lie Leu Phe Leu Val Ala Thr Ala Thr Gly

15/74

15 10 15

gtc gac tec cag gtc cag ctg cag cag tct gga cct gac ctg gta aag 96
Val Asp Ser Gin Val Gin Leu Gin Gin Ser Gly Pro Asp Leu Val Lys

20 25 30

cct ggg get tea gtg aag atg tec tgc aag get tct gga tac acc ttc 144
Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe

35 40 45

gtt aac cat gtt atg cac tgg gtg aag cag aag cca ggg cag ggc ctt 192
Val Asn His Val Met His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu

50 55 60

gag tgg att gga tat att tat cct tac aat gat ggt act aag tac aat 240
Glu Trp lie Gly Tyr He Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn
65 70 75 80

gag aag ttc aag ggc aag gec aca ctg act tea gag aaa tec tec age 288
Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ser Glu Lys Ser Ser Ser

85 90 95

gca gec tac atg gag etc age age ctg gec tct gag gac tct gcg gtc 336
Ala Ala Tyr Met Glu Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val

100 105 110

tac tac tgt gca aga ggg ggt tac tat agt tac gac gac tgg ggc caa 384
Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Ser Tyr Asp Asp Trp Gly Gin

115 120 125

ggc acc act etc aca gtc tec tea ggt ggt ggt ggt teg ggt ggt ggt 432
Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

130 135 140

ggt teg ggt ggt ggc gga teg gat gtt gtg atg acc caa act cca etc 480
Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gin Thr Pro Leu
145 150 155 160

16/74

tec ctg cct gtc agt ctt gga gat caa gec tec ate tct tgc aga tct 528

Ser Leu Pro Val Ser Leu Gly Asp Gin Ala Ser He Ser Cys Arg Ser

165 170 175

agt cag age ctt eta cac agt aaa gga aac ace tat tta caa tgg tac 576

Ser Gin Ser Leu Leu His Ser Lys Gly Asn Thr Tyr Leu Gin Trp Tyr

180 185 190

eta cag aag cca ggc cag tct cca aag etc ctg ate tac aaa gtt tec 624

Leu Gin Lys Pro Gly Gin Ser Pro Lys Leu Leu He Tyr Lys Val Ser

195 200 205

aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt gga tea ggg 672

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly

210 215 220

aca gat ttc aca etc aag ate age aga gtg gag get gag gat ctg gga 720

Thr Asp Phe Thr Leu Lys lie Ser Arg Val Glu Ala Glu Asp Leu Gly

225 230 235 240

gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg tec gga ggg 768

Val Tyr Phe Cys Ser Gin Ser Thr His Val Pro Tyr Thr Ser Gly Gly

245 250 255

ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac gat aaa taa 816

Gly Thr Lys Leu Glu He Lys Asp Tyr Lys Asp Asp Asp Asp Lys

260 265 270

tga 819

<210> 24
<211> 828
<212> DNA
<213> Mus
<220>

17/74

<221> CDS
<222> (1). . . (822)
<223> pscM2. MABL2-scFv
<400> 24

atg aaa tac eta ttg cct acg gca gec get gga ttg tta tta etc get 48

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala

1 5 .10 15

gec caa cca gec atg gcg cag gtc cag ctg cag cag tct gga cct gaa 96

Ala Gin Pro Ala Met Ala Gin Val Gin Leu Gin Gin Ser Gly Pro Glu

20 25 30

ctg gta aag cct ggg get tea gtg aag atg tec tgc aag get tct gga 144

Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly

35 40 45

tac acc ttc get aac cat gtt att cac tgg gtg aag cag aag cca ggg 192

Tyr Thr Phe Ala Asn His Val lie His Trp Val Lys Gin Lys Pro Gly

50 55 60

cag ggc ctt gag tgg att gga tat att tat cct tac aat gat ggt act 240

Gin Gly Leu Glu Trp He Gly Tyr He Tyr Pro Tyr Asn Asp Gly Thr

65 70 75 80

aag tat aat gag aag ttc aag gac aag gec act ctg act tea gac aaa 288

Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys

85 90 95

tec tec acc aca gec tac atg gac etc age age ctg gec tct gag gac 336

Ser Ser Thr Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp

100 105 110

tct gcg gtc tat tac tgt gca aga ggg ggt tac tat act tac gac gac 384

Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp

115 120 125

18/74

tgg ggc caa ggc acc act etc aca gtc tec tea ggt ggt ggt ggt teg 432

Trp Gly Gin Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser

130 135 140

ggt ggt ggt ggt teg ggt ggt ggc gga teg gat gtt gtg atg acc caa 480

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gin

145 150 155 160

agt cca etc tec ctg cct gtc agt ctt gga gat caa gee tec ate tct 528

Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp Gin Ala Ser He Ser

165 170 175

tgc aga tea agt cag age ctt gtg cac agt aat gga aag acc tat tta 576

Cys Arg Ser Ser Gin Ser Leu Val His Ser Asn Gly Lys Thr Tyr

180 185 190

cat tgg tac ctg cag aag cca ggc cag tct cca aaa etc ctg ate tac 624

His Trp Tyr Leu Gin Lys Pro Gly Gin Ser Pro Lys Leu Leu He Tyr

195 200 205

aaa gtt tec aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt 672

Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser

210 215 220

gga tea gtg aca gat ttc aca etc atg ate age aga gtg gag get gag 720

Gly Ser Val Thr Asp Phe Thr Leu Met He Ser Arg Val Glu Ala Glu

225 230 235 240

gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg 768

Asp Leu Gly Val Tyr Phe Cys Ser Gin Ser Thr His Val Pro Tyr Thr

245 250 255

ttc gga ggg ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac 816

Phe Gly Gly Gly Thr Lys Leu Glu lie Lys Asp Tyr Lys Asp Asp Asp

260 265 270
gat aaa taatga 828

19/74

Asp Lys

<210> 25

<211> 819

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1). ... (813)

<223> pCH0M2. MABL2-scFv

<400> 25

atg gga tgg age tgt ate ate etc ttc ttg gta gca aca get aca ggt 48
Met Gly Trp Ser Cys He He Leu Phe Leu Val Ala Thr Ala Thr Gly

15 10 15

gtc gac tec cag gtc cag ctg cag cag tct gga cct gaa ctg gta aag 96
Val Asp Ser Gin Val Gin Leu Gin Gin Ser (Sly Pro Glu Leu Val Lys

20 25 30

cct ggg get tea gtg aag atg tec tgc aag get tct gga tac acc ttc 144
Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe

35 40 45

get aac cat gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt 192
Ala Asn His Val He His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu

50 55 60

gag tgg att gga tat att tat cct tac aat gat ggt act aag tat aat 240
Glu Trp lie Gly Tyr lie Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn
65 70 75 80

gag aag ttc aag gac aag gee act ctg act tea gac aaa tec tec acc 288
Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr

20/74

85 90 95

aca gcc tac atg gac etc age age ctg gec tct gag gac tct gcg gtc 336

Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val

100 105 110

tat tac tgt gca aga ggg ggt tac tat act tac gac gac tgg ggc caa 384

Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp Gly Gin

115 120 125

ggc acc act etc aca gtc tec tea ggt ggt ggt ggt teg ggt ggt ggt 432

Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

130 135 140

ggt teg ggt ggt ggc gga teg gat gtt gtg atg acc caa agt cca etc 480

Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gin Ser Pro Leu

145 150 155 160

tec ctg cct gtc agt ctt gga gat caa gcc tec ate tct tgc aga tea 528

Ser Leu Pro Val Ser Leu Gly Asp Gin Ala Ser lie Ser Cys Arg Ser

165 170 175

agt cag age ctt gtg cac agt aat gga aag acc tat tta cat tgg tac 576

Ser Gin Ser Leu Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr

180 185 190

ctg cag aag cca ggc cag tct cca aaa etc ctg ate tac aaa gtt tec 624

Leu Gin Lys Pro Gly Gin Ser Pro Lys Leu Leu He Tyr Lys Val Ser

195 200 205

aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt gga tea gtg 672

Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Val

210 215 220

aca gat ttc aca etc atg ate age aga gtg gag get gag gat ctg gga 720

Thr Asp Phe Thr Leu Met He Ser Arg Val Glu Ala Glu Asp Leu Gly

225 230 235 240

21/74

gtt tat ttc tgc
Val Tyr Phe Cys

ggg acc aag ctg
Gly Thr Lys Leu
260

tga

tct caa agt aca
Ser Gin Ser Thr
245

gaa ata aaa gac
Glu He Lys Asp

cat gtt ccg tac acg
His Val Pro Tyr Thr
250

tac aaa gac gat gac
Tyr Lys Asp Asp Asp
265

ttc gga ggg 768
Phe Gly Gly
255

gat aaa taa 816

Asp Lys

270

819

<210> 26

<211> 456

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (450)

<223> pCHO-shlAP. Soluble human

<400> 26

atg tgg ccc ctg gta gcg gcg ctg
Met Trp Pro Leu Val Ala Ala Leu

1 5
tea get cag eta eta ttt aat aaa
Ser Ala Gin Leu Leu Phe Asn Lys
20

tgt aat gac act gtc gtc att cca
Cys Asn Asp Thr Val Val He Pro
35 40
caa aac act act gaa gta tac gta
Gin Asn Thr Thr Glu Va] Tyr Val

IAP

ttg ctg ggc teg gcg tgc tgc gga 48
Leu Leu Gly Ser Ala Cys Cys Gly

10 15
aca aaa tct gta gaa ttc acg ttt 96
Thr Lys Ser Val Glu Phe Thr Phe

25 30
tgc ttt gtt act aat atg gag gca 144
Cys Phe Val Thr Asn Met Glu Ala
45

aag tgg aaa ttt aaa gga aga gat 192
Lys Trp Lys Phe Lys Gly Arg Asp

22/74

50 55 60

att tac acc ttt gat gga get eta aac aag tec act gtc ccc act gac 240
lie Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp
65 70 75 80

ttt agt agt gca aaa att gaa gtc tea caa tta eta aaa gga gat gee 288
Phe Ser Ser Ala Lys lie Glu Val Ser Gin Leu Leu Lys Gly Asp Ala

85 90 95

tct ttg aag atg gat aag agt gat get gtc tea cac aca gga aac tac 336
Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr

100 105 110

act tgt gaa gta aca gaa tta acc aga gaa ggt gaa acg ate ate gag 384
Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr lie He Glu

115 120 125

eta aaa tat cgt gtt gtt tea tgg ttt tct cca aat gaa aat gac tac 432
Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn Asp Tyr

130 135 140

aag gac gac gat gac aag tgatag 456
Lys Asp Asp Asp Asp Lys
145 150

<210> 27
<211> 46
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 27

ggaattccat atgcaagtgc aacttcaaca gtctggacct gaactg 46

23/74

<210> 28
<211> 31
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 28

ggaattctca ttattttatt tccagcttgg t 31

<210> 29

<211> 741

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1). . . (735)

<223> pscM2DEin02. MABL2-scFv

<400> 29

atg caa gtg caa ctt caa cag tct gga cct gaa ctg gta aag cct ggg 48
Met Gin Val Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly

1 5 10 15

get tea gtg aag atg tec tgc aag get tct gga tac acc ttc get aac 96
Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Asn

20 25 30

cat gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt gag tgg 144
His Val lie His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu Glu Trp
35 40 45

24/74

att gga tat att tat cct tac aat gat ggt act aag tat aat gag aag 192
He Gly Tyr lie Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys

50 55 60

ttc aag- gac aag gcc act ctg act tea gac aaa tec tec acc aca gec 240
Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr Thr Ala
65 70 75 80

tac atg gac etc age age ctg gcc tct gag gac tct gcg gtc tat tac 288
Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr

85 90 95

tgt gca aga ggg ggt tac tat act tac gac gac tgg ggc caa ggc acc 336
Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp Gly Gin Gly Thr

100 105 110

act etc aca gtc tec tea ggt ggt ggt ggt teg ggt ggt ggt ggt teg 384
Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser

115 120 125

ggt ggt ggc gga teg gat gtt gtg atg acc caa agt cca etc tec ctg 432
Gly Gly Gly Gly Ser Asp Val Val Met Thr Gin Ser Pro Leu Ser Leu

130 135 140

cct gtc agt ctt gga gat caa gcc tec ate tct tgc aga tea agt cag 480
Pro Val Ser Leu Gly Asp Gin Ala Ser lie Ser Cys Arg Ser Ser Gin
145 150 155 160

age ctt gtg cac agt aat gga aag acc tat tta cat tgg tac ctg cag 528
Ser Leu Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr Leu Gin

165 170 175

aag cca ggc cag tct cca aaa etc ctg ate tac aaa gtt tec aac cga 576
Lys Pro Gly Gin Ser Pro Lys Leu Leu He Tyr Lys Val Ser Asn Arg

180 185 190

ttt tct ggg gtc cca gac agg ttc agt ggc agt gga tea gtg aca gat 624

25/74

Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Val Thr Asp

195 200 205

ttc aca etc atg ate age aga gtg gag get gag gat ctg gga gtt tat 672
Phe Thr Leu Met He Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr

210 215 220

ttc tgc tct caa agt aca cat gtt ccg tac acg ttc gga ggg ggg acc 720
Phe Cys Ser Gin Ser Thr His Val Pro Tyr Thr Phe Gly Gly Gly Thr
225 230 235 240

aag ctg gaa ata aaa taatga 741
Lys Leu Glu lie Lys
245

<210> 30
<211> 18
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 30

cagacagtgg ttcaaagt 18

<210> 31
<211> 72
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 31

26/74

cgcgtcgacc gatccgccac cacccgaacc accaccaccc gaaccaccac caccttttat 60
ttccagcttg gt 72

<210> 32

<211> 1605

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1). . . (1599)

<223> pCHOM2(Fv)2. MABL2-SC (Fv) 2

<400> 32

atg gga tgg age tgt ate ate etc ttc ttg gta gca aca get aca ggt 48
Met Gly Trp Ser Cys He lie Leu Phe Leu Val Ala Thr Ala Thr Gly

15 10 15

gtc gac tec cag gtc cag ctg cag cag tct gga cct gaa ctg gta aag 96
Val Asp Ser Gin Val Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Lys

20 25 30

cct ggg get tea gtg aag atg tec tgc aag get tct gga tac acc ttc 144
Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe

35 40 45

get aac cat gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt 192
Ala Asn His Val He His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu

50 55 60

gag tgg att gga tat att tat cct tac aat gat ggt act aag tat aat 240
Glu Trp He Gly Tyr He Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn
65 70 75 80

gag aag ttc aag gac aag gec act ctg act tea gac aaa tec tec acc 288

27/74

Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr

85 90 95

aca gcc tac atg gac etc age age ctg gee tct gag gac tct gcg gtc 336
Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val

100 105 110

tat tac tgt gca aga ggg ggt tac tat act tac gac gac tgg ggc caa 384
Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp Gly Gin

115 120 125

ggc acc act etc aca gtc tec tea ggt ggt ggt ggt teg ggt ggt ggt 432
Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly

130 135 140

ggt teg ggt ggt ggc gga teg gat gtt gtg atg acc caa agt cca etc 480
Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gin Ser Pro Leu
145 150 155 160

tec ctg cct gtc agt ctt gga gat caa gcc tec ate tct tgc aga tea 528
Ser Leu Pro Val Ser Leu Gly Asp Gin Ala Ser lie Ser Cys Arg Ser

165 170 175

agt cag age ctt gtg cac agt aat gga aag acc tat tta cat tgg tac 576
Ser Gin Ser Leu Val His Ser Asn Gly Lys Thr Tyr Leu His Trp Tyr

180 185 190

ctg cag aag cca ggc cag tct cca aaa etc ctg ate tac aaa gtt tec 624
Leu Gin Lys Pro Gly Gin Ser Pro Lys Leu Leu He Tyr Lys Val Ser

195 200 205

aac cga ttt tct ggg gtc cca gac agg ttc agt ggc agt gga tea gtg 672
Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Val

210 215 220

aca gat ttc aca etc atg ate age aga gtg gag get gag gat ctg gga 720
Thr Asp Phe Thr Leu Met He Ser Arg Val Glu Ala Glu Asp Leu Gly

28/74

225 230 235 240

gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg ttc gga ggg 768

Val Tyr Phe Cys Ser Gin Ser Thr His Val Pro Tyr Thr Phe Gly Gly

245 250 255

ggg acc aag ctg gaa ata aaa ggt ggt ggt ggt teg ggt ggt ggt ggt 816
Gly Thr Lys Leu Glu He Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly

260 265 270

teg ggt ggt ggc gga teg gtc gac tec cag gtc cag ctg cag cag tct 864
Ser Gly Gly Gly Gly Ser Val Asp Ser Gin Val Gin Leu Gin Gin Ser

275 280 285

gga cct gaa ctg gta aag cct ggg get tea gtg aag atg tec tgc aag 912
Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Met Ser Cys Lys

290 295 300

get tct gga tac acc ttc get aac cat gtt att cac tgg gtg aag cag 960
Ala Ser Gly Tyr Thr Phe Ala Asn His Val lie His Trp Val Lys Gin
305 310 315 320

aag cca ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat 1008
Lys Pro Gly Gin Gly Leu Glu Trp He Gly Tyr He Tyr Pro Tyr Asn

325 330 335

gat ggt act aag tat aat gag aag ttc aag gac aag gec act ctg act 1056
Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr

340 345 350

tea gac aaa tec tec acc aca gee tac atg gac etc age age ctg gee 1104
Ser Asp Lys Ser Ser Thr Thr Ala Tyr Met Asp Leu Ser Ser Leu Ala

355 360 365

tct gag gac tct gcg gtc tat tac tgt gca aga ggg ggt tac tat act 1152
Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr
370 375 380

29/74

tac gac gac tgg
Tyr Asp Asp Trp
385

ggt ggt teg ggt
Gly Gly Ser Gly

atg acc caa agt
Met Thr Gin Ser
420

tec ate tct tgc
Ser He Ser Cys
435

acc tat tta cat
Thr Tyr Leu His
450

ctg ate tac aaa
Leu lie Tyr Lys
465

agt ggc agt gga
Ser Gly Ser Gly

gag get gag gat
Glu Ala Glu Asp
500

ccg tac acg ttc
Pro Tyr Thr Phe

515 520
gac gat gac gat aaa taatga

ggt ggt 1200
Gly Gly
400

gtt gtg 1248
Val Val
415

caa gee 1296
Gin Ala

gga aag 1344
Gly Lys

aaa etc 1392
Lys Leu

agg ttc 1440
Arg Phe
480

aga gtg 1488
Arg Val
495

cat gtt 1536
His Val

tac aaa 1584
Tyr Lys
525

1605

ggc caa ggc acc act etc aca gtc tec tea
Gly Gin Gly Thr Thr Leu Thr Val Ser Ser

390 395
ggt ggt ggt teg ggt ggt ggc gga teg gat
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp
405 410
cca etc tec ctg cct gtc agt ctt gga gat
Pro Leu Ser Leu Pro Val Ser Leu Gly Asp
425 430
aga tea agt cag age ctt gtg cac agt aat
Arg Ser Ser Gin Ser Leu Val His Ser Asn

440 445
tgg tac ctg cag aag cca ggc cag tct cca
Trp Tyr Leu Gin Lys Pro Gly Gin Ser Pro

455 460
gtt tec aac cga ttt tct ggg gtc cca gac
Val Ser Asn Arg Phe Ser Gly Val Pro Asp

470 475
tea gtg aca gat ttc aca etc atg ate age
Ser Val Thr Asp Phe Thr Leu Met He Ser
485 490
ctg gga gtt tat ttc tgc tct caa agt aca
Leu Gly Val Tyr Phe Cys Ser Gin Ser Thr
505 510
gga ggg ggg acc aag ctg gaa ata aaa gac
Gly Gly Gly Thr Lys Leu Glu lie Lys Asp

30/74

Asp Asp Asp Asp Lys
530

<210> 33
<211> 23
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 33

tgaggaattc ccaccatggg atg 33

<210> 34
<211> 40
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 34

cacgacgtca ctcgagactg tgagagtggt gccttggccc

<210> 35
<211> 40
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 35

31/74

agtctcgagt gacgtcgtga tgacccaaag tccactctcc 40

<210> 36
<211> 31
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 36

gactggatcc tcattattta tcgtcatcgt c 31

<210> 37
<211> 22
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 37

cgcgtaatac gactcactat ag 22

<210> 38
<211> 46
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 38

gcaattggac ctgttttatc tcgagcttgg tcccccctcc gaacgt

32/74

<210> 39
<211> 45
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 39

gctcgagata aaacaggtcc aattgcagca gtctggacct gaact 45

<210> 40
<2L1> 60
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 40

gactggatcc tcattattta tcgtcatcgt ctttgtagtc tgaggagact gtgagagtgg

<210> 41
<211> 32
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 41

gactgaattc ccaccatgaa gttgcctgtt ag 32

33/74

<210> 42
<211> 40
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 42

cagtctcgag tggtggttcc gacgtcgtga tgacccaaag 40

<210> 43
<211> 43
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 43

cagtctcgag tggtggtggt tccgacgtcg tgatgaccca aag 43

<210> 44
<211> 46
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 44

cagtctcgag tggtggtggt ggttccgacg tcgtgatgac ccaaag 46

<210> 45

34/74

<211> 49
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 45

cagtctcgag tggtggtggt ggtggttccg acgtcgtgat gacccaaag 49

<210> 46
<211> 52
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 46

cagtctcgag tggtggtggt ggtggtggtt ccgacgtcgt gatgacccaa ag

<210> 47
<211> 20
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 47

ggccgcatgt tgtcacgaat 20

<210> 48
<211> 780

35/74

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1). . . (768)

<223> CF2HL-0/pC0Sl. MABL2-scFv<HL-0>
<400> 48

atg gga tgg age tgt ate ate etc ttc ttg gta gca aca get aca ggt gtc 51
MET Gly Trp Ser Cys He He Leu Phe Leu Val Ala Thr Ala Thr Gly Val

5 10 15

gac tec cag gtc cag ctg cag cag tct gga cct gaa ctg gta aag cct ggg 102
Asp Ser Gin Val Gin Leu Gin Gin Ser Gly Pro Glu Leu Val Lys Pro Gly

20 25 30

get tea gtg aag atg tec tgc aag get tct gga tac ace ttc get aac cat 153
Ala Ser Val Lys MET Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ala Asn His

35 40 45 50

gtt att cac tgg gtg aag cag aag cca ggg cag ggc ctt gag tgg att gga 204
Val He His Trp Val Lys Gin Lys Pro Gly Gin Gly Leu Glu Trp He Gly

55 60 65

tat att tat cct tac aat gat ggt act aag tat aat gag aag ttc aag gac 255
Tyr He Tyr Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp
70 75 80 85

aag gec act ctg act tea gac aaa tec tec acc aca gec tac atg gac etc 306
Lys Ala Thr Leu Thr Ser Asp Lys Ser Ser Thr Thr Ala Tyr MET Asp Leu

90 95 100

age age ctg gec tct gag gac tct gcg gtc tat tac tgt gca aga ggg ggt 357
Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly
105 110 115

36/74

tac tat act tac gac gac tgg ggc caa ggc acc act etc aca gtc teg agt 408

Tyr Tyr Thr Tyr Asp Asp Trp Gly Gin Gly Thr Thr Leu Thr Val Ser Ser

120 125 130 135

gac gtc gtg atg acc caa agt cca etc tec ctg cct gtc agt ctt gga gat 459

Asp Val Val MET Thr Gin Ser Pro Leu Ser Leu Pro Val Ser Leu Gly Asp

140 145 150

caa gec tec ate tct tgc aga tea agt cag age ctt gtg cac agt aat gga 510

Gin Ala Ser lie Ser Cys Arg Ser Ser Gin Ser Leu Val His Ser Asn Gly

155 160 165 170

aag acc tat tta cat tgg tac ctg cag aag cca ggc cag tct cca aaa etc 561

Lys Thr Tyr Leu His Trp Tyr Leu Gin Lys Pro Gly Gin Ser Pro Lys Leu

175 180 185

ctg ate tac aaa gtt tec aac cga ttt tct ggg gtc cca gac agg ttc agt 612

Leu lie Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser

190 195 200

ggc agt gga tea gtg aca gat ttc aca etc atg ate age aga gtg gag get 663

Gly Ser Gly Ser Val Thr Asp Phe Thr Leu MET lie Ser Arg Val Glu Ala

205 210 215 220

gag gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg tac acg 714

Glu Asp Leu Gly Val Tyr Phe Cys Ser Gin Ser Thr His Val Pro Tyr Thr

225 230 235

ttc gga ggg ggg acc aag ctg gaa ata aaa gac tac aaa gac gat gac gat 765

Phe Gly Gly Gly Thr Lys Leu Glu lie Lys Asp Tyr Lys Asp Asp Asp Asp

240 245 250 255

aaa taa tga gga tec 780
Lys

<210> 49

37/74

<211> 45
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 49

caagctcgag ataaaatccg gaggccaggt ccaattgcag cagtc 45

<210> 50
<211> 48
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 50

caagctcgag ataaaatccg gaggtggcca ggtccaattg cagcagtc 48

<210> 51
<211> 51
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 51

caagctcgag ataaaatccg gaggtggtgg ccaggtccaa ttgcagcagt c

<210> 52
<211> 54

38/74

<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 52

caagctcgag ataaaatccg gaggtggtgg tggccaggtc caattgcagc agtc 54

<210> 53
<211> 57
<212> DNA

<213> Artificial Sequence
<220>

<223> PCR primer
<400> 53

caagctcgag ataaaatccg gaggtggtgg tggtggccag gtccaattgc agcagtc 57

<210> 54

<211> 780

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (1)... (768)

<223> CF2LH-0/pCOSl. MABL2-scFv<LH-0>
<400> 54

atg aag ttg cct gtt agg ctg ttg gtg ctg atg ttc tgg att cct ggt tec
MET Lys Leu Pro Val Arg Leu Leu Val Leu MET Phe Trp lie Pro Gly Ser
5 10 15

39/74

age agt gat gtt gtg atg acc caa agt cca etc tec ctg cct gtc agt ctt 102
Ser Ser Asp Val Val MET Thr Gin Ser Pro Leu Ser Leu Pro Val Ser Leu

20 25 30

gga gat caa gee tec ate tct tgc aga tea agt cag age ctt gtg cac agt 153
Gly Asp Gin Ala Ser He Ser Cys Arg Ser Ser Gin Ser Leu Val His Ser

35 40 45 50

aat gga aag acc tat tta cat tgg tac ctg cag aag cca ggc cag tct cca 204
Asn Gly Lys Thr Tyr Leu His Trp Tyr Leu Gin Lys Pro Gly Gin Ser Pro

55 60 65

aaa etc ctg ate tac aaa gtt tec aac cga ttt tct ggg gtc cca gac agg 255
Lys Leu Leu He Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg
70 75 80 85

ttc agt ggc agt gga tea gtg aca gat ttc aca etc atg ate age aga gtg 306
Phe Ser Gly Ser Gly Ser Val Thr Asp Phe Thr Leu MET He Ser Arg Val

90 95 100

gag get gag gat ctg gga gtt tat ttc tgc tct caa agt aca cat gtt ccg 357
Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser Gin Ser Thr His Val Pro

105 110 115

tac acg ttc gga ggg ggg acc aag etc gag ata aaa cag gtc caa ttg cag 408
Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu He Lys Gin Val Gin Leu Gin
120 125 130 135

cag tct gga cct gaa ctg gta aag cct ggg get tea gtg aag atg tec tgc 459
Gin Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys MET Ser Cys

140 145 150

aag get tct gga tac acc ttc get aac cat gtt att cac tgg gtg aag cag 510
Lys Ala Ser Gly Tyr Thr Phe Ala Asn His Val lie His Trp Val Lys Gin
155 160 165 170

aag cca ggg cag ggc ctt gag tgg att gga tat att tat cct tac aat gat 561

40/74

Lys Pro Gly Gin Gly Leu Glu Trp He Gly Tyr He Tyr Pro Tyr Asn Asp

175 180 185

ggt act aag tat aat gag aag ttc aag gac aag gcc act ctg act tea gac 612
Gly Thr Lys Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Ser Asp

190 195 200

aaa tec tec acc aca gcc tac atg gac etc age age ctg gcc tct gag gac 663
Lys Ser Ser Thr Thr Ala Tyr MET Asp Leu Ser Ser Leu Ala Ser Glu Asp
205 210 215 220

tct gcg gtc tat tac tgt gca aga ggg ggt tac tat act tac gac gac tgg 714
Ser Ala Val Tyr Tyr Cys Ala Arg Gly Gly Tyr Tyr Thr Tyr Asp Asp Trp

225 230 235

ggc caa ggc acc act etc aca gtc tec tea gac tac aaa gac gat gac gat 765
Gly Gin Gly Thr Thr Leu Thr Val Ser Ser Asp Tyr Lys Asp Asp Asp Asp
240 245 250 255

aaa taa tga gga tec 780
Lys

<210> 55

<211> 351

<212> DNA

<213> Human

<220>

<221> CDS

<222> (1). . . (351)

<223> 12B5HV. 1-351 peptide

<400> 55

cag gtg cag ctg gtg cag tct ggg gga ggc ttg gtc egg ccc ggg ggg 48
Gin Val Gin Leu Val Gin Ser Gly Gly Gly Leu Val Arg Pro Gly Gly

41/74

1 5 10 15

tec ctg agt etc tec tgt gca gtc tct gga ate ace etc agg ace tac 96
Ser Leu Ser Leu Ser Cys Ala Val Ser Gly He Thr Leu Arg Thr Tyr

20 25 30

ggc atg cac tgg gtc cgc cag get cca ggc aag ggg ctg gag tgg gtg 144
Gly Met His Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

gca ggt ata tec ttt gac gga aga agt gaa tac tat gca gac tec gtg 192
Ala Gly He Ser Phe Asp Gly Arg Ser Glu Tyr Tyr Ala Asp Ser Val

50 55 60

cag ggc cga ttc acc ate tec aga gac agt tec aag aac acc ctg tat 240
Gin Gly Arg Phe Thr lie Ser Arg Asp Ser Ser Lys Asn Thr Leu Tyr
65 70 75 80

ctg caa atg aac age ctg aga gec gag gac acg get gtg tat tac tgt 288
Leu Gin Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys

85 90 95

gcg aga gga gca cat tat ggt ttc gat ate tgg ggc caa ggg aca atg 336
Ala Arg Gly Ala His Tyr Gly Phe Asp lie Trp Gly Gin Gly Thr Met

100 105 110

gtc acc gtc teg agt 351
Val Thr Val Ser Ser
115

<210> 56
<211> 57
<212> DNA
<213> Human
<220>

42/74

<221> CDS
<222> (1)... (57)
<223> reader sequence
<400> 56

atg gag ttt ggg ctg age tgg gtt ttc etc gtt get ctt tta aga ggt 48
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly

5 10 15

gtc cag tgt 57
Val Gin Cys

<210> 57
<211> 115
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VH-1
<400> 57

atggagtttg ggctgagctg ggttttcctc gttgctcttt taagaggtgt ccagtgtcag 60
gtgcagctgg tgcagtctgg gggaggcttg gtccggcccg gggggtccct gagtc 115

<210> 58
<211> 115
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VH-2
<400> 58

43/74

aaggatatac ctgccaccca ctccagcccc ttgcctggag cctggcggac ccagtgcatg 60
ccgtaggtcc tgagggtgat tccagagact gcacaggaga gactcaggga ccccc 115

<210> 59
<211> 115
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VH-3
<400> 59

ggcaggtata tcctttgacg gaagaagtga atactatgca gactccgtgc agggccgatt 60
caccatctcc agagacagtt ccaagaacac cctgtatctg caaatgaaca gcctg 115

<210> 60
<211> 108
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VH-4
<400> 60

actcgagacg gtgaccattg tcccttggcc ccagatatcg aaaccataat gtgctcctct 60
cgcacagtaa tacacagccg tgtcctcggc tctcaggctg ttcatttg 108

<210> 61
<211> 32
<212> DNA

<213> Artificial Sequence
<220>

44/74

<223> 12B5VH-S, PCR primer
<400> 61

ttcaagcttc caccatggag tttgggctga gc 32

<210> 62
<211> 34
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VH-A, PCR primer
<400> 62

ttgggatcca ctcaccactc gagacggtga ccat 34

<210> 63
<211> 588
<212> DNA
<213> Human
<220>
<221> CDS

<222> (236). . . (558)

<223> 1-235; intron, 236-558;Human IgG constant region (partial)
<400> 63

gaattcgtga gtggatccca agctagcttt ctggggcagg ccaggcctga ccttggcttt 60
ggggcaggga gggggctaag gtgaggcagg tggcgccagc caggtgcaca cccaatgccc 120
atgagcccag acactggacg ctgaacctcg cggacagtta agaacccagg ggcctctgcg 180
ccctgggccc agctctgtcc cacaccgcgg tcacatggca caacctctct tgca gcc 237

Ala
1

45/74

tec acc aag ggc cca teg gtc ttc ccc ctg gca ccc tec tec aag age 285
Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser

5 10 15

acc tct ggg ggc aca gcg gee ctg ggc tgc ctg gtc aag gac tac ttc 333
Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe

20 25 30

ccc gaa ccg gtg acg gtg teg tgg aac tea ggc gee ctg acc age ggc 381
Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly

35 40 45

gtg cac acc ttc ccg get gtc eta cag tec tea gga etc tac tec etc 429
Val His Thr Phe Pro Ala Val Leu Gin Ser Ser Gly Leu Tyr Ser Leu
50 55 60 65

age age gtg gtg acc gtg ccc tec age age ttg ggc acc cag acc tac 477
Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr

70 75 80

ate tgc aac gtg aat cac aag ccc age aac acc aag gtg gac aag aaa 525
He Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys

85 90 95

gtt gag ccc aaa tct tgt gac aaa act cac aca 558
Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
100 105

<210> 64
<211> 27
<212> DNA

<213> Artificial Sequence
<220>

<223> G1CH1-S, PCR primer

46/74

<400> 64

tgagaattcg tgagtggatc ccaagct 27

<210> 65
<211> 60
<212> DNA

<213> Artificial Sequence
<220>

<223> G1CH1-A, PCR primer
<400> 65

aaaagatctt tatcatgtgt gagttttgtc acaagatttg ggctcaactt tcttgtccac 60

<210> 66

<211> 432

<212> DNA

<213> Human

<220>

<221> CDS

<222> (12)... (419)

<223> HEF-12B5H-g gamma. 12-419 peptide
<400> 66

aagcttccac c atg gag ttt ggg ctg age tgg gtt ttc etc gtt get ctt 50
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu
1 5 10

tta aga ggt gtc cag tgt cag gtg cag ctg gtg cag tct ggg gga ggc 98
Leu Arg Gly Val Gin Cys Gin Val Gin Leu Val Gin Ser Gly Gly Gly

15 20 25

ttg gtc egg ccc ggg ggg tec ctg agt etc tec tgt gca gtc tct gga 146

47/74

Leu Val Arg Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Val Ser Gly
30 35 40 45

ate ace etc agg acc tac ggc atg cac tgg gtc cgc cag get cca ggc 194
lie Thr Leu Arg Thr Tyr Gly Met His Trp Val Arg Gin Ala Pro Gly

50 55 60

aag ggg ctg gag tgg gtg gca ggt ata tec ttt gac gga aga agt gaa 242
Lys Gly Leu Glu Trp Val Ala Gly lie Ser Phe Asp Gly Arg Ser Glu

65 70 75

tac tat gca gac tec gtg cag ggc cga ttc acc ate tec aga gac agt 290
Tyr Tyr Ala Asp Ser Val Gin Gly Arg Phe Thr He Ser Arg Asp Ser

80 85 90

tec aag aac acc ctg tat ctg caa atg aac age ctg aga gee gag gac 338
Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp

95 100 105

acg get gtg tat tac tgt gcg aga gga gca cat tat ggt ttc gat ate 386
Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ala His Tyr Gly Phe Asp He
110 115 120 125

tgg ggc caa ggg aca atg gtc acc gtc teg agt ggtgagtgga tec 432
Trp Gly Gin Gly Thr Met Val Thr Val Ser Ser
130 135

<210> 67

<211> 321

<212> DNA

<213> Human

<220>

<221> CDS

<222> (1). . . (321)

48/74

<223> 12B5LV. 1-321 peptide
<400> 67

gac ate cag atg acc cag tct cct tec acc ctg tct gca tct att gga 48
Asp lie Gin Met Thr Gin Ser Pro Ser Thr Leu Ser Ala Ser He Gly

15 10 15

gac aga gtc acc ate acc tgc egg gec age gag ggt att tat cac tgg 96
Asp Arg Val Thr lie Thr Cys Arg Ala Ser Glu Gly He Tyr His Trp

20 25 30

ttg gee tgg tat cag cag aag cca ggg aaa gec cct aaa etc ctg ate 144
Leu Ala Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu lie

35 40 45

tat aag gec tct agt tta gec agt ggg gee cca tea agg ttc age ggc 192
Tyr Lys Ala Ser Ser Leu Ala Ser Gly Ala Pro Ser Arg Phe Ser Gly

50 55 60

agt gga tct ggg aca gat ttc act etc acc ate age age ctg cag cct 240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr lie Ser Ser Leu Gin Pro
65 70 75 80

gat gat ttt gca act tat tac tgc caa caa tat agt aat tat ccg etc 288
Asp Asp Phe Ala Thr Tyr Tyr Cys Gin Gin Tyr Ser Asn Tyr Pro Leu

85 90 95

act ttc ggc gga ggg acc aag ctg gag ate aaa 321
Thr Phe Gly Gly Gly Thr Lys Leu Glu He Lys
100 105

<210> 68
<211> 66
<212> DNA
<213> Human

49/74

<220>

<221> CDS

<222> (1). . . (66)

<223> reader sequence

<400> 68

atg gac atg agg gtc ccc get cag etc ctg ggg etc ctg ctg etc tgg 48
MET Asp MET Arg Val Pro Ala Gin Leu Leu Gly Leu Leu Leu Leu Trp

5 10 15

etc cca ggt gcc aaa tgt 66
Leu Pro Gly Ala Lys Cys
20

<210> 69
<211> 110
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VL-1
<400> 69

atggacatga gggtccccgc tcagctcctg gggctcctgc tgctctggct cccaggtgcc 60
aaatgtgaca tccagatgac ccagtctcct tccaccctgt ctgeatctat 110

<210> 70
<211> 110
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VL-2

50/74

<400> 70

ggagtttagg ggctttccct ggcttctgct gataccaggc caaccagtga taaataccct 60
cgctggcccg gcaggtgatg gtgactctgt ctccaataga tgcagacagg 110

<210> 71
<211> 110
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VL-3
<400> 71

aagcccctaa actcctgatc tataaggcct ctagtttagc cagtggggcc ccatcaaggt 60
tcagcggcag tggatctggg acagatttca ctctcaccat cagcagcctg 110

<210> 72
<211> 103
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VL-4
<400> 72

tttgatctcc agcttggtcc ctccgccgaa agtgagcgga taattactat attgttggca 60
gtaataagtt gcaaaatcat caggctgcag gctgctgatg gtg 103

<210> 73
<211> 32
<212> DNA

<213> Artificial Sequence

51/74

<220>

<223> 12B5VL-S, PCR primer
<400> 73

ttcaagcttc caccatggac atgagggtcc cc 32

<210> 74
<211> 35
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5VL-A, PCR primer
<400> 74

tctaggatcc actcacgttt gatctccagc ttggt 35

<210> 75

<211> 415

<212> DNA

<213> Human

<220>

<221> CDS

<222> (12). . . (398)

<223> HEF-12B5H-g kappa. 12-398 peptide
<400> 75

aagcttccac c atg gac atg agg gtc ccc get cag etc ctg ggg etc ctg 50
Met Asp Met Arg Val Pro Ala Gin Leu Leu Gly Leu Leu
1 5 10

ctg etc tgg etc cca ggt gec aaa tgt gac ate cag atg ace cag tct 98
Leu Leu Trp Leu Pro Gly Ala Lys Cys Asp lie Gin Met Thr Gin Ser

52/74

15 20 25

cct tec acc ctg tct gca tct att gga gac aga gtc acc ate acc tgc 146
Pro Ser Thr Leu Ser Ala Ser lie Gly Asp Arg Val Thr lie Thr Cys
30 35 40 45

egg gec age gag ggt att tat cac tgg ttg gee tgg tat cag cag aag 194
Arg Ala Ser Glu Gly He Tyr His Trp Leu Ala Trp Tyr Gin Gin Lys

50 55 60

cca ggg aaa gee cct aaa etc ctg ate tat aag gec tct agt tta gee 242
Pro Gly Lys Ala Pro Lys Leu Leu lie Tyr Lys Ala Ser Ser Leu Ala

65 70 75

a gt ggg g°c cca tea agg ttc age ggc agt gga tct ggg aca gat ttc 290
Ser Gly Ala Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe

80 85 90

act etc acc ate age age ctg cag cct gat gat ttt gca act tat tac 338
Thr Leu Thr lie Ser Ser Leu Gin Pro Asp Asp Phe Ala Thr Tyr Tyr

95 100 105

tgc caa caa tat agt aat tat ccg etc act ttc ggc gga ggg acc aag 386
Cys Gin Gin Tyr Ser Asn Tyr Pro Leu Thr Phe Gly Gly Gly Thr Lys
110 115 120 125

ctg gag ate aaa cgtgagtgga tcctaga 415
Leu Glu He Lys

<210> 76
<211> 24
<212> DNA

<213> Artificial Sequence
<220>

<223> FLAG tag sequence

53/74

<400> 76

gac tac aag gat gac gac gat aag 24
Asp Tyr Lys Asp Asp Asp Asp Lys
5

<210> 77
<211> 31
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5-S, PCR primer
<400> 77

atagaattcc accatggagt ttgggctgag c 31

<210> 78
<211> 24
<212> DNA

<213> Artificial Sequence
<220>

<223> HuVHJ3, PCR primer
<400> 78

tgaagagacg gtgaccattg tccc 24

<210> 79
<211> 28
<212> DNA

<213> Artificial Sequence
<220>

54/74

<223> RhuJH3, PCR primer
<400> 79

ggacaatggt caccgtctct tcaggtgg 28

<210> 80
<211> 32
<212> DNA

<213> Artificial Sequence
<220>

<223> RhuVTCl, PCR primer
<400> 80

ggagactggg tcatctggat gtccgatccg cc 32

<210> 81
<211> 23
<212> DNA

<213> Artificial Sequence
<220>

<223> HuVKl. 2, PCR primer
<400> 81

gacatccaga tgacccagtc tec 23

<210> 82
<211> 59
<212> DNA

<213> Artificial Sequence
<220>

<223> 12B5F-A, PCR primer

55/74

<400> 82

attgcggccg cttatcactt atcgtcgtca tccttgtagt ctttgatctc cagcttggt 59

<210> 83
<211> 45
<212> DNA

<213> Artificial Sequence
<220>

<223> Linker amino acid sequence and nucleotide sequence
<400> 83

get ggt ggt ggt teg ggt ggt ggt ggt teg ggt ggt ggc gga teg 45
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
5 10 15

<210> 84

<211> 823

<212> DNA

<213> Human

<220>

<221> CDS

<222> (12)... (809)

<223> scl2B5, Single chain Fv

<400> 84

aagcttccac c atg gag ttt ggg ctg age tgg gtt ttc etc gtt get ctt 50
Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu
1 5 10

tta aga ggt gtc cag tgt cag gtg cag ctg gtg cag tct ggg gga ggc 98
Leu Arg Gly Val Gin Cys Gin Val Gin Leu Val Gin Ser Gly Gly Gly

56/74

15 20 25

ttg gtc egg ccc ggg ggg tec ctg agt etc tec tgt gca gtc tct gga 146
Leu Val Arg Pro Gly Gly Ser Leu Ser Leu Ser Cys Ala Val Ser Gly
30 35 40 45

ate acc etc agg acc tac ggc atg cac tgg gtc cgc cag get cca ggc 194
lie Thr Leu Arg Thr Tyr Gly Met His Trp Val Arg Gin Ala Pro Gly

50 55 60

aag ggg ctg gag tgg gtg gca ggt ata tec ttt gac gga aga agt gaa 242
Lys Gly Leu Glu Trp Val Ala Gly He Ser Phe Asp Gly Arg Ser Glu

65 70 75

tac tat gca gac tec gtg cag ggc cga ttc acc ate tec aga gac agt 290
Tyr Tyr Ala Asp Ser Val Gin Gly Arg Phe Thr He Ser Arg Asp Ser

80 85 90

tec aag aac acc ctg tat ctg caa atg aac age ctg aga gec gag gac 338
Ser Lys Asn Thr Leu Tyr Leu Gin Met Asn Ser Leu Arg Ala Glu Asp

95 100 105

acg get gtg tat tac tgt gcg aga gga gca cat tat ggt ttc gat ate 386
Thr Ala Val Tyr Tyr Cys Ala Arg Gly Ala His Tyr Gly Phe Asp He
110 115 120 125

tgg ggc caa ggg aca atg gtc acc gtc teg agt ggt ggt ggt ggt teg 434
Trp Gly Gin Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser

130 135 140

ggt ggt ggt ggt teg ggt ggt ggc gga teg gac ate cag atg acc cag 482
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp He Gin Met Thr Gin

145 150 155

tct cct tec acc ctg tct gca tct att gga gac aga gtc acc ate acc 530
Ser Pro Ser Thr Leu Ser Ala Ser He Gly Asp Arg Val Thr lie Thr
160 165 170

57/74

tgc egg gec age
Cys Arg Ala Ser
175

aag cca ggg aaa
Lys Pro Gly Lys
190

gec agt ggg gec
Ala Ser Gly Ala

ttc act etc ace
Phe Thr Leu Thr
225

TAC TGC CAA CAA
Tyr Cys Gin Gin
240

aag ctg gag ate
Lys Leu Glu lie
255

cgc

gag ggt att tat
Glu Gly He Tyr
180

gec cct aaa etc
Ala Pro Lys Leu
195

cca tea agg ttc
Pro Ser Arg Phe
210

ate age age ctg
He Ser Ser Leu

TAT AGT AAT TAT
Tyr Ser Asn Tyr
245

aaa gac tac aag
Lys Asp Tyr Lys
260

cac tgg ttg gee tgg
His Trp Leu Ala Trp
185

ctg ate tat aag gee
Leu He Tyr Lys Ala
200

age ggc agt gga tct
Ser Gly Ser Gly Ser
215

cag cct gat gat ttt
Gin Pro Asp Asp Phe
230

CCG CTC ACT TTC GGC
Pro Leu Thr Phe Gly
250

gat gac gac gat aag
Asp Asp Asp Asp Lys
265

tat cag cag 578
Tyr Gin Gin

tct agt tta 626
Ser Ser Leu
205

ggg aca gat 674
Gly Thr Asp
220

gca act tat 722
Ala Thr Tyr
235

GGA GGG ACC 770
Gly Gly Thr

tgataagegg c 820
823

<210> 85

<211> 114

<212> PRT

<213> Human

<400> 85

Gin Val Gin Leu Gin Gin Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
15 10 15

58/74

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser He Ser Ser Tyr

20 25 30

Tyr Trp Ser Trp He Arg Gin Pro Pro Gly Lys Gly Leu Glu Trp He

35 40 45

Gly Tyr He Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys

50 55 60

Ser Arg Val Thr He Ser Val Asp Thr Ser Lys Ser Gin Phe Ser Leu
65 70 75 80

Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala

85 90 95

Arg Gly Arg Tyr Phe Asp Val Trp Gly Arg Gly Thr Met Val Thr Val
100 105 110

Ser Ser

<210> 86

<211> 342

<212> DNA

<213> Human

<400> 86

caggtgcagc

tgcagcagtc

gggcccagga

ctggtgaagc

cttcggagac

cctgtccctc

60

acctgcactg

tctctggtga

ctccatcagt

agttactact

ggagctggat

tcggcagccc

120

ccagggaagg

gactggagtg

gattgggtat

atctattaca

gtgggagcac

caactacaac

180

ccctccctca

agagtcgagt

caccatatca

gtagacacgt

ccaagagcca

gttctccctg

240

aagctgagct

ctgtgaccgc

cgcagacacg

gecgtgtatt

actgtgcgag

agggcggtac

300

ttcgatgtct

ggggccgtgg

caccatggtc

actgtctcct

ca

342

<210> 87

59/74

<211> 57

<212> DNA

<213> Human

<220>

<221> CDS

<222> (1). .. (57)

<223> reader sequence

<308> GenBank No. AF062252

<400> 87

atg aaa cat ctg tgg ttc ttc ctt etc ctg gtg gca get ccc aga tgg 48
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala Pro Arg Trp

15 10 15

gtc ctg tec 57
Val Leu Ser

<210> 88
<211> 110
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VH1
<400> 88

atgaaacatc tgtggttctt ccttctcctg gtggcagctc ccagatgggt cctgtcccag 60
gtgcagctgc ageagteggg cccaggactg gtgaagcett cggagaccct 110

<210> 89
<211> 110
<212> DNA

60/74

<213> Artificial Sequence
<220>

<223> 12E10VH2
<400> 89

acccaatcca ctccagtccc ttccctgggg gctgccgaat ccagctccag tagtaactac 60
tgatggagtc accagagaca gtgcaggtga gggacagggt ctccgaaggc 110

<210> 90
<211> 110
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VH3
<400> 90

tggagtggat tgggtatatc tattacagtg ggagcaccaa ctacaacccc tccctcaaga 60
gtcgagtcac catatcagta gacacgtcca agagccagtt ctccctgaag 110

<210> 91
<211> 114
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VH4
<400> 91

tgaggagaca gtgaccatgg tgccacggcc ccagacatcg aagtaccgcc ctctcgcaca 60
gtaatacacg gccgtgtctg cggcggtcac agagctcagc ttcagggaga actg 114

<210> 92

61/74

<211> 32
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VHS, PCR primer
<400> 92

ttcaagcttc caccatgaaa catctgtggt tc 32

<210> 93
<211> 34
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VHA, PCR primer
<400> 93

ttgggatcca ctcacctgag gagacagtga ccat 34

<210> 94

<211> 426

<212> DNA

<213> Mus

<220>

<221> CDS

<222> (12). . . (417)

<223> 12E10H, H chain V region

<400> 94

aagcttccac c atg aaa cat ctg tgg ttc ttc ctt etc ctg gtg gca get 50
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala

62/74

1 5 10

ccc aga tgg gtc ctg tec cag gtg cag ctg cag cag teg ggc cca gga 98
Pro Arg Trp Val Leu Ser Gin Val Gin Leu Gin Gin Ser Gly Pro Gly

15 20 25

ctg gtg aag cct teg gag ace ctg tec etc ace tgc act gtc tct ggt 146
Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
30 35 40 45

gac tec ate agt agt tac tac tgg age tgg att egg cag ccc cca ggg 194
Asp Ser He Ser Ser Tyr Tyr Trp Ser Trp He Arg Gin Pro Pro Gly

50 55 60

aag gga ctg gag tgg att ggg tat ate tat tac agt ggg age acc aac 242
Lys Gly Leu Glu Trp He Gly Tyr He Tyr Tyr Ser Gly Ser Thr Asn

65 70 75

tac aac ccc tec etc aag agt cga gtc acc ata tea gta gac acg tec 290
Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr lie Ser Val Asp Thr Ser

80 85 90

aag age cag ttc tec ctg aag ctg age tct gtg acc gee gca gac acg 338
Lys Ser Gin Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr

95 100 105

gee gtg tat tac tgt gcg aga ggg egg tac ttc gat gtc tgg ggc cgt 386
Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Phe Asp Val Trp Gly Arg
110 115 120 125

ggc acc atg gtc act gtc tec tea ggtgagtgga tcccaa 426
Gly Thr Met Val Thr Val Ser Ser
130

<210> 95
<211> 110

63/74

<212> PRT
<213> Mus

<400> 95

Ser Tyr Val Leu Thr Gin Pro Pro Ser Val Ser Gly Ser Pro Gly Gin

15 10 15

Ser lie Thr He Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr

20 25 30

Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu

35 40 45

Met He Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe

50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie Ser Gly Leu
65 70 75 80

Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg

85 90 95

Ser Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> 96
<211> 330
<212> DNA
<213> Mus

<400> 96

tcctatgtgc tgactcagcc accctcggtg tcagggtctc ctggacagtc gatcaccatc 60

tcctgcactg gaaccagcag tgacgttggt ggttataact atgtctcctg gtaccaacag 120

cacccaggca aagcccccaa actcatgatt tatgagggca gtaaacggcc ctcaggggtt 180

64/74

tctaatcgct tctctggctc caagtctggc aacacggcct ccctgaccat ctctgggctc 240
caggctgagg acgaggctga ttattactgc agctcatata caaccagaag cactcgggtg 300
ttcggcggag ggaccaagct gaccgtccta 330

<210> 97
<211> 57
<212> DNA
<213> Human
<220>
<221> CDS
<222> (1). . . (57)
<223> reader sequence
<310>
<400> 97

atg gcc tgg acc gtt etc etc etc ggc etc etc tct cac tgc aca ggc
Met Ala Trp Thr Val Leu Leu Leu Gly Leu Leu Ser His Cys Thr Gly

15 10 15

tct gtg acc
Ser Val Thr

<210> 98
<211> 110
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VL1, PCR primer
<400> 98

atggcctgga ccgttctcct cctcggcctc ctctctcact gcacaggctc tgtgacctcc 60

65/74

tatgtgctga ctcagccacc ctcggtgtca gggtctcctg gacagtcgat 110

<210> 99
<211> 62
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VL2, PCR primer
<400> 99

tcatgagttt gggggctttg cctgggtgct gttggtacca ggagacatag ttataaccac
caacgtcact gctggttcca gtgcaggaga tggtgatcga ctgtccagga

<210> 100
<211> 110
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VL3, PCR primer
<400> 100

cccccaaact catgatttat gagggcagta aacggccctc aggggtttct aatcgcttct 60
ctggctccaa gtctggcaac acggcctccc tgaccatctc tgggctccag 110

<210> 101
<211> 102
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VL4, PCR primer

66/74

<400> 101

taggacggtc agcttggtcc ctccgccgaa cacccgagtg cttctggttg tatatgagct 60
gcagtaataa tcagcctcgt cctcagcctg gagcccagag at 102

<210> 102
<211> 31
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VLS, PCR primer
<400> 102

atcaagcttc caccatggcc tggaccgttc t 31

<210> 103
<211> 36
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10VLA, PCR primer
<400> 103

ctaggatccg ggctgaccta ggacggtcag cttggt 36

<210> 104
<211> 387
<212> DNA
<213> Mus
<220>
<221> CDS

67/74

<222> (1)... (387)

<223> 12E10L, L chain V region

<310>

<400> 104

atg gcc tgg acc gtt etc etc etc ggc etc etc tct cac tgc aca ggc 48
Met Ala Trp Thr Val Leu Leu Leu Gly Lev Leu Ser His Cys Thr Gly

15 10 15

tct gtg acc tec tat gtg ctg act cag cca ccc teg gtg tea ggg tct 96
Ser Val Thr Ser Tyr Val Leu Thr Gin Pro Pro Ser Val Ser Gly Ser

20 25 30

cct gga cag teg ate acc ate tec tgc act gga acc age agt gac gtt 144
Pro Gly Gin Ser He Thr lie Ser Cys Thr Gly Thr Ser Ser Asp Val

35 40 45

ggt ggt tat aac tat gtc tec tgg tac caa cag cac cca ggc aaa gcc 192
Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gin Gin His Pro Gly Lys Ala

50 55 60

ccc aaa etc atg att tat gag ggc agt aaa egg ccc tea ggg gtt tct 240
Pro Lys Leu Met He Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser
65 70 75 80

aat cgc ttc tct ggc tec aag tct ggc aac acg gcc tec ctg acc ate 288
Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr lie

85 90 95

tct ggg etc cag get gag gac gag get gat tat tac tgc age tea tat 336
Ser Gly Leu Gin Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr

100 105 110

Aca acc aga age act egg gtg ttc ggc gga ggg acc aag ctg acc gtc 384
Thr Thr Arg Ser Thr Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val
115 120 125

eta
Leu

387

<210> 105
<211> 24
<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (1). . . (24)

<223> FLAG, reader sequence

<400> 105

gac tac aag gat gac gac gat aag 24
Asp Tyr Lys Asp Asp Asp Asp Lys

<210> 106
<211> 30
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10S, PCR primer
<400> 106

tatgaattcc accatgaaac atctgtggtt 30

<210> 107
<211> 38
<212> DNA

<213> Artificial Sequence

69/74

<220>

<223> DB2, PCR primer
<400> 107

taggagctac cgcctccacc tgaggagaca gtgaccat 38

<210> 108
<211> 44
<212> DNA

<213> Artificial Sequence
<220>

<223> DB1, PCR primer
<400> 108

gtctcctcag gtggaggcgg tagctcctat gtgctgactc agcc 44

<210> 109
<211> 59
<212> DNA

<213> Artificial Sequence
<220>

<223> 12E10FA, PCR primer
<400> 109

attgcggccg cttatcactt atcgtcgtca tccttgtagt ctaggacggt cagcttggt 59

<210> 110
<211> 792
<212> DNA

<213> Artificial Sequence
<220>

70/74

<221> CDS

<222> (11)... (778)

<223> 12E10, Single chain Fv

<400> 110

gaattccacc atg aaa cat ctg tgg ttc ttc ctt etc ctg gtg gca get 49
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala
1 5 10

ccc aga tgg gtc ctg tec cag gtg cag ctg cag cag teg ggc cca gga 97
Pro Arg Trp Val Leu Ser Gin Val Gin Leu Gin Gin Ser Gly Pro Gly

15 20 25

ctg gtg aag cct teg gag acc ctg tec etc ace tgc act gtc tct ggt 145
Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
30 35 40 45

gac tec ate agt agt tac tac tgg age tgg att egg cag ccc cca ggg 193
Asp Ser He Ser Ser Tyr Tyr Trp Ser Trp He Arg Gin Pro Pro Gly

50 55 60

aag gga ctg gag tgg att ggg tat ate tat tac agt ggg age acc aac 241
Lys Gly Leu Glu Trp He Gly Tyr He Tyr Tyr Ser Gly Ser Thr Asn

65 70 75

tac aac ccc tec etc aag agt cga gtc acc ata tea gta gac acg tec 289
Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr lie Ser Val Asp Thr Ser

80 85 90

aag age cag ttc tec ctg aag ctg age tct gtg acc gee gca gac acg 337
Lys Ser Gin Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr

95 100 105

gee gtg tat tac tgt gcg aga ggg egg tac ttc gat gtc tgg ggc cgt 385
Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Phe Asp Val Trp Gly Arg
110 115 120 125

71/74

ggc acc atg gtc act gtc tec tea ggt gga ggc ggt age tec tat gtg 433

Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Ser Tyr Val

130 135 140

ctg act cag cca ccc teg gtg tea ggg tct cct gga cag teg ate acc 481

Leu Thr Gin Pro Pro Ser Val Ser Gly Ser Pro Gly Gin Ser lie Thr

145 150 155

ate tec tgc act gga acc age agt gac gtt ggt ggt tat aac tat gtc 529

lie Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val

160 165 170

tec tgg tac caa cag cac cca ggc aaa gec pec aaa etc atg att tat 577

Ser Trp Tyr Gin Gin His Pro Gly Lys Ala Pro Lys Leu Met lie Tyr

175 180 185

gag ggc agt aaa egg ccc tea ggg gtt tct aat cgc ttc tct ggc tec 625

Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser
190 195 200 205

aag tct ggc aac acg gee tec ctg acc ate tct ggg etc cag get gag 673

Lys Ser Gly Asn Thr Ala Ser Leu Thr He Ser Gly Leu Gin Ala Glu

210 215 220

gac gag get gat tat tac tgc age tea tat aca acc aga age act egg 721

Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Thr Arg Ser Thr Arg

225 230 235

gtg ttc ggc gga ggg acc aag ctg acc gtc eta gac tac aag gat gac 769

Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Asp Tyr Lys Asp Asp

240 245 250

gac gat aag tgataagegg cege 792
Asp Asp Lys
255

<210> 111
<211> 62
<212> DNA

<213> Artificial Sequence
<220>

<223> sc4. 3, PCR primer
<400> 111

ggtggctgag tcagcacata ggacgatccg

cc

<210> 112
<211> 61
<212> DNA

<213> Artificial Sequence
<220>

<223> scl. 3, PCR primer
<400> 112

gcaccatggt cactgtctcc tcaggtggtg
g

<210> 113
<211> 822
<212> DNA

<213> Artificial Sequence

<220>

<221> CDS

<222> (11). . . (807)

<223> scl2E10, Single chain Fv

72/74

ccaccacccg aaccaccacc acccgaacca 60

62

gtggttcggg tggtggtggt tcgggtggtg 60

61

73/74

<400> 113

gaattccacc atg aaa cat ctg tgg ttc ttc ctt etc ctg gtg gca get 49
Met Lys His Leu Trp Phe Phe Leu Leu Leu Val Ala Ala
1 5 10

ccc aga tgg gtc ctg tec cag gtg cag ctg cag cag teg ggc cca gga 97
Pro Arg Trp Val Leu Ser Gin Val Gin Leu Gin Gin Ser Gly Pro Gly

15 20 25

ctg gtg aag cct teg gag acc ctg tec etc acc tgc act gtc tct ggt 145
Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
30 35 40 45

gac tec ate agt agt tac tac tgg age tgg att egg cag ccc cca ggg 193
Asp Ser lie Ser Ser Tyr Tyr Trp Ser Trp lie Arg Gin Pro Pro Gly

50 55 60

aag gga ctg gag tgg att ggg tat ate tat tac agt ggg age acc aac 241
Lys Gly Leu Glu Trp lie Gly Tyr He Tyr Tyr Ser Gly Ser Thr Asn

65 70 75

tac aac ccc tec etc aag agt cga gtc acc ata tea gta gac acg tec 289
Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr He Ser Val Asp Thr Ser

80 85 90

aag age cag ttc tec ctg aag ctg age tct gtg acc gee gca gac acg 337
Lys Ser Gin Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr

95 100 105

gec gtg tat tac tgt gcg aga ggg egg tac ttc gat gtc tgg ggc cgt 385
Ala Val Tyr Tyr Cys Ala Arg Gly Arg Tyr Phe Asp Val Trp Gly Arg
110 115 120 125

ggc acc atg gtc act gtc tec tea ggt ggt ggt ggt teg ggt ggt ggt 433
Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
130 135 140

74/74

ggt teg ggt ggt ggc gga teg tec tat gtg ctg act cag cca ccc teg 481
Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gin Pro Pro Ser

145 150 155

gtg tea ggg tct cct gga cag teg ate ace ate tec tgc act gga acc 529
Val Ser Gly Ser Pro Gly Gin Ser He Thr lie Ser Cys Thr Gly Thr

160 165 170

age agt gac gtt ggt ggt tat aac tat gtc tec tgg tac caa cag cac 577
Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gin Gin His

175 180 185

cca ggc aaa gec ccc aaa etc atg att tat gag ggc agt aaa egg ccc 625
Pro Gly Lys Ala Pro Lys Leu Met He Tyr Glu Gly Ser Lys Arg Pro
190 195 200 205

tea ggg gtt tct aat cgc ttc tct ggc tec aag tct ggc aac acg gec 673
Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala

210 215 220

tec ctg acc ate tct ggg etc cag get gag gac gag get gat tat tac 721
Ser Leu Thr He Ser Gly Leu Gin Ala Glu Asp Glu Ala Asp Tyr Tyr

225 230 235

tgc age tea tat aca acc aga age act egg gtg ttc ggc gga ggg acc 769
Cys Ser Ser Tyr Thr Thr Arg Ser Thr Arg Val Phe Gly Gly Gly Thr

240 245 250

aag ctg acc gtc eta gac tac aag gat gac gac gat aag tgataagegg 818
Lys Leu Thr Val Leu Asp Tyr Lys Asp Asp Asp Asp Lys

255 260 265

cege 822